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ABSTRACT
Evaluation of Human Umbilical Vein Endothelial Cells in Blood Vessel Mimics through
Changes in Gene Expression and Caspase Activity
Conor Charles Hedigan
Blood vessel mimics (BVMs) are simple tissue engineered blood vessel constructs
intended for preclinical testing of vascular devices. This thesis developed and
implemented methods to characterize two of these components. The first aim of this
thesis investigated the effect of cell culture duration and flow conditions on endothelial
cell gene expression, especially regarding endothelial-to-mesenchymal transition
(EndMT). A trend of decreased endothelial marker gene expression and increased
mesenchymal marker gene expression would indicate EndMT. qPCR analysis revealed
that increased cell culture duration did not result in EndMT, and in fact increased
endothelial marker expression as cell culture duration increased. Disturbed flow
conditions decreased endothelial marker and increased mesenchymal marker expression
relative to static culture.
The second aim of this thesis developed methods to determine cytotoxicity of, and
endothelial cell adhesion to, novel BTEAC salt scaffolds. Immunostaining was used to
visualize these scaffold effects. The cytotoxicity elution assay showed that BTEAC salt
scaffolds were not more cytotoxic than the standard PLGA scaffold. Direct contact assays
spanning several timepoints also found that BTEAC salt scaffolds were not more
cytotoxic than standard scaffolds but had higher endothelial cell adhesion and coverage
than standard scaffolds. Overall, this thesis developed and implemented methods to
characterize the endothelial cells used in the BVM model.
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CHAPTER 1. INTRODUCTION

1.1 Blood Vessel Mimic Background
Cal Poly’s Tissue Engineering Laboratory creates blood vessel mimics (BVMs) to
test intravascular devices in an environment that simplistically mimics the anatomy and
physiology of native blood vessels. The BVMs are fabricated using endothelial cells
(ECs), smooth muscle cells (SMCs), and a polymer scaffold tube assembled in a
bioreactor. While this design is simple, it offers a three-dimensional environment with
some physiologic relevance, which can be used to determine the interaction between cells
and vascular devices. This model serves as an intermediate step between basic in vitro
testing and in vivo testing of devices. A full explanation of BVM relevance for
cardiovascular device testing will be explained in the next section.

1.1.1 Relevance

1.1.1.1 Cardiovascular Disease and Intravascular Devices
Heart disease is responsible for one of every four deaths per year in the United
States, with coronary artery disease (CAD) being the most common type of heart
disease1. Coronary heart disease results in the hardening and thickening of coronary
arteries and the formation of atherosclerotic plaques. These plaques are composed of
immune cells, SMCs, myofibroblasts, lipids, and extracellular matrix, and develop
preferentially at areas of disturbed flow in the vessels 2. These plaques, impede blood
delivery to the heart and are prone to rupturing, which can result in a myocardial
1

infarction or stroke1. Figure 1 displays the progression of atherosclerotic plaque building
and the resulting flow.

Figure 1: The Effects of Plaque on Blood Flow. Blood flow is impeded as
atherosclerotic plaque buildup progresses1.

Intervention is often necessary to reduce the area of plaque blockage and increase
blood flow to downstream tissue. Coronary artery bypass grafting (CABG) is a procedure
commonly used to bypass the occluded vessel and restore blood flow, but the procedure
is invasive. Minimally invasive procedures include coronary balloon angioplasty and
stenting. Coronary balloon angioplasty uses a balloon to push the plaque against the wall
of the vessel, widening the lumen of the vessel 3. Stenting restores blood flow, similar to
coronary balloon angioplasty, but leaves a stent in the artery.

1.1.1.2 Preclinical Cardiovascular Device Testing in Blood Vessel Mimics
The BVM model is intended as an intermediate testing environment for
intravascular devices, such as coronary stents, to support safety of the device. These types
of devices must show safety and efficacy in vitro, in vivo, and during clinical trials. Most
in vitro testing simply uses cells cultured in a two-dimensional plate to determine cell
2

interaction with the device material. Testing then progresses to in vivo studies, where
devices are tested in animal models. There is a disparity between how cells interact in a
plate with a device and how a living organism interacts with that device. In vivo studies
are also expensive, so alternative testing environments can be useful in determining
safety as well as reducing testing costs. BVMs can be used as a testing environment to
bridge current in vitro and in vivo testing, which is shown in Figure 2.

Figure 2: Testing Methods before FDA Approval. BVMs can provide valuable data on
device safety and efficacy between in vitro and in vivo testing 4.

1.1.2 Blood Vessel Mimic Design

1.1.2.1 Native Blood Vessel Anatomy
The BVM model is designed to have a simpler anatomy than a native vessel.
Different types of blood vessels vary slightly in anatomy but share three main tunica
layers and a lumen. The lumen is an open tube at the center of the vessel and is the site of
blood flow. The tunica intima is the innermost layer which interacts with blood in the
lumen and is composed of the endothelium and basement membrane 5. The endothelium is
composed of ECs and acts as a barrier between the body and blood while being
selectively permeable to chemicals, white blood cell, and waste movement 6. The
basement membrane anchors the endothelium to the connective tissue of the middle layer
3

of blood vessel tissue, the tunica media. The tunica media contains smooth muscle cells
and connective tissue and is responsible for vasoconstriction and vasodilation 5. The
outermost layer, the tunica adventitia, consists of collagenous connective tissue,
fibroblasts, and nerves7. A diagram of these layers is shown in Figure 3. BVMs attempt to
include the lumen, tunica intima, tunica media, and tunica adventitia.

Figure 3: The anatomy of native arteries, veins, and capillaries 8.

1.1.2.2 Blood Vessel Mimic Fabrication
BVMs are fabricated using three components: an exterior polymer scaffold tube, a
middle layer of SMCs, and an interior layer of ECs9. The scaffold is composed of polylactic-co-glycolic-acid (PLGA) fibers, in which fibers are created through
electrospinning. During the electrospinning process, a solution of chloroform and PLGA
is charged and pulled to a grounded metal mandrel. The mandrel translates and rotates to
collect the fibers, which typically range between 4 µm to 5 µm in fiber diameter.
The scaffold is then conditioned in high serum media within a bioreactor attached
to a peristaltic pump, where proteins from the media intercalate the scaffold. These
proteins enhance cell adhesion and proliferation once cells are sodded on the scaffold.

4

With the current model, human umbilical artery smooth muscle cells (HUASMCs) are
pressure sodded to the interior of the polymer tube, followed by human umbilical vein
endothelial cells (HUVECs) after conditioning. The fully fabricated BVM is cultured
inside of the bioreactor, which is connected to an 8-roller peristaltic pump that pushes
media through the lumen of the BVM. After reaching the appropriate time point, the
BVM is removed from the bioreactor and prepared for one of several techniques to
analyze the resulting construct, including confocal imaging, scanning electron
microscope (SEM) imaging, and gene expression analysis.

1.1.2.3 Blood Vessel Mimic Anatomy
Due to the fabrication technique, and as introduced above, the BVM has an
anatomy mimicking the three basic layers of a native vessel. The polymer scaffold acts as
the tunica adventitia of the BVM, supporting the geometry and providing a matrix for
SMC growth. Figure 4 displays the layer of HUASMCs acting as the tunica media, and
the layer of HUVECs acting as the tunica intima.

Figure 4: Blood Vessel Mimic Anatomy.

5

1.1.3 Types of Blood Vessel Mimics
Cal Poly’s Tissue Engineering Lab currently creates three different types of
BVMs for use with different devices or diseases. The straight BVM is the standard model
used to mimic a healthy blood vessel and has primarily been used for stent and
intravascular imaging testing9. Aneurysm BVMs are fabricated to mimic the geometry of
an aneurysm in a vessel10. Several aneurysm geometries have been created, including
blister, fusiform, and saccular, which are useful for testing neurovascular devices such as
flow diverters10. A diabetic BVM has also been developed, which uses diabetic cells
instead of non-diseased ECs and SMCs11,12. Stenting in diabetic patients has a lower rate
of success than in non-diabetic patients, so further testing of devices that will be used in
diabetics may be important to understand safety concerns.
Although the examples described above incorporated both ECs and SMCs, BVMs
using only endothelial cells have also been developed and implemented in the past.
Cardinal et al. initially developed these BVMs using ePTFE scaffolds that were sodded
with only human microvessel endothelial cells 4. It was observed that cell coverage was
significantly reduced upon the implementation of PLGA scaffolds in the BVM model, so
SMCs were introduced to promote EC adhesion. While the addition of SMCs makes the
model anatomically more similar, it also adds an increased amount of additional
resources and time to create the model. The addition of SMCs also complicates analysis
of the BVMs, requiring the ability to distinguish between cells types and understand the
interactions of the two cell types. Therefore, it would be beneficial for the Tissue
Engineering Lab to have the capability to create EC only BVMs. Analysis of cell-cell
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interactions, cell-scaffold interactions, and cell-device interactions in these BVMs would
be simplified.

1.1.4 Importance of Endothelial Cell Characterization
Device testing has always been the goal for the BVM model. The interaction
between the device and endothelial cells is the primary consideration for analysis since
this cell-device interaction is the dominant interaction in vivo; therefore, the endothelial
cells used in the model are of utmost importance. These considerations lead to the
necessity of understanding how the ECs are reacting during culture, in interaction with
scaffolds, and when exposed to shear flow. Efforts need to be made to characterize
endothelial cell behavior, especially since endothelial cells commonly undergo
morphological changes in vitro. These changes have been observed in the Tissue
Engineering Lab and documented in literature13–16. Analyzing these changes enhances the
legitimacy of the model by ensuring that the endothelial cells retain their endothelial-like
phenotype and function throughout culture and sodding.
In order to develop EC-only BVMs, new scaffolds would likely need to be
implemented. While several different scaffolds have been proposed and manufactured in
the past, use of these scaffolds could not be justified over the standard 75:25 PLGA
scaffolds. Current models with PLGA have been working, and no methods have been
established to investigate scaffold cytotoxicity, cell adhesion, or cell proliferation
between scaffold types. These methods must be developed in order to propose novel
scaffolds that can be used for EC only BVMs. Important considerations include the
ability to sterilize the scaffold, retention of scaffold geometry, scaffold cytotoxicity, EC
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adhesion at short timepoints, and EC coverage at longer timepoints. The BVM model
must be broken down component by component to thoroughly assess the completed
model.

1.2 BVM Characterization
BVMs must be characterized by the individual components of cells and scaffolds,
both separately and together. qPCR and immunostaining are useful techniques to analyze
cells. qPCR collects quantitative measurements of gene expression, which indicate
changes to specific genetic markers. This technique is used in molecular diagnostics to
detect and quantify bacteria, as well as in disease diagnostics to understand how genetic
markers change with disease onset and progression17. Immunostaining uses antibodies to
label proteins in cells, which can be visualized by confocal microscopy to identify protein
presence or intensity11. Both techniques can be applied to BVM characterization through
analyzing gene expression and protein changes in ECs 11,12,18. Gene expression analysis
will be extensively covered in Chapter 2 of this thesis.
Methods are also necessary to characterize scaffolds before cells are sodded.
Scanning electron microscopy (SEM) focuses an electron beam on a sample and collects
the scattered electrons to generate an image. These high-resolution images work well for
imaging electrospun scaffolds, where the images can be used to quantify data regarding
fiber diameter and porosity. This quantification processing can be done using software
like ImageJ or MATLAB19.
Once the individual components have been characterized, the interaction between
cells and scaffold can be evaluated. The previously identified methods are useful for this
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process. SEM can visualize cell coverage, either in the lumen of scaffolds or on deployed
stents. qPCR can quantify cell changes as they interact with different scaffold types, flow
conditions, or lengths of time cultured in bioreactors. Immunostaining can be used for
similar purposes, characterizing the cell interaction with the scaffold through
investigations of adhesion, proliferation, or cell identification.

1.2.1 Previous Characterization
Several techniques have been investigated and implemented over the years in the
Tissue Engineering Lab to characterize cells in the BVMs. Multiple previous projects
have attempted to characterize BVMs through qPCR. Tristin McGuffick evaluated gene
expression changes in stented and unstented vessels. PECAM, ICAM, SMA, Ki67, and
BAX were chosen as endothelial cell, inflammation, smooth muscle, proliferation, and
apoptosis markers, respectively. She found downregulation of PECAM after stent
deployment in umbilical BVMs, while coronary BVMs downregulated SMA and
upregulated Ki67 and BAX18. Shelby Kunz and Gabriella Sugerman used gene
expression to characterize ECs cultured in high glucose conditions. Kunz used the
markers eNOS, PECAM, and RAGE to characterize and compare HUVECs and diabetic
human coronary artery ECs (DHCAECs). DHCAECs had higher expression of RAGE
and eNOS compared to HUVECs. HUVECs treated with high glucose media had
increased expression of RAGE compared to normal media. These findings set baseline
gene expression levels and showed how BVMs using HUVECs differed from those using
DHCAECs12. Sugerman continued work with high glucose treatments of ECs, using IL-6
and CD36 as markers for oxidative stress. She found that IL-6 expression increased with
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glucose treatment11. These three theses struggled to identify a consistent housekeeping
gene, making conclusions regarding treatment trends more difficult to confirm.
Imaging techniques have been implemented in many projects, mostly through
SEM imaging or immunostaining. SEM images are routinely used to verify a confluent
cell lining in the lumen of the BVM. While useful, this technique cannot easily quantify
cell presence. Immunostaining techniques have also been used for various purposes. Most
common have been nuclear stains to identify and quantify cell presence. Another
important project has been to implement staining protocols to distinguish ECs versus
SMCs in BVMs20. PECAM has been used as a marker for ECs. Myosin heavy chain, ⍺smooth muscle actin (⍺SMA), and, most recently, calponin have been used to identify
SMCs.

1.2.2 Need for Assessment
Despite the past work done, there is still need for additional characterization of
cells, scaffolds, and BVMs. It has been observed that endothelial cells undergo
morphological and genetic changes during culture in vitro21. The endothelial lining of the
BVMs is, arguably, the most important component of the model. Intravascular devices
will theoretically primarily interact with the endothelial lining of the BVMs, and that
interaction will provide useful preclinical data. Observations of interest, such as a change
in proliferation, migration over the stent, or death, are all observations that have to do
with changes in ECs. Therefore, further characterization of ECs specifically is of great
importance.
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There are several potential areas where better characterization of endothelial cells
would progress our research. The first is to better understand how ECs change at different
timepoints in the BVM fabrication process. The first interval is the time between when
ECs begin culture in flasks until just before sodding into scaffolds. This information
would allow us to track the utility of our cells as they age and identify an optimal passage
number to use in BVMs. Depending on how, or if, the cells change, it would also suggest
how culture procedures could be changed to optimize EC cell growth. The second
interval is the time between when cells are sodded into scaffolds and the resultant BVM
is taken down for assessment. There is a need to assess the effect of shear stress on
endothelial cells in the BVM model, and to compare how those cells have changed
relative to the initial cells that were sodded. A third time interval, when a device is
implanted in the BVM, could be included in this section; however, the first two intervals
were the focus of this thesis.
The second area for better characterization involves the cell-scaffold interaction.
This includes both the cell interaction with the scaffold and the scaffold interaction with
the cells. The Tissue Engineering Lab has no current methods to assess these interactions,
and without these protocols there is no way to justify or quantify a change from one type
of scaffold to another. This must be assessed through initial adhesion data at short
timepoints, as well as multi-day time points to address cell proliferation on the scaffold.
Scaffold cytotoxicity must also be investigated, especially regarding changes in polymer
type or the addition of supplements to the electrospinning solution.
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1.3 Summary and Aims of the Thesis
BVMs have proven to be a useful model for testing vascular devices. This utility
warrants more exploration into the details of the individual components being used in the
model. Before the components can be investigated, methods must be established and
verified. These methods will be applied to current problems encountered by the Tissue
Engineering Lab to determine the effectiveness of the methods. The overall goal of this
thesis was to establish methods that could be used to understand endothelial cell changes
in the BVM model. In order to accomplish this goal, two aims were pursued: 1) to
characterize ECs alone through changes in gene expression, and 2) to characterize ECscaffold interactions. Each aim is further summarized below.

1.3.1 Aim 1: Endothelial Cell Characterization through Changes in Gene
Expression
The goal of the first aim of this thesis was to analyze gene expression changes in
endothelial cells with a focus on endothelial cell dedifferentiation. The markers explored
can also be applied to a broader understanding of cell-cell interactions between ECs. This
first aim can be divided into two components relating to changes in HUVEC gene
expression. The first component studied the effect of culture time on EC expression,
where the treatment groups were defined by the passage number of the cells. The
hypothesis was that increasing cell culture duration would decrease endothelial marker
gene expression and increase mesenchymal marker gene expression. The second
investigation sought to examine the effect of three flow conditions on gene expression.
The flow conditions in question were static culture, disturbed flow, and laminar flow. The
12

hypothesis here was that static and disturbed flow would decrease endothelial marker
expression and increase mesenchymal marker expression, while laminar flow would have
the opposite effect on endothelial and mesenchymal markers.

1.3.2 Aim 2: Characterization of Endothelial Cell and Scaffold Interaction
The second aim of this thesis sought to establish methods for investigating and
quantifying cell-scaffold interactions. This was achieved through designing two assays.
The first assay investigated scaffold cytotoxicity through exposure of ECs to scaffold
elution products. The second assay was developed to understand cell adhesion on
scaffolds at shorter timepoints and cell coverage in BVMs at longer timepoints. Cell
apoptosis and dead cell presence were also quantified, respectively, through Caspase and
Propidium Iodide activity. These assays were developed and applied to an initial
investigation of novel nanofiber scaffolds, with the potential of replacing the current
scaffolds used by the Tissue Engineering Lab with the novel scaffolds.
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CHAPTER 2. AIM 1: GENE EXPRESSION CHANGES OF ENDOTHELIAL
CELLS IN CULTURE AS A FACTOR OF TIME AND FLOW CONDITION

2.1 Introduction
The first aim of this thesis explored the gene expression changes experienced by
endothelial cells in culture as a factor of time and flow condition. In order to understand
these changes, several topics must be prefaced, including flow environment, cell
phenotype, endothelial-mesenchymal transition, the mechanosensory complex, and
qPCR. These topics will provide background and justification for the methods chosen in
this aim and will help with explanation of the resulting data.

2.1.1 Flow Environment
Endothelial cells are highly reactive to flow conditions of fluid across the cells.
Native flow environments within blood vessels are dynamic; vasodilation and
constriction, changes in blood pressure and heart rate, and bifurcations all effect blood
shear forces across the endothelium. BVMs have consistent and controlled flow, but the
forces within BVM are not representative of physiological conditions. Flow within native
vessels and BVMs will be described in this section.

2.1.1.1 Native Flow Environment
A baseline set of in vivo flow conditions must be established to compare the BVM
model against. The lumen diameter of BVMs range from 3 mm to 4 mm depending on
the fabrication technique. Therefore, comparable arteries should have similar lumen sizes
and previously measured hemodynamic force values for shear stress and cyclic strain.
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Shear stress is the tangential force of blood flowing over the endothelial cells of the
tunica intima, and has values ranging from 10 to 70 dynes/cm 2 22. Vasoregulatory
mechanisms attempt to maintain a shear stress around 15 dynes/cm 2 23. Cyclic strain is
derived from blood pressure and produces forces that stretch the vessel
circumferentially24. While shear stress mostly affects the tunica intima, cyclic strain
affects all three layers of the vessel22. For the purpose of this thesis, shear stress will be
the primary focus of hemodynamic force, which is indicated in Figure 5.

Figure 5: Forces Acting on Blood Vessels. Hemodynamic forces of shear stress (SS),
pressure (P), and tensile stress on the endothelium24.

One such artery that is a suitable comparison for the BVM model is the left
coronary artery, which is on average 4.0 mm in diameter and has wall shear stress forces
between 15 and 40 dynes/cm2 in areas of undisturbed flow25,26. The coronaries are also a
common sight of device use, with 91% of percutaneous artery interventions involving
stenting in 200627. The carotid artery is also useful for comparing to BVMs. While larger
than BVMs at 4.3 to 7.7 mm in lumen diameter, the mean wall shear stress is lower than
that of the left coronary artery at 12 to 15 dynes/cm2 28,29. The carotids are also a site
where stenting is a common treatment 30. The HUVECs used in the BVMs are sourced
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from umbilical veins, which have an average wall shear stress of 5.2 dynes/cm 2 and a
lumen diameter of between 600 and 800 µm 31,32.
Native vessels have areas of laminar and disturbed flow, shown in Figure 6, so
wall shear stress is not consistent33. Disturbed flow is common near bifurcations and
bending in the vessel path where blood flow enters low pressure regions, slows the blood
velocity, and causes circulation24. These areas, like the one shown in Figure 7, experience
less shear stress than under laminar flow, inducing an active phenotype in the ECs that
have proinflammatory, pro-adhesive, procoagulant, and pro-proliferative properties 34,35.
Laminar flow and high shear stress, on the other hand, induces a quiescent phenotype that
promotes cell alignment and survival while reducing proliferation 22,34.

Figure 6: Laminar Flow versus Shear Flow22.
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Figure 7: Flow in a Bifurcation. Disturbed flow results at areas of bifurcation, which
results in EC activation 36.

2.1.1.2 Previously Determined Flow Conditions in Blood Vessel Mimics
Previous Biomedical Engineering graduate student Marc Dawson explored
physiological flow conditions in BVMs 37. He completed his thesis in 2009, so almost 10
years have passed since his explorations of BVM flow conditions. Dawson explored two
main facets of flow: pressure and wall shear stress (WSS). In vivo changes in pressure
only significantly affect the tunica media, which corresponds to changes in the layer of
SMCs in BVMs. Therefore, changes in pressure may not significantly affect the EC layer
in the BVM, which is the primary concern of this thesis. In his pressure tests, Dawson did
determine that the 8-roller pump produced a pressure profile with only small pressure
fluctuations at high RPMs. At 100 RPMs, or 10 mL/min, the 8-roller pump produced
pressures of 16 mmHg at maximum and 8 mmHg at minimum. This testing lead to the
implementation of an 8-roller peristaltic pump over a 3-roller, so all shear stress
measurements were made using the 8-roller pump.
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Dawson determined that his BVM systems had shear stress values of about 0.35
dyne/cm2, which is significantly lower than physiological shear stress of around 10
dyne/cm2. Since previous studies determined that EC alignment occurred between 6-10
dyne/cm2, Dawson attempted to produce WSS values of between 6-8 dyne/cm 2. He
initially used Dextran and Methylcellulose as additives to cell media to increase the
viscosity, and therefore shear stress, in the BVMs. However, Methylcellulose was
determined to be too difficult to implement so only Dextran was pursued as an additive.
The lowest flow rate used in calculating WSS was 15 mL/min, or 140 RPMs, which
produced WSS of 6.04 dyne/cm2 for a 4 mm vessel and 14.4 dyne/cm2 for a 3 mm vessel.
To produce this WSS the viscosity of the media would need to be 15.2 cP, or almost 30%
Dextran. That percentage of Dextran could negatively affect cell growth, so a lower
percentage was implemented in the BVMs. He used 14% Dextran at 28 mL/min (270
RPM) to produce a WSS of 6.4 dyne/cm2. This concentration of Dextran was not found
to significantly disrupt cell growth, but the desired cell morphology was not produced.
Several important changes have been made to the model since Dawson’s thesis.
Scaffolds constructed of ePTFE used to be used in the BVMs, and the standard size of
these scaffolds were 4 mm. The current model uses PLGA scaffolds, which have
significantly different porosity and cellular interactions, and a standard vessel size of 3
mm. The flow tested by Dawson, especially regarding his exploration of increasing WSS
by increasing media viscosity, resulted in higher shear values than in the current model.
The lowest flow rate he investigated at standard media viscosity was 10 mL/min, which
corresponds with 100 RPMs on the 8-roller peristaltic pump. The current model uses a
maximum flow rate of 90 RPMs. These differences have significant impacts on fluid
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flow, especially regarding shear stress. The use of a 3 mm vessel instead of 4 mm could
make the implementation of dextran in cell media more feasible since a lower percentage
of dextran would produce the same shear stress. However, the lower RPMs of the pump
could counteract any difference that the smaller diameter increases the WSS. Exploration
of these differences may be necessary in future work, as adjustments to the flow
conditions currently used in BVMs may benefit cellular responses like cell adhesion,
growth, and phenotype. Nevertheless, this information is just worth noting for this current
thesis as background on the model.

2.1.2 BVM Cell Phenotype
Phenotype refers to the appearance of a cell as a result of genetic and
environmental interactions. In the BVM model, culture conditions and flow conditions
contribute to a distinct EC phenotype. Whether this phenotype is similar to a physiologic
phenotype has yet to be determined, but this section will elucidate the current
understanding of EC phenotype in BVMs and offer a probable explanation for this
observed phenotype as background for the methods and experiments in this chapter.

2.1.2.1 Immunostaining of HUVECs in the Tissue Engineering Lab
A previous project in the Tissue Engineering Lab worked to implement
immunostaining for the purpose of discerning between ECs and SMCs in BVMs. During
the process of developing this protocol, it was noticed that the HUVECs were staining
positive for alpha smooth muscle actin (𝛼SMA), which was the marker that was being
used to identify SMCs. This finding is shown in Figure 8. After testing for bleed through
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from other channels and testing controls for the primary and secondary probes, it was
concluded that the HUVECs were expressing 𝛼SMA, which was hypothesized to
potentially be due to the cells undergoing EndMT.

DAPI 40x

𝛼SMA 40x

Figure 8: Endothelial Cells Stain for 𝛼SMA. HUVECs stained for DAPI, left, and
𝛼SMA, right, show expression of 𝛼SMA in HUVEC cytoplasm and nucleus.

2.1.2.2 Endothelial-to-Mesenchymal Transition
Endothelial-to-mesenchymal transition (EndMT) is a process where endothelial
cells lose endothelial features and gain fibrotic features13,38. During this process, the
expression of EC markers, such as VE-Cadherin (VE-cad), platelet endothelial cell
adhesion molecule (PECAM), and vascular endothelial growth factor receptor 2
(VEGFR2), decrease while the cells increasingly begin to express fibrotic and smooth
muscle markers like 𝛼SMA, calponin, and transgelin (SM22𝛼)21,39–41. The mesenchymal
phenotype is also characterized by the loss of cell-cell junctions and the gain of migratory
abilities42. This process may be the reason that HUVECs in the Tissue Engineering Lab
express 𝛼SMA. Context behind EndMT is necessary to understanding why the
phenomenon occurs, and the utility and hinderance of EndMT in vitro and in vivo. The
following sections will summarize these topics.

20

2.1.2.2.1 EndMT in Heart Development
EndMT was first discovered as a mechanism of heart development in utero2,42,43.
In the early stages of heart development, no valves exist to prevent backflow 44.
Endocardial cushions are thick areas of tissue in the forming heart that eventually
develop into the septum, mitral valve, and tricuspid valve 45,46. During endocardial
cushion formation, ECs undergo EndMT and the mesenchymal cells migrate to the
endocardial cushions42,45. The endocardial cushions elongate to form the septum and
valves at different stages of heart formation45.

2.1.2.2.2 EndMT in Disease Progression
EndMT is involved in various diseases, including fibrosis (cardiac, pulmonary,
kidney, liver)41,47,48, cancer tumor growth16,41,42,47, fibrodysplasia ossificans progressiva
(FOP)40,47, atherosclerosis and coronary artery disease2,49–52, and cerebral cavernous
malformation40,53. The involvement of EndMT continues to be discovered in increasing
types of diseases.
As previously discussed, blood vessels have areas of laminar and disturbed flow;
these areas of disturbed flow are prone to the formation of atherosclerotic lesions 2,49,50.
Specific areas of disturbed flow include carotid bifurcations, the aortic arch, and
branching points of the coronary arteries51. EndMT-derived fibroblast-like cells have
been identified in human atherosclerotic plaque through the co-expression of endothelial
and smooth muscle markers49,50. This process is caused by TGF-ꞵ signaling, oxidative
stress, and hypoxia. Fibroblast growth factor (FGF) signaling is an inhibitor of EndMT,
but disturbed flow inhibits FGF signaling by blocking expression of FGF receptors.
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Hypertension, hyperglycemia, and obesity increase endothelial oxidative stress, making
those conditions risk factors of EndMT and atherosclerosis 2,49,54.
Solid tumors are composed of multiple cell types, including cancer cells,
endothelial cells, inflammatory cells, and fibroblasts 16,40,47. Cancer-associated-fibroblasts
(CAFs) are a subpopulation of fibroblasts in tumors and have been identified as
promoters of tumor growth and progression41,47. Up to 40% of CAFs in tumors may be
derived through EndMT, but the underlying mechanisms for CAF activation and
development from EndMT must be further studied 42,47.
It is still debated as to the extent that EndMT causes fibrosis; other sources of
activated fibroblasts arise from local fibroblasts, epithelial-to-mesenchymal transition
(EMT), and from the bone marrow15. All fibrotic conditions display elevated expression
of genes encoding for collagens and ECM and a reduction in ECM degrading enzymes 48.
In three mouse models of kidney fibrosis, 30% to 50% of fibroblasts originated from
endothelial origin15. A mouse model for cardiac fibrosis demonstrated that 27% to 35%
of fibroblasts in the fibrosis tissue originated from EndMT55. The contribution of EndMT
in human tissue has less robust evidence. However, a study analyzing myocardial tissue
from patients with cardiac fibrosis showed that about 17% of fibroblasts in the fibrotic
myocardium were derived from EndMT48. This suggests that dedifferentiated endothelial
cells are a significant component of atherosclerotic plaque in humans.

2.1.2.2.3 EndMT in Tissue Regeneration
While EndMT is highly involved in disease progressions, it also has the potential
to assist in tissue regeneration in vitro and in vivo. Since EndMT differentiates ECs into a
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mesenchymal stem cell-like phenotype, those mesenchymal cells can be further
differentiated into other tissue types, as shown in Figure 9 53,56. One potential application
for EndMT in tissue regeneration is for the treatment of osteoarthritis and
temporomandibular joint disorder (TMJD)53. Chondrogenesis is the process by which
cartilage is formed, where chondrogenic mesenchymal cells proliferate into
precartilaginous nodules before differentiation into chondrocytes producing cartilage
ECM57. Cartilage grafts could be produced using EndMT derived chondrocytes. A
similar concept was shown with osteogenesis in mice, where endothelial cells labeled
with fluorescent quantum dots and treated with TGFβ2 were seeded onto scaffolds,
implanted, and locally treated with differentiation media. The scaffolds were explanted
and stained for bone, in which it was found that the scaffolds stained for bone in the same
region that the quantum dot fluorescence occurred58. This displays the utility of
endothelial cells and the ability of the cells to readily differentiate in proper conditions.
The conditions of static culture and of BMVs may be appropriate conditions to cause
EndMT.

Figure 9: EndMT in Tissue Engineering. Potential use of EndMT in tissue engineering
through dedifferentiating ECs into multiple other cell types 56.
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2.1.2.3 EndMT Activation Pathways
The progression of EndMT in ECs is most easily explained through the pathways
of the different inducers, which includes transforming growth factor beta (TGF-β), the
pro-inflammatory cytokines interleukin-1 beta (IL1-β) and tumor necrosis factor-alpha
(TNFα), transcription factor NF-kB, and oxidative stress 38. Each of these inducers will be
introduced below.

2.1.2.3.1 Transforming Growth Factor Beta
The most well studied EndMT inducer is TGF-β, a growth factor that has roles in
cell proliferation, differentiation, apoptosis, and migration. It has three isoforms (TGFβ1, TGF-β2, TGF-β3) that bind to TGF-β transmembrane receptor type II (TGFβ-RII).
This phosphorylates and activates one of two TGF-β type I receptors, either activin
receptor-like kinase 5 (ALK5) or ALK1. ALK5 phosphorylation activates SMAD2/3,
while ALK1 activates SMAD1/5. Both SMAD2/3 and SMAD1/5 form complexes with
co-SMAD (SMAD4) and move into the nucleus. High levels of TGF-β will signal
mainly through ALK5, while low levels of TGF-β will signal through ALK5 and ALK1.
Endoglin (END) acts as an auxiliary receptor that inhibits ALK5 signaling and promotes
ALK1 signaling13,38,48,59.
This point in the signaling is important, as ALK1 and ALK5 cause opposite
effects. ALK1 signaling promotes EC proliferation, migration, and organization; ALK5
signaling inhibits EC proliferation, migration, organization, and continues the EndMT
pathway. SMAD2/3 induces expression of Snail1, Slug (Snail2), Twist1, and GATA4.
These are the transcriptional regulators of EndMT in the nucleus of ECs. GATA4

24

regulates Twist1 expression, which induces Snail pathway activation in ECs 2. The Snail
pathways downregulate VE-cadherin, an important protein in cell-cell interactions and an
indicator of EndMT progression60–62. However, the Snail pathway alone is insufficient in
inducing EndMT: GSK-3β, the inhibitor of Snail, needs to be inhibited through
phosphorylation for EndMT to occur62.
TGF-β also activates mitogen-activated protein kinase (MAPK) pathways that
activate the Snail pathway downstream. This includes extracellular signal-regulated
kinase (ERK)1/2, p38 MAPK, and c-Jun-N-terminal kinase (JNK) [50]. The TGF-β
provides a pathway for positive feedback that sustains EndMT progression. TGF-β
activates TGF-β-activated kinase 1 (TAK1), which activates p38 MAPK expression. p38
MAPK increases the expression of TGF-β, creating a positive feedback loop for EndMT 2.
Therefore, EndMT can occur without constant stimulation by TGF-β, making this
pathway a possible source of EndMT in vitro.

2.1.2.3.2 Notch Signaling
While TGF-β is considered the main inducer of EndMT, several other pathways
contribute by aiding the TGF-β pathway62. Notch can activate Twist1 expression,
contributing to the activation of the Snail pathway2. Notch also upregulated mesenchymal
genes by recruiting Smad3 to Smad binding sites48. Snail can also be directly upregulated
by Notch signaling; however, this role of is more robust during development of the
cardiac cushion60.
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2.1.2.3.3 Wnt/β-catenin Signaling
Wnt/β-catenin signaling is necessary for heart valve development in utero, but
also plays a role in tissue fibrosis48. It contributes indirectly to EndMT by stabilizing
Snail, while contributing directly by inducing expression of transgelin (SM22-α) 2. The
Wnt pathway also plays a role in EndMT caused by hyperglycemic conditions 63.

2.1.2.3.4 Pro-inflammatory Cytokines
Several cytokines associated with the inflammatory response have been shown to
induce EndMT. Interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor
alpha (TNF-𝛼) activate NF-𝜅B through the Akt pathway38,64. NF-𝜅B translocates to the
nucleus where it affects gene expression. It is not apparent exactly how NF-𝜅B changes
gene expression, but NF-𝜅B is required for EndMT to occur. When the NF-𝜅B inhibitor
I𝜅B𝛼 remained active in HUVECs, mesenchymal markers were not expressed 65.
Interestingly, the treatment of these cytokines themselves does not seem to create
enough stimulus to cause EndMT. IL-1β treated ECs only increased expression of SM22𝛼 when they were also treated with TGFβ, suggesting that IL-1β alone does not cause
EndMT66. These cytokines also have varying strengths of inducing EndMT, with TNF-𝛼
being a more potent inducer than IL-664.

2.1.2.3.5 Oxidative Stress
Reactive oxygen species (ROS) include hydroxyl radicals, superoxide radicals,
hydrogen peroxide, and peroxynitrite. Most ROS production is the result of NADPH
oxidase system, specifically NOX4, with which the production of ROS activates NF-𝜅B
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and leads to EndMT38,55. ROS production also activates p38, which leads to the
production of TGF-β and continues the TGF-β signaling of EndMT 38. In normal cell
functioning, TGF-β stimulates the generation of ROS, so the TGF-β pathway of inducing
EndMT will inherently cause ROS production, adding another source of EndMT
stimulus67.

2.1.2.3.6 Disturbed Flow
Areas of disturbed flow, where it was previously established that EndMT occurs,
are prone to the activation of the pathways that cause EndMT. Disturbed flow activates
inflammatory signaling, ROS production, and TGF-β 2. Areas of disturbed flow are also
prone to high blood pressure and stiffening of the vascular walls, which causes high
cyclic strain. Cyclic strain is the stretch force circumferentially experienced by ECs. This
strain further activates TGF-β, while additionally activating Wnt/β-catenin signaling.
While BVM should experience low levels of circumferential strain, it is possible that the
flow through BVMs results in inflammatory pathway activation.

2.1.2.4 Inhibitors of EndMT
Although many factors lead to EndMT onset, there are treatments to inhibit this
transition, which may be useful as cell treatments during culture. Common media
additives like FGF2 induce the expression of microRNA-20a (miR-20a). MiR-20a blocks
ALK5 (TGFβRI) and TGFβRII, inhibiting TGFβ activation of Smad2 68. FGF also
increases the expression of VEGF in ECs 54; the combination of reduced TGFβ activity
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and increased VEGF expression results in reduction of EndMT. Other proteins that, when
added to cell media, reduce EndMT include VEGF-A and BMP7 53.
Several drugs reduce the effects of EndMT, which are briefly outlined in table I.
However, some have only proven efficacy in animal models, such as Relaxin.

Table 1: Drugs that Inhibit or Reduce EndMT 53.
Drug

Effect

Linagliptin

DPP-4 inhibitor, blocks TGFβ2

Rapamycin

Blocks mTOR signaling

Relaxin

Disrupts Notch signaling

Macitentan

Endothelin-1 receptor inhibitor

Kallistatin

MMP inhibitor

Spironolactone

Aldosterone receptor blocker, inhibit Notch1 expression

Scutellarin

Reduces Notch1 expression

Losartan

Inhibits angiotensin II type 1 receptor

Cinacalcet

Suppresses hormone levels

Hydrocortisone Enhances EC adhesion

Alterations in mechanical stimuli can also reduce EndMT. Opposite to how
disturbed flow can induce dedifferentiation, laminar shear stress can protect endothelial
cells from EndMT. The activation of Kruppel-like factor (KLF) 2 and 4 by extracellular
signal-related kinase 5 (Erk5) are responsible; Erk5 is continuously activated by laminar
shear stress, and KLF2/4 are transcription factors activated downstream that have a wide
range of effects, but mainly target the NF-kB and TGFβ pathways 69,70. KLF2/4 directly
inhibits NF-kB activation while suppressing activator protein 1 (AP-1) and Smad2
28

nuclear translocation, both important proteins in the TGFβ pathway 70,71. Furthermore,
KLF4 binds to and activates the VE-cadherin promoter, leading to the stabilization of
adherens junctions72.
The investigation of laminar shear stress offers a plausible and logical starting
point to impacting and potentially reducing EndMT in the BVM model. These alterations
would not require media supplements or drugs which may be expensive, difficult to
obtain, and whose effect may have unanticipated consequences such as toxicity or
decreased cell viability. In order to determine if any treatments affect EndMT, gene
markers must be identified that correlate with EndMT progression as a result of flow
changes.

2.1.3 The Mechanosensory Complex
Mechanical connections between endothelial cells are generally known as
adherens junctions, which in ECs are important for monolayer integrity, contact
inhibition of growth, and apoptosis73. One type of adherens junction specific to ECs,
known as the mechanosensory complex, is composed of PECAM, VE-cadherin, and
VEGFR2. This set of proteins is commonly used to identify and quantify
EndMT14,21,49,50,64,69,74,75, which may also be applicable for use in characterizing EndMT
in HUVECs used for BVMs. The mechanosensory complex is not the only
mechanotransducer that causes cellular changes after exposure to flow, as shown in
Figure 10. G-proteins, primary cilia, integrins, intermediate filaments, glycocalyx,
caveolae, ion channels, and the actin cytoskeleton all have proposed roles in flow
transduction36,76. However, the mechanosensory complex is primarily responsible for
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maintaining the EC monolayer, and its functions have been well researched in relation to
EndMT. This section will discuss the proteins in this complex, how they interact, and
how they are stimulated in response to different flow conditions.

Figure 10: Types of Endothelial Mechanosensors. A depiction of the many
mechanotransducers present on endothelial cells 36.

2.1.3.1 Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1)
PECAM-1 primarily functions as a mechanosensor and transmitter of mechanical
force from shear stress to the cytoskeleton70,73,77. Shear stress induces rapid
phosphorylation of PECAM and eventual downstream phosphorylation and activation of
VEGFR2, making it the principal initiator of the mechanosensory complex when exposed
to stresses73,77. The expression of PECAM-1, as well as the phosphorylation of PECAM,
is highly dependent on cell confluence. 100% confluent HUVEC cultures showed
significantly more PECAM-1 and phosphorylated PECAM-1 expression than 50%
confluent cultures78. The Cal Poly Tissue Engineering Lab has verified through
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immunostaining that PECAM-1 expression is reduced in areas where cell confluency is
reduced, as cell-cell contact is necessary for PECAM-1 expression 20. Furthermore, for
confluent HUVEC cultures, less phosphorylated PECAM-1 was expressed after exposure
to disturbed flow versus laminar flow78. This is an important consideration, as PECAM-1
phosphorylation is necessary for mechanosensory complex function.
Several studies have investigated the role of PECAM under direct exposure of
mechanical stimuli. Ferromagnetic beads coated with PECAM-1 antibody were used to
stimulate the protein with direct mechanical force. After 10 minutes of magnetic
exposure, Western blots showed the phosphorylation of both PECAM-1 and ERK 2 79. As
previously discussed, ERK 2 is implicated in the activation of Snail, a major contributor
of EndMT, and this activation of ERK 2 was verified in ECs exposed to shear stress.
Fluorescence resonance energy transfer (FRET) based tension sensors were designed to
quantify changes in direct force across PECAM-1 during shear stress exposure 80. Shear
stress on bovine aortic endothelial cells (BAECs) resulted in an increase in tension on
PECAM-1 and an association between PECAM-1 and vimentin, an intermediate
filament81. In the same study, the role of vimentin was explored with a vimentin
knockdown, which resulted in blocking the tension increase on PECAM-1. It was
concluded that vimentin transmits the mechanical force from flow shear stress to
PECAM-1 in order to initiate downstream effects 80.
Not all literature agrees on the role of PECAM-1 during EC exposure to shear
stress, as some studies implicate it in inducing atherosclerosis instead of protecting from
or reducing atherosclerosis82. PECAM knockout mice showed reduced atherosclerotic
lesions in the aortic arch, as well as a decrease in NF-𝜅B83. This may indicate that
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PECAM-1 is associated with NF-𝜅B-induced EndMT and atherosclerosis. It may also
indicate that PECAM-1 knockout simply dampens general inflammatory signaling in
ECs36. This is most likely the case: since ENOS is deregulated in the absence of PECAM1, PECAM knockout mice have high NO production which suppresses inflammation 54.
Based on this information, the assumed role of PECAM-1 as atheroprotective remains
valid; regardless, the necessity of PECAM for transmitting fluid forces and retaining the
function of the mechanosensory complex makes it a marker of interest for this aim.

2.1.3.2 Vascular Endothelial Cadherin (VE-Cad)
While the application of force directly to PECAM-1 triggers the same responses
as flow shear stress, these effects are not seen when force is applied to VE-cad 76,80. This
demonstrates the functional difference between the two proteins; VE-cad acts as an
adaptor molecule that links the mechanical force transduced by PECAM-1 to
VEGFR270,73,76,84. This is achieved through the formation of complexes that bind to the
actin cytoskeleton that then transfer signals within ECs 70,77,85. These complexes are
formed with alpha and beta catenin, plakoglobin, vinculin, and cingulin 77. VE-cad binds
directly to ꞵ-catenin or plakoglobin, which then binds the actin binding protein αcatenin86.
VE-cad is the major determinant of EC contact integrity, so remodeling of VEcad is important to adapt to changes in stimulus 77,86. During angiogenesis the interactions
formed between VE-cad and neighboring cells, as well as the interactions between VEcad and cytoplasmic proteins, must be broken to allow cell migration and for new cellcell adhesions to form87. VE-cad interactions are also disrupted with increased matrix
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stiffness due to changes in cytoskeletal mechanics, resulting in increased EC monolayer
permeability73. Arterial fibrosis associated with EndMT results in positive feedback
where increasing matrix stiffness disrupts EC monolayers and encourages uncontrolled
cell migration. This relaxation of the EC monolayer was demonstrated with FRET-based
tension sensors which saw a rapid 25% decrease in tension across VE-cad with the onset
of flow80.
VE-cad plays other important role in response to flow in vitro. VE-cad depleted
ECs aligned at lower rates than depleted cells transfected with VE-cad after exposure to
12 dynes/cm^2 of shear stress for 18 hours88. VE-cad expression does not change in VEcad depleted cells exposed to static or shear flow, but expression doubled in VE-cad
positive cells exposed to shear stress versus a static condition 14. Therefore, VE-cad
expression is necessary for HUVECs used in BVMs to align in the direction of flow.
VE-cad also has an important relationship with KLF4, which was previously
discussed as an inhibitor of EndMT. VE-cad is transcriptionally regulated by KLF4, in
which KLF4 binds the promoter region of VE-cad and induces VE-cad transcription 72.
This promotes VE-cad interactions to sustain the EC monolayer, helping to reduce cell
migration and EndMT. VE-cad may be a useful marker to study in HUVECs intended for
BVMs, as high expression of VE-cad would suggest EndMT inhibition.

2.1.3.3 Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
VEGFR2 is the component of the mechanosensory complex that activates
biochemical signaling and is necessary for EC migration, proliferation, angiogenesis, and
regulation of cell death73,85. VEGFR2 is the main RTK that mediates VEGF signaling,
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and thus will be focused on even though VEGFR3 has recently been recognized as a
member of the mechanosensory complex73. Binding of VEGF to VEGFR2 initiates
activation of PI3K and MEKK3, causing downstream activation of Akt and
MEK5/Erk570. Erk5 is an inhibitor of EndMT and activates KLF2/4 which promotes VEcad transcription, demonstrating only one of many interactions between VE-cad and
VEGFR2. The role of VEGFR2 is highly dependent on its interaction with VE-cad and
should therefore be discussed together.

2.1.3.4 VE-Cadherin Regulation of VEGFR2
VE-cad alters cell proliferation and apoptosis through modulating VEGFR2
function. Cell confluence is one critical component on which VE-cad acts to inhibit
VEGFR2 function in vitro. Cadherins in general, including VE-cad, transfer negative
intracellular signals upon the establishment of cell-cell contact such as when confluence
is reached. This results in a decreased response to growth factors like VEGF.
Lampugnani et al. investigated the relationship between confluent or sparse VE-cad-null
and VE-cad-positive cells stimulated with or without VEGF85. VE-cad-null cells
continued growth into over-confluence, while VE-cad-positive cells arrested growth at
confluence, demonstrating the growth restricting role of VE-cad. VE-cad-null cells were
responsive to VEGF regardless of confluence, while VE-cad-positive cells were only
responsive in the sparse condition. The lack of response in the VE-cad-positive confluent
condition was associated with a reduction of VEGFR2 phosphorylation. The same trend
was verified in HUVECs, where an upregulation of VEGFR2 phosphorylation in VEGF
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occurred in sparsely distributed cells. The role of cell density on expression will be
important to control during experiments studying VE-cad and VEGFR2.
That study, as well as others, ultimately concluded these interactions were a result
of VE-cad forming a complex with VEGFR2 and density-enhanced receptor-like tyrosine
phosphatase (DEP-1)14,85,88. In sparse ECs in vitro, VEGF binds VEGFR2 to activate the
Erk1/2 pathway. Erk1/2 phosphorylates VE-cad, which causes the detachment of ꞵcatenin from VE-cad. ꞵ-catenin translocates to the nucleus where it initiates transcription
that results in cell proliferation. In confluent ECs, DEP-1 congregates at cell-cell
junctions and inhibits Erk1/2 phosphorylation of VEGFR2, blocking ꞵ-catenin
detachment and nuclear translocation89,90. This mechanism is depicted in Figure 11.

Figure 11: Mechanisms of VE-Cad and VEGFR2 on Cell Seeding Density 89.

While those interactions are important for understanding the mechanosensory
complex in quiescent EC monolayers in vivo and in vitro, it lacks the context of how
these interactions fare with alternative, non-physiologic flow conditions such as in
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BVMs. Parallel plate flow models showed that, upon exposure to shear stress, VEGFR2
expression increased and VE-cad promoted VEGFR2 activation instead of inhibiting
it91,92. ꞵ-catenin phosphorylation increased in HUVECs exposed to shear stress,
indicating that cells were being induced into a proliferative state 93. The same study found
that fluid shear stress causes the dissociation of VE-cad and ꞵ-catenin. While the
mechanism isn’t entirely elucidated, shear stress ultimately contributes to EC survival by
VEGFR294. Interestingly, the type of laminar flow does not affect cell survival in vitro. A
TUNEL assay of cells exposed to static media, steady laminar flow, pulsatile laminar
flow, and to-and-fro laminar flow showed no difference in percent of apoptotic cells 95.
The length of time in which cells are exposed to these conditions plays a key role in VEcad and VEGFR2 activation, and this duration is key for the induction of EndMT.

2.1.3.5 Mechanosensory Complex and EndMT
The important roles of the mechanosensory complex in maintaining EC
monolayers and in flow signaling is undisputed, making it an ideal candidate for
understanding and quantifying EndMT in ECs in culture or in BVMs. For this, and to
better understand the second component of Aim 1, the focus must shift back to the effects
of laminar versus disturbed flow on ECs and how the mechanosensory complex changes.
The general difference between these two flow conditions that should be emphasized are
as follows: ECs adapt to flow under laminar flow so that EndMT events are
downregulated after the initial stimulation, while these events are sustained in disturbed
flow14. An important example of this involves the activation of Erk1/2 by both PECAM
and VEGFR2. Erk1/2 activation stimulates the TGFꞵ pathway, activates Snail, and
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eventually leads to EndMT. However, this activation comes with the same caveat, where
type of flow is the major consideration in adaptive expression versus sustained
expression. While expression of Erk1/2 is sustained over time, the phosphorylated form is
not sustained in laminar flow50.
The general characteristics of EndMT, identified by expression of
mechanosensory complex markers, is the downregulation of PECAM-1, VE-cad, and
VEGFR2. Therefore, if EndMT was occurring during HUVEC culture or BVM creation,
all three of those markers would be downregulated. In the case of partial EndMT or
partial laminar flow, the expression profile of the mechanosensory complex would not be
as straightforward. While stimulation of the mechanosensory complex changes
expression of the endothelial markers of EndMT, it does not capture fibrotic changes to
the endothelial cells. These changes are evaluated through upregulation of mesenchymal
markers.

2.1.4 Mesenchymal Markers
EC markers indicate the extent of EndMT away from endothelial characteristics,
but mesenchymal markers (also referred to as smooth muscle or fibroblast characteristics
in the literature) indicate the extent of EndMT towards the fibrotic state. Common
markers include 𝛼-smooth muscle actin (𝛼SMA), transgelin (SM22𝛼), fibroblast specific
protein 1 (FSP-1), calponin, and smooth muscle-myosin heavy chain 2 (SMMHC2)21,49,50,62,64,69,74,75. These markers will generally be associated with cells double
positive for EC and mesenchymal/SMC markers, which identify intermediate stages of
EndMT.

37

Smooth muscle cell differentiation can give insight into mesenchymal marker
onset in EndMT. Five molecular markers are commonly used to assess SMC
differentiation, which are also markers used to assess EndMT. These include 𝛼SMA,
transgelin, calponin, caldesmon, and myosin heavy chain (MHC), where 𝛼SMA and
transgelin are early markers of SMCs and calponin, caldesmon, and MHC are
intermediate to late markers96. The early expression of 𝛼SMA and its abundance in
differentiated SMCs makes 𝛼SMA the most widely used marker for EndMT
identification74. Therefore, 𝛼SMA is a candidate to include in EndMT evaluation for this
aim, especially because 𝛼SMA expression has already been observed in HUVECs used in
BVMs.
The pathways of EndMT previously discussed stimulate the onset of these
mesenchymal markers, especially through the TGFꞵ pathway. TGFꞵ stimulates the
expression of many genes associated with fibrosis, including varieties of collagen and
fibronectin, through Smad2/3 and p38 MAPK activation. This pathway also induces
collagen cross-linking, which increases stability, and stimulates the synthesis of protease
inhibitors, increasing ECM production62. In vitro analysis reveals the onset of
mesenchymal markers through TGFꞵ stimulation. HUVECs in static media stimulated
with TGFꞵ were found to increase expression of calponin and transgelin, while the same
cells in laminar flow did not increase expression of mesenchymal markers 50. This
indicates that EndMT can be induced without flow induction. Erk5, which protects EC
monolayers from EndMT, was then silenced and resulted in increased calponin and
transgelin expression regardless of the flow condition with TGFꞵ stimulation. A different
study used orbital shakers without TGFꞵ stimulation to induce disturbed flow. They
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found that HUVECs in this these conditions expressed Snail, Slug, and αSMA, markers
which indicate that disturbed flow alone was enough to activate EndMT pathways 69.
Mesenchymal markers are also found in vivo in EC monolayers. ECs positive for
αSMA have been found in the aorta of rats, mice, and humans; these cells were
determined to be of EC origin based on their co-expression of VE-cad with αSMA 74.
While these cells were sparsely distributed, the presence of these cells displays EndMT
progression in an atheroprone region. Mesenchymal markers are also abundant in
atherosclerotic plaques, where EndMT contributes to cell migration and
transdifferentiation in these plaques. Atherosclerotic lesions on a porcine bifurcation
expressed αSMA, transgelin, and calponin; similarly, human atherosclerotic plaque was
shown to co-expresses PECAM-1 and αSMA13.

2.1.5 Using Endothelial and Mesenchymal Markers to Determine EndMT
Progression
The Tissue Engineering Lab should be concerned with EndMT at all stages of
BVM fabrication. EndMT can result from both static culture and disturbed flow.
Therefore, the first consideration for this aim was whether the sodded ECs are sustaining
an EC phenotype after their time in culture, defined by a cobblestone appearance and the
expression of endothelial markers without mesenchymal markers. It has previously been
noted that ECs cultured in the Tissue Engineering Lab develop a spindle-like phenotype
over time in culture. This consideration has been verified in literature. Freshly isolated
adult bovine ECs positive for VE-cad and PECAM-1 displayed EndMT over time in
static culture21. At day one of culture, cells displayed a cobblestone appearance and were
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negative for SMC marker expression. By the second day of culture, cell-cell contact was
disrupted and 𝛼SMA was lightly expressed. By day 5 ECs acquired an elongated
morphology, increased 𝛼SMA expression, and no longer expressed VE-cad. Flow models
have also displayed EndMT onset. In a bifurcation model of flow, in which areas
downstream of the bifurcation were characterized by disturbed flow, shown in Figure 12,
VE-cad expression decreased while transgelin expression increased 49. Collagen I was
also prevalent in the area of disturbed flow, which is the most prevalent collagen type in
atherosclerotic plaques. The onset and co-expression of EC and mesenchymal markers
allow for EndMT assessment in vitro. However, to understand the progression of
EndMT, changes in mesenchymal and endothelial markers must be quantified.

Figure 12: VE-cad and Transgelin Expression in a Simple Flow Model. (1) VE-cad is
expressed upstream. (2) Upon turbulent flow induction transgelin expression is present 50.

2.1.6 RT-qPCR Background
Studies of gene expression have previously been implemented in the Tissue
Engineering Lab11,18, and the technique of reverse transcription quantitative polymerase
chain reaction (RT-qPCR) has been used throughout literature to identify changes in
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EndMT49,50,59,69,97–99. For the characterization of ECs, this technique is a powerful and
efficient method of determining alterations in genes that are associated with a
mesenchymal phenotype over an endothelial phenotype. This technique quantifies the
amount of mRNA present in a cell with the assumption that these mRNA will become
proteins and effect cell function and behavior. However, total RNA, not specifically
mRNA, is often used; total RNA involves fewer purification steps, a higher yield, and
less chance of skewed results from different recovery yields. Therefore, total RNA is
more often used since relative quantification of the genes of interest (GOI) is more
important than the sensitivity of detection of mRNA 100. Paired with properly designed
experiments, qPCR data can convey changes in gene expression across many treatments
groups and communicate trends within these groups.
Before beginning qPCR, the RNA of cells must be isolated. Kits for RNA
isolation are readily available from manufacturers, but there are methods that do not
require kits which yield high purity RNA. Next, the single stranded RNA must be diluted,
to normalize the amount of RNA per treatment group, and made into double stranded
complementary DNA (cDNA) for use as template DNA. cDNA is produced by adding
RNA, unpaired nucleotides (dNTPs), DNA polymerase, and reverse transcriptase to a
thermocycler to create one cDNA molecule for every RNA strand added. This cDNA can
then be used for qPCR, where the cDNA, primers specific for each GOI, probes, dNTPs,
and DNA polymerase are combined and added to a thermal cycler that heats and cools
the samples repeatedly, replicating the template strand. Primers that bind to each
replication fluoresce to indicate a new replicate of the GOI, and this fluorescence is
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counted by a camera. The thermocycler repeats this for forty cycles, generating an
amplification curve with the amount of fluorescence at each cycle for every sample 11,101.
As the cycles increase during qPCR, fluorescence linearly increases until a
plateau is reached indicating that all dNTPs have been depleted. A common threshold of
fluorescent intensity is established to compare the amount of cycles necessary for each
sample to achieve that threshold, in which this cycle number is known as the cycles to
threshold (Ct)17. This Ct value is the numerical value used in the analysis of the data. The
Ct value is shown in Figure 13 at the intersection of the amplification curve and threshold
line.

Figure 13: qPCR Amplification Curve. An example amplification curve with the three
phases and threshold labeled 17.

The fluorescence measurement is the “quantitative” portion of qPCR and results
from the type of probe used in the primers. Therefore, the function of these probes must
be expanded on. Primers are a short single strand of nucleotides that serves as the starting
point for DNA synthesis. During each cooling cycle by the thermocycler primers initiate

42

the extension of new double stranded DNA (dsDNA) from the single stranded DNA
(ssDNA). During this extension probes are utilized to indicate the replication of the
template DNA, in which two main types of probes are commonly used: SYBR Green and
TaqMan. TaqMan probes, also known as hydrolysis probes, are composed of a
fluorescent reporter and quencher attached to a specific nucleotide sequence. During
annealing the probe binds to the specific target sequence. As extension occurs, the
quencher is cleaved from the probe. The change in proximity of the quencher allows the
reporter to fluoresce. These probes, while more specific, are also far more expensive than
SYBR Green probes. Therefore, SYBR Green probes were used in all experiments in this
thesis. SYBR Green is a DNA-binding dye which binds nonspecifically to any dsDNA.
Figure 14 depicts how SYBR Green intercalates within the nucleotides of the extending
dsDNA, and this binding event causes fluorescence of the dye 102.

Figure 14: Types of Primers. Depictions of SYBR Green intercalation in double
stranded DNA versus TaqMan labeling103.
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Since SYBR Green binds to any dsDNA, it is possible to have fluorescence
measured when non-template DNA intercalates SYBR Green. One example of this is
primer-dimer formation, when two primers hybridize to each other, which leads to false
fluorescence measurements. Therefore, a dissociation (or melt) curve must be run when
using SYBR Green after the amplification cycle to test that the qPCR assay has yielded
single, specific products104. The dissociation curve measures the change in fluorescence
when the SYBR Green dissociates from the dsDNA as temperature increases 101. Ideally,
qPCR products will melt at the same time, so the resulting change in fluorescence over
time will result in a similar curve between samples. These ideal curves are labelled
“specific products” in Figure 15.

Figure 15: Example Dissociation Curves. Dissociation curves can be used to
distinguish PCR products from false signals caused by primer dimers 105.

Housekeeping genes are necessary for any qPCR experiment in order to analyze
the Ct values. These genes are selected to have stable expression regardless of treatment
44

group, which is then used to normalize the Ct values between experimental groups. While
many genes theoretically fit this requirement, there is no agreed upon, consistently stable
housekeeping gene. Housekeeping genes must be selected and verified based on the
experiment type in which they will be used. Two housekeeping genes were initially
selected for Aim 1. The first, 𝛽-actin (𝛽ACT), is one of several types of actin that are a
part of the cytoskeleton microfilaments. It is commonly used in experiments regarding
EndMT106–109. The second, 𝛽 glucuronidase (GUS𝛽), is an enzyme involved in the
breakdown of glycosaminoglycans (GAGs) in lysosomes110. Both GUS𝛽 and 𝛽ACT were
shown to be a stable reference gene for experiments using HUVECs when challenged
against many other common housekeeping genes 111,112.

2.1.7 Summary
This introduction to Chapter 2 has discussed a variety of topics in order to gain an
understanding of all components that apply to this aim. A stark difference between
physiologic and BVM flow conditions was established. Normal EC phenotype was
defined and compared against the phenotype of ECs undergoing EndMT. A general, yet
comprehensive, review of EndMT was provided in order to understand the complexity of
EC dedifferentiation in vitro and in vivo. This introduction identified EC markers and
mesenchymal markers that can be useful in identifying gene expression changes. Finally,
an introduction to qPCR was presented, which will be the primary analysis method of EC
characterization in the following section. The following section will describe the methods
that were used in this aim to culture cells, implement a disturbed flow condition, create
BVMs, and perform qPCR to evaluate phenotype and EndMT markers in HUVECs.
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2.2 Materials and Methods

2.2.1 Gene Selection and Primer Acquisition
Many relevant genes were identified and discussed in Section 2.1. This list needed
to be narrowed down to identify only a few genes of interest (GOI). To track EndMT
progression representative endothelial and mesenchymal markers had to be selected. It
was decided that genes coding for the three main proteins of the mechanosensory
complex would be used as endothelial markers: PECAM-1, VE-Cadherin, VEGFR2. The
genes 𝛼SMA and calponin were selected as mesenchymal markers, with 𝛼SMA as an
early indicator of mesenchymal acquisition and calponin as a late transition marker. The
markers 𝛽ACT and GUS𝛽 were chosen as housekeeping genes.
With GOI selected, primers for each gene needed to be acquired. Previous
projects attempted to design primers, resulting in poor primer selection. Therefore,
preverified primers were used throughout all experiments. PrimeTime qPCR primers
(IDT, Coralville, IA) were ordered, which include forward and reverse primers that have
already been tested for greater than 90% efficiency. Sequences of the primers, as well as
other primer characteristics, can be found in Appendix A.
Primer assays, which include both the forward and reverse primer, were
resuspended in 500 µL of IDTE buffer for a final desired concentration of 20x. While
these preverified primers are guaranteed to have an efficiency of greater than 90%, it was
still necessary to test primer efficiency once resuspended to ensure that storage and
resuspension had not affected the quality of the primers. Primer efficiency shows how
well the target sequence doubles during each replication cycle. If each molecule of target
sequence doubles during each cycle, the primer has an efficiency of 100%. It is necessary
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to verify that efficiencies are between 90% and 110% to correctly analyze results.
Calculations of gene expression assumes that primer efficiencies are comparable between
primers113.
Primer efficiency was calculated by running a logarithmic dilution of cDNA with
each primer, then evaluating the slope of the Ct values for the dilutions. The efficiency
(E) percentage was calculated using this slope, which can be seen in Equation 1.

Equation 1

Efficiency (%) = (10(-1/Slope)-1)*100

The protocol for primer efficiency testing can be found in Appendix B. PECAM1,
VEGFR2, VE-cadherin, and GUS𝛽 used the same HUVEC cDNA to test for efficiency,
while ACTA2 and CNN1 used SMC cDNA. The use of SMC cDNA was necessary since
there was not a high enough expression of ACTA2 and CNN1 in the HUVEC cDNA to
accurately dilute cDNA and observe a linear decrease in cycles to threshold.

2.2.2 RNA Isolation
Several commercial kits are available for RNA isolation. The RNeasy Mini Kit
(QIAGEN) has previously been used to yield high purity RNA, so the use of this kit was
continued for experiments with cells only (the kit cannot be used for RNA isolation from
BVMs). The RNeasy kit uses spin columns to isolate up to 100 µg of RNA longer than
200 bases. A high-salt buffer system binds RNA to silica membranes 114. The samples
were first snap-frozen in liquid nitrogen to preserve the RNA and disrupt the cell
membranes. The samples were then lysed and homogenized before binding to the
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RNeasy spin column, where multiple wash steps purify the RNases. The final RNA
product was eluted from the membranes using water.
Once RNA was isolated, the purity and concentration of the RNA product was
assessed. The NanoDrop 2000 Spectrophotometer (Thermo Scientific) was used to
measure 2 µL RNA samples. The spectrophotometer measures the absorbance of a
solution and breaks the signal into functions of wavelength. Measurements on nucleic
acid content include concentration, A260, A280, 260/280, and 260/230. The
concentration is measured as ng/nL based on the absorbance at 260 nm; this measurement
is important in order to normalize the amount of RNA added to each reverse transcription
reaction. A260 and A280 are the absorbance at 260 and 280 nm, respectively. The
260/280 and 260/230 measurements are ratios of absorbance that indicate the purity of
the RNA. A 260/280 ratio of approximately 2.0 is accepted as pure, and values above or
below 2.0 indicate a contaminant near 280 nm. The 260/230 ratio is a secondary
measurement of purity with an accepted ratio between 1.8 and 2.2 115. A full protocol for
RNA isolation using the RNeasy Mini Kit and purity assessment using the NanoDrop
2000 can be found in Appendix C.

2.2.3 Reverse Transcription
After verifying that the purity of isolated RNA was acceptable, cDNA was
synthesized through reverse transcription. The iScript cDNA Synthesis Kit (Bio-Rad)
contains only three components: 5x iScript Reaction Mix, iScript Reverse Transcriptase,
nuclease-free water. The reaction mix contains a blend of oligo(dT) and random hexamer
primers. The reverse transcriptase is RNase H+, which improves the amplification
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sensitivity, and contains RNase inhibitors to prevent sample degradation 18,116. The RNase
free water was used to dilute RNA concentrations to maintain constant concentrations
across all samples. That way, the same amount of cDNA product will be created, and
amplification during qPCR will not be a factor of cDNA concentration. The equation for
calculating the volume of RNA to add per sample is shown in Equation 2 for 1000 ng of
RNA per sample. The calculated volume of water was subtracted from 15 uL to
determine the volume of water needed for the reaction.

Equation 2

(1000 ng RNA)*(1 mL/[RNA concentration] ng/nL) = [Volume RNA] µL

The 5x iScript Reaction Mix, reverse transcriptase, nuclease-free water, and RNA
were added to a nuclease free tube. Each reaction contains a total of 20 µL per well. After
loading the samples in a thermocycler, the samples were heated and cooled for one cycle
to produce the double-stranded cDNA. The samples were then diluted with 80 µL of
nuclease-free water and stored at -20 C. The full protocol for cDNA synthesis can be
found in Appendix D.

2.2.4 Quantitative Polymerase Chain Reaction
Once ds cDNA was synthesized and diluted, qPCR was performed. SYBR Green
dye was used for the reactions, in which the Fast SYBR Green Master Mix (Life
Technologies) was used. This master mix contains SYBR Green dye, DNA polymerase,
uracil-DNA glycosylase, ROX passive reference dye, and dNTPs 117. In a 96-well plate, 4
µL SYBR Green Master Mix, 3.2 µL cDNA, 1 µL primers, and 11.8 µL of water was
loaded in each well for a total reaction volume of 20 µL. Triplicates of each sample were
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run, as well as non-template controls (NTCs) for each primer. NTCs contain no cDNA
(the volume of cDNA is replaced by water) and are included to monitor for
contamination and primer-dimer formation, both of which could produce false positive
results118.
Once loaded into the well plate, the plate was placed into the qPCR 7500 Fast
System (Applied Biosystems). A standard run time was selected, to which the cycle
settings can be found in Appendix E, and a dissociation cycle was added. After the cycles
were complete, the Ct values were exported for analysis. Several assumptions must be
verified for different qPCR analysis methods. The method selected for this thesis, relative
abundance, assumes a primer efficiency with an efficiency of 2 and a stable reference
gene were used. The assumption of primer efficiency was checked and verified as
described in Section 2.2.1, and the assumption of using a stable reference gene was
checked after each experiment. Relative abundance was measured by the 2 -ΔCt value,
where ΔCt is calculated as shown by Equation 3.

Equation 3

ΔCt = Ct(GOI) - Ct(reference gene)

2.2.5 Experiment 1 Pilot: Change in EC Expression with Increasing Passage
Number
As previously established, the goal of Aim 1 was to determine how endothelial
cell-gene expression changes in respect to passage number and flow conditions, with the
understanding that increased time in culture and disturbed flow should contribute to
EndMT. The effect of increasing time in culture was initially investigated. This
preliminary pilot served to establish an understanding of how gene expression changed
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during just a few passage numbers, as well as to check the stability of the housekeeping
genes as passage number increased. RNA was isolated from HUVECs at passages 4, 6, 7,
8, 9, and 10, cDNA synthesized, and qPCR run. Relative abundance was calculated, and
this data, along with the results of the dissociation cycle, were analyzed. Ct values for the
housekeeping genes 𝛽ACT and GUS𝛽 were also examined in order to determine the
viability of the genes as housekeepers.

2.2.6 Experiment 1: Change in EC Expression with Increasing Passage Number
Experiment 1 served as a more thorough investigation of the goals established by
the Experiment 1 Pilot. The goal of the experiment was still to examine changes in gene
expression as culture time increased as well as to add more passage number conditions
for the HUVECs. This experiment also added SMCs at early and late passages to
compare mesenchymal marker expression to endothelial expression of the same markers.
RNA was isolated from HUVECs at passage 3, 5, 7, 9, 11, and 13, whole RNA was
isolated from SMCs at passage 6 and 11.

2.2.7 Experiment 2: Changes in EC Expression from Disturbed Flow Conditions
Experiment 2 investigated the effect of disturbed flow on EC gene expression;
disturbed flow should induce changes in gene expression towards a mesenchymal state.
In order to mimic disturbed flow conditions, 6-well plates of HUVECs were secured to
an orbital shaker in an incubator and allowed to run at 210 RPM for 24 hours. This
technique was borrowed from Mahmoud et al., which found that the orbital shaker caused
low shear stress (about 5 dyne/cm2) with variations in direction in the center of the 6-
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well, and high shear stress (about 15 dyne/cm 2) at the edge of the 6-well with uniform
flow direction69. However, since it was unknown to what extent these conditions would
cause changes in gene expression towards a mesenchymal phenotype, a positive control
was necessary. Therefore, HUVECs were cultured in SMC specific media for 48 hours,
which will induce phenotypic changes in HUVECs towards a mesenchymal phenotype.
This would serve as the positive control for which to compare the HUVECs exposed to
disturbed flow. HUVECs cultured in static conditions were used as a no-treatment group.
The static, disturbed flow, and SMC-media conditions included passage numbers 6, 10,
and 14.

2.2.8 Experiment 3 Preparation: Development of RNA Isolation Protocol for BVMs
The previous experiments used only cells cultured in dishes. In order to
investigate the changes in gene expression of cells in a BVM, the RNeasy Mini Kit for
RNA isolation could not be used. Therefore, a new isolation protocol needed to be
developed and verified for high purity and appropriate concentration RNA. One method
to isolate RNA from BVMs was to homogenize the BVM, scaffold and cells, into a
solution and then isolate the RNA. Trizol (Life Technologies) isolation is a common
procedure in which tissue is homogenized in Trizol and then RNA is extracted from that
solution. This method was pursued for RNA isolation from BVMs.
Many protocols for Trizol isolation are available, and most have only minor
differences. A reliable protocol that had been used previously at an internship was
employed for the isolation in this thesis, and can be found in Appendix C. The BVMs
were frozen in liquid nitrogen directly after removal from bioreactors and stored at -80 C
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until use. The BVMs were then cut into small pieces using scissors, and 5 mL of Trizol
was added before homogenizing the BVM in the Trizol using a TissueRuptor (Qiagen).
Chloroform was added to the homogenate, and the solution was centrifuged to separate a
Trizol and aqueous phase. The aqueous phase, which contains the RNA, was removed
and added to 99% IPA. GlycoBlue (Thermo Fisher Scientific) was also added to the
solution before centrifugation. The supernatant was removed, leaving only a blue pellet
containing RNA in the bottom of the centrifuge tube. The pellet was resuspended in 75%
EtOH and stored at -80 C overnight. The following day the tube was centrifuged, and the
supernatant removed. The pellet dried completely before resuspending in nuclease-free
water. The RNA purity and concentration were checked as described in Section 2.2.2.
In order to compare the product of this isolation protocol against the RNA
isolation from the RNeasy Mini Kit, both protocols were used for the isolation of RNA
from HUVECs. The purity and concentrations were then compared to determine whether
the Trizol isolation was comparable to the RNeasy isolation.

2.2.9 Experiment 3 Pilot: Changes in Gene Expression in BVMs
Having already investigated HUVECs in static culture and in disturbed flow, as
well as having developed an RNA isolation protocol for use on BVMs, the proper criteria
had been met to investigate gene expression changes in BVMs. This pilot experiment
used only two BVMs that ran for 24 hours. A static condition and a disturbed flow
condition were also used to compare all three flow types. The passage number was kept
constant in this pilot to remove the variability of expression as cells remain in culture for
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different lengths of time. The three flow condition groups (BVM, static, and disturbed
flow) used HUVECs at passage number 6.
The disturbed flow condition with HUVECs in 6-well plates underwent a ramp-up
period on the orbital shaker. This change was implemented as a result of a high percent of
cell death in the disturbed flow groups in Experiment 2. The ramp-up period increased
the orbital shaker from 50 RPM to 200 RPM at intervals of 50 RPM every 2 hours. The
plates remained at 200 RPM for 24 hours.

2.3 Results

2.3.1 Primer Efficiency
Preverified primers should not need to be checked for efficiency; however,
appropriate efficiencies are necessary to meet the assumptions for relative abundance
calculations. A representative graph of primer efficiency is shown in Figure 16, and all
efficiency plots can be found in Appendix G. Slope, R 2, and efficiency percentage values
for all GOI can be found in Table 2. Efficiency percentages ranged from 86.5% to 99.5%,
with GUS𝛽 having the lowest efficiency. An efficiency range between 90% and 110% is
adequate to meet the assumptions for relative abundance, of which VEGFR2 and GUS𝛽
fell outside of this range at 86.5% and 88.6%, respectively. All R 2 values were above
0.97, in which this linearity indicates pipetting accuracy for the dilutions. The efficiency
for 𝛽ACT was not calculated, as this gene had already been eliminated as a viable
housekeeping gene at the time of efficiency testing. This decision will be discussed in
Section 2.4.
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Figure 16: Primer Efficiency Plot. Representative primer efficiency graph of the log of
the cDNA dilution factor versus the average Ct value. The slope of the trendline is used
for efficiency calculations.

Table 2: Primer Efficiency. Efficiency data from GOI, which includes the slope, R 2, and
efficiency percentage.
Slope

R2

Efficiency (%)

PECAM

-3.3333

0.9714

99.52761

VEGFR2

-3.6301

0.999

88.57083

VE-Cadherin

-3.4575

0.9988

94.63741

ACTA2

-3.3482

0.9943

98.91519

CNN1

-3.4528

0.9848

94.81393

GUS𝛽

-3.6939

0.9979

86.51621

2.3.2 Experiment 1 Pilot Results
This pilot served to investigate the effect of static culture time on gene expression
in HUVECs, evaluate 𝛽ACT and GUS𝛽 as housekeeping genes, and accumulate data in
order to better design Experiment 1. Figure 17A shows relative abundance of all GOI as
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compared to 𝛽ACT. VE-cadherin had the highest abundance among the GOI, followed
by VEGFR2. A slight trend can be seen for both VE-cad and VEGFR2, with increasing
abundance as passage number increased. VEGFR2 followed this trend except at passage
6. VE-cad had a maximum abundance at passage 8, where abundance slightly decreased
at passages 9 and 10. The high abundance of VE-cad made identifying trends in PECAM,
ACTA2 and CNN1 expression difficult, so Figure 17B shows the same data as Figure
17A but excluded VE-cad and VEGFR2 data. Interestingly, PECAM and ACTA2 had
similar abundance in HUVECs regardless of the passage number. Calponin had almost no
expression.
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A

B

Figure 17: Experiment 1 Pilot Relative Abundance Relative to 𝛽-Actin. (A) Relative
abundance of all genes of interest using 𝛽-Actin (𝛽ACT) as the housekeeping gene. (B)
Platelet Endothelial Cell Adhesion Molecule (PECAM), Alpha Actin (ACTA2), and
Calponin (CNN1) relative abundance using 𝛽ACT as the housekeeping gene.

Figure 18A shows relative abundance levels of all GOI compared to GUS𝛽 as the
housekeeping gene. Like the previous figure, Figure 18B shows the same data as Figure
18A but excludes VE-cad and VEGFR2. The trends of VE-cad and VEGFR2 relative to
GUS𝛽 followed closely with the trends compared to 𝛽ACT. However, the abundance
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levels compared to GUS𝛽 were about half that as when compared to 𝛽ACT. PECAM and
ACTA2 also had lower abundance levels when compared to GUS𝛽 than 𝛽ACT. No trend
persisted for PECAM or ACTA2 as passage number increases. Furthermore, calponin
had almost no expression.
A

B

Figure 18: Experiment 1 Pilot Relative Abundance Relative to 𝛽 Galactosidase. (A)
HUVEC relative abundance of all genes of interest using 𝛽 Galactosidase (GUS𝛽) as the
housekeeping gene. (B) HUVEC relative abundance of PECAM, ACTA2, and CNN1
using GUS𝛽 as the housekeeping gene.
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It is important to check for the stable expression of housekeeping genes during
every experiment to determine whether new treatment groups affect the genes viability as
a housekeeper. Figure 19 shows plots of the average Ct for 𝛽ACT and GUS𝛽 at each
passage number. The Ct average for 𝛽ACT was variable between groups, ranging from
20.87 and 24.10 cycles. GUS𝛽 displayed more stable Ct values, which range between
20.77 and 21.26 cycles.
A

Figure 19: Experiment 1 Pilot Housekeeping Gene Stability. Average Ct values of (A)
𝛽ACT and (B) GUS𝛽 from each treatment condition.

2.3.3 Experiment 1 Results
Based on the results of the previous pilot study, Experiment 1 increased the range
of passage numbers in order to accentuate any trends that were previously identified and
to reveal other trends that may exist in HUVECs in static culture. Experiment 1 also
added an early and late passage of HUASMCs to compare the expression of
mesenchymal markers between HUVECs and HUASMCs. Since 𝛽ACT Ct values were
more variable than GUS𝛽 in the pilot, expression of the housekeeping genes were
analyzed first before analyzing relative abundance data. Figure 20 displays how 𝛽ACT Ct
values fluctuated between 16.83 and 25.46 cycles, while GUS𝛽 Ct values remained
relatively stable between 17.44 and 20.37 cycles. As a result of the instability of 𝛽ACT
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identified in the pilot and this experiment, 𝛽ACT was eliminated as a housekeeping gene.
From this point forward, only GUS𝛽 was used while running qPCR and during data
analysis.
A

Figure 20: Experiment 1 Housekeeping Gene Stability. Average Ct values of (A)
𝛽ACT and (B) GUS𝛽 from each treatment condition.

Figure 21A shows the relative abundance of all GOI in HUVECs of increasing
passage number in static culture. VE-cad and VEGFR2 had a positive trend between
relative abundance and passage number. Consistent with the results of the pilot study,
these two EC markers were more highly expressed than PECAM. No trends were
identified in expression of PECAM and ACTA2, as seen in Figure 21B. Calponin
abundance was negligible in HUVECs.
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A

B

Figure 21: Experiment 1 Relative Abundance. HUVEC relative abundance of (A) all
GOI and (B) PECAM, ACTA2, and CNN1 using GUS𝛽 as the housekeeping gene.

Relative abundance of mesenchymal markers ACTA2 and calponin in early
passage (passage 6) and late passage (passage 11) HUASMCs in static culture are shown
in Figure 22. ACTA2 was highly expressed compared to calponin in HUASMCs.
Expression of ACTA2 and calponin in HUVECs was almost negligible when compared
to expression in HUASMCs.
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A

Figure 22: Experiment 1 Pilot Relative Abundance of Mesenchymal Markers in
SMCs. (A) HUASMCs relative abundance of ACTA2 and CNN1 using GUS𝛽 as the
housekeeping gene. (B) HUASMC relative abundance of CNN1 using GUS𝛽 as the
housekeeping gene.

SYBR Green dye will intercalate any double stranded DNA, including primerdimers and contaminating DNA. Dissociation curve analysis will detect whether primerdimers or contaminating DNA are present in the qPCR product, and in this way is a
check of quality for a single product. A dissociation curve for a product will have a single
peak at the same temperature for genes of the same type regardless of treatment. Figure
23 displays examples dissociation curves for each GOI. Dissociation curves were
analyzed prior to the analysis of each data set to identify individual samples or entire
groups that had abnormal dissociation curves.
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Figure 23: Representative dissociation curves of all GOI. (A) 𝛽ACT, (B) GUS𝛽, (C)
VEGFR2, (D) VE-cad, (E) PECAM, (F) ACTA2, (G) calponin from ECs, (H) calponin
from SMCs.
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Dissociation curves appeared acceptable for all except one GOI. Figure 23G
shows the dissociation curve from PCR products for calponin from ECs. These curves
had several peaks and low derivative values, indicating poor quality of PCR product.
However, this most likely occurred because not enough product could be produced since
the abundance of calponin was so low in ECs. The dissociation curve for calponin from
SMCs, shown in Figure 23H, showed a single peak. Therefore, the primer was still
verified to be working properly and producing high quality PCR products. Figure 23A-F
shows single peaks for all other GOI.

2.3.4 Experiment 2 Results
While some trends were identified between EC marker expression and passage
number in Experiment 1, these results are not as meaningful unless compared against
conditions that are known to induce EndMT in ECs. Two treatment groups were added in
Experiment 2 in which to compare the non-treatment group of HUVECs cultured in static
EC media: HUVECs cultured in disturbed flow, and HUVECs cultured in static SMC
media. In each group three passage numbers were chosen to investigate the effect of
culture time.
The relative abundance of all GOI are shown in Figure 24A. Unfortunately, due
to high amounts of cell death in the disturbed flow treatment groups, a high enough
concentration of RNA was only isolated from HUVECs at passage 14. The RNA
concentrations at passages 6 and 10 were too low to continue those groups in the
experiment.
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VE-cad and VEGFR2 expression increased with passage number in the nontreatment group, while the expression of these two markers decreased with passage
number in the SMC media treated group. VE-cad expression of the disturbed flow
treatment was lower than that of any non-treatment groups but was higher than the
passage 14 SMC media treated group. VEGFR2 expression showed a slight positive trend
between culture time and relative abundance in the non-treatment group, and a slight
negative trend in the SMC media treatment group. However, the SMC media treatment
group had a higher relative abundance at all passages than the non-treatment passage 6
and 10. The disturbed flow treatment had a lower relative abundance of VEGFR2 than all
other groups.
PECAM expression was slightly lower in the disturbed flow and SMC mediatreated groups, but not statistically. There was no difference in ACTA2 expression
between the non-treatment group and the disturbed flow group. ACTA2 expression
trended towards increasing with passage time in the SMC media treated group. Calponin
expression was negligible in all groups.
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A

B

Figure 24: Experiment 2 Relative Abundance. HUVEC relative abundance of (A) all
GOI and (B) PECAM, ACTA2, and CNN1 using GUS𝛽 as the housekeeping gene.

Since two treatment groups were included in Experiment 2, analysis of the
stability of GUS𝛽 was important to determine whether the treatments affected the
viability of GUS𝛽 as a housekeeper. Figure 25 shows that GUS𝛽 expression remained
relatively constant through all treatments, ranging between 19.62 and 20.45 cycles.
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Figure 25: Experiment 2 Housekeeping Gene Stability. Average Ct values of GUS𝛽
from each treatment condition.

2.3.5 Verification of RNA Isolation Protocol for BVMs
A new method had to be developed to be able to isolate RNA from BVMs. It was
necessary to verify that this extraction protocol rendered equivalent RNA as the RNeasy
Mini Kit. The resulting concentrations, 260/280, and 260/230 values from both isolation
processes are shown in Table 3. The concentration of RNA from the Trizol extraction did
not differ from the Mini Kit (p > 0.05). The 260/280 and 260/230 ratios did not differ
between the isolation methods (p>0.05), and the purity average of both methods was
within the accepted range. Based on this, the Trizol extraction method was deemed
acceptable for BVM RNA isolation.
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Table 3: Comparison of RNA isolation from the RNeasy Mini Kit and Trizol
extraction.
RNeasy RNeasy RNeasy
Mini Kit Mini Kit Mini Kit
1
2
Average

Trizol
Extraction
1

Trizol
Extraction
2

Trizol
Extraction
Average

Concentration
(ng/nL)

2682.9

2593.9

2638.4

2604.3

2655.7

2630.0

260/280

2.03

2.06

2.045

1.97

2.01

1.99

260/230

2.18

2.24

2.21

2.07

2.19

2.13

2.3.6 Experiment 3 Pilot Results
Experiments 1 and 2 worked to investigate gene expression of HUVECs in static
and disturbed flow conditions. With those conditions established, Experiment 3 served to
explore gene expression in the laminar flow conditions of BVMs in bioreactors. Before
performing an entire study, a pilot was completed which included the three flow
conditions but controlled for passage number. Gene expression was analyzed for passage
6 HUVECs in static culture, disturbed flow, and laminar flow. Since a high amount of
cell death occurred in Experiment 2 for the disturbed flow condition, a ramp-up period
was employed to reduce the shock of the flow on the cells. Figure 26 displays white light
images of HUVECs after the ramp-up period and culture for 24 hours at 200 RPM. The
well plate remained confluent at the center and edges, indicating that the ramp-up period
reduced cell death. Cells at the center of the well were oriented randomly, while cells at
the edge of the well were highly aligned and stretched in the direction of flow.
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A

Figure 26: HUVEC Morphology in Turbulent Flow Condition. HUVECs in 6-well
plates after 24 hours on a rotator plate at 200 RPM. (A) HUVECs in the center of the well
are not aligned. (B) HUVECs on the edge of the well plate align in the direction of flow.
Since a new treatment condition was added to this experiment, Ct data had to be
analyzed to determine whether the treatment affected the utility of GUS𝛽 as a
housekeeper. GUS𝛽 Ct values are plotted for each treatment group in Figure 27, which
makes clear that the Ct values varied based on treatment. The non-treated, static culture
condition had a Ct average of 19.9, which was similar to the results seen in previous
experiments. The Ct values for both BVMs differed, with vessel 8 and 9 having Ct values
of 27.72 and 23.57, respectively. Surprisingly, the disturbed flow treatment had a Ct of
39.49, even though the Ct average for the same condition in Experiment 2 was 20.45.
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Figure 27: Experiment 3 Housekeeping Gene Stability. Average Ct values of GUS𝛽
from each treatment condition.

Upon consulting the dissociation curves, it was observed that all GOI in the
turbulent flow condition, excluding PECAM, had multiple peaks. Therefore, these
samples were excluded from the study. Only PECAM had a melt curve with a single
peak, which can be seen by the peak on the right side of Figure 28. However, the
abundance value was over 1700 for PECAM, making it an obvious outlier. Therefore,
this sample was also excluded from the study, so the entire disturbed flow condition was
not included in the results. In doing so, the Ct values of GUS𝛽 were more stable. An
average between GUS𝛽 values for the static condition and vessels was used for
normalizing the data.
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Figure 28: Disturbed Flow Dissociation Curves. Dissociation curve of all GOI for the
disturbed flow condition in Experiment 3.

The static condition had higher expression of both VEGFR2, VE-cad, and
PECAM than the two BVMs, as shown in Figure 29. The BVMs had comparable
expression of VEGFR2, PECAM, and ACTA2. Only VE-cad was expressed higher in
Vessel B than Vessel A. ACTA2 had higher expression in the static condition than either
of the BVMs.
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B

Figure 29: Experiment 3 Relative Abundance. HUVEC relative abundance of all GOI
using GUS𝛽 as the housekeeping gene. (A) all GOI and (B) PECAM, ACTA2, and
CNN1.

Based on the results of this pilot, a full Experiment 3 was not explored. This study
would have included more BVM replicates and multiple cell passage numbers. However,
these three experiments did not indicate EndMT with the ECs during static culture or
during culture in BVMs, which will be discussed in detail in the following section.
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2.4 Discussion and Conclusion

2.4.1 Experiment 1 Pilot and Experiment 1
The purpose of Aim 1 was to investigate and characterize the gene expression
changes experienced by HUVECs in vitro with respect to increasing culture time and
changing flow conditions during culture. The effect of cell culture time on HUVEC gene
expression was established first through analyzing three endothelial markers and two
mesenchymal markers. The primers for these markers were verified by calculating the
efficiency of each primer assay. PECAM, VE-cad, ACTA2, and calponin had efficiency
values between 90 and 100%. Even though VEGFR2 and GUS𝛽 had efficiency values of
88.57 and 86.5, respectively, it was decided that these efficiency values were still
acceptable, especially considering the primers were already preverified. Therefore, all six
primers were concluded to be acceptable for use in qPCR experiments.
The pilot for Experiment 1 used HUVECs at passages 4, 6, 7, 8, 9, and 10 to study
the effect of culture time on gene expression. The qPCR results were then analyzed using
one of two housekeeping genes, 𝛽ACT or GUS𝛽. The use of either housekeeper in
analyzing relative abundance revealed similar trends. VE-cad had the highest abundance,
followed by VEGFR2. Passage 4 HUVECs had significantly lower expression of VE-cad
than passages 6 through 10 cells. Passages 6 and 7 had significantly lower expression
than passages 8 through 10, creating a slight positive correlation between passage number
and relative abundance. A slight positive correlation was also shown between passage
number and VEGFR2 abundance. This trend is unexpected, as literature suggests that
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expression of endothelial markers like VE-cad and VEGFR2 decreases as passage
number increases. However, the opposite trend was seen with this data.
The third EC marker, PECAM, did not have any expression differences between
passage numbers when compared to 𝛽ACT or GUS𝛽. Like with the other EC markers, it
would be expected that PECAM abundance would decrease with increased culture time.
PECAM abundance was also much lower than the other EC markers, and had an
abundance closer to ACTA2. This observation was interesting, especially considering the
expression of ACTA2 in HUVECs seen by immunostaining. The mesenchymal markers,
ACTA2 and calponin, had no correlation between passage time and abundance. While
literature suggests that these genes should increase with culture time, this was not
observed.
Another important consideration of this pilot was the viability of 𝛽ACT and
GUS𝛽 as housekeepers. The Ct data for 𝛽ACT showed variability between passage time,
making the gene non-ideal as a housekeeper. GUS𝛽 expression, on the other hand, was
stable over culture time. With this in mind, 𝛽ACT was still included as a housekeeper in
Experiment 1 to determine whether the inconsistent stability would be observed again.
Based on the results of the pilot, it was decided to expand the passage numbers
used for Experiment 1; the culture times of the pilot may have not included early and late
enough passages to elucidate all trends in gene expression. Therefore, passage times were
increased to include passages 3, 5, 7, 9, and 11. The results of the Ct values for 𝛽ACT
and GUS𝛽 in Experiment 1 confirmed the results seen in the pilot. 𝛽ACT was not stably
expressed, while GUS𝛽 expression remained relatively constant. Therefore, 𝛽ACT was
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eliminated as a housekeeping gene, and GUS𝛽 was used for data analysis in Experiment
1 and in all other experiments.
Experiment 1 result trends resembled those of the pilot. The later passages (9, 11,
13) had higher expression of VE-cad than the early passages (3, 5, 7). VEGFR2
expression increased with increased culture time. PECAM, ACTA2, and calponin
expression did not change with increasing culture time. These data do not support the
trends identified in literature, where HUVECs decrease expression of EC markers and
increase expression of mesenchymal markers as EndMT occurs. In fact, this data suggests
that the HUVECs are sustaining, and even forming, stronger cell-cell interactions as
culture time increases. Two of the three mechanosensory complex markers, VE-cad and
VEGFR2, increased abundance between early and late passages. The stability of PECAM
expression with respect to culture time also supports the idea that culture time does not
result in dedifferentiation.
The relationships seen in these data are difficult to explain. PECAM stability over
culture time can be attributed to its function as a transmitter of mechanical force. Shear
stress phosphorylates and activates PECAM; in the static culture condition, no shear
forces was present to activate PECAM. PECAM RNA transcription should change as a
result of mechanical force stimulation, so static culture should not increase PECAM
expression. While this explanation seems plausible for PECAM, it contradicts VE-cad
and VEGFR2 expression data. PECAM transmits mechanical force to VE-cad, which
responds by modulating VEGFR2. Since no mechanical force is being transmitted by
PECAM, VE-cad expression would be expected to remain constant. If VE-cad expression
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was constant, there should be no modulation of VEGFR2. However, both VE-cad and
VEGFR2 were upregulated despite the lack of mechanical force.
One explanation for increased VE-cad expression could be the confluency of
HUVECs used in the study. HUVECs were cultured to between 90 and 100% confluency,
meaning high amounts of cell-cell interactions and establishment of contact integrity by
VE-cad. However, by this explanation VEGFR2 expression would decrease, which was
not the observed response. A simpler explanation is perhaps the result of a response
initiated by VEGFR2 and not PECAM or VE-cad. HUVEC media contains VEGF, which
binds VEGFR2 and causes downstream increases in VE-cad transcription. This explains
the increase in expression over culture time, since an increase in culture time means more
time spent in media containing VEGF. This pathway is also independent of PECAM,
explaining the stability of PECAM expression over culture time. Regardless of any of
these explanations, this endothelial marker data did not indicate any dedifferentiation
occurring within the ECs.
The stability of the mesenchymal markers adds to the conclusion that culture time
does not contribute to dedifferentiation, or at least suggests that a mesenchymal genetic
change does not occur in the culture period tested here. Furthermore, the expression of
mesenchymal markers in HUVECs was almost negligible when compared to the same
markers in HUASMCs. It would not be expected that HUVECs would express those
markers at an abundance even close to that of HUASMCs. However, one study showed
that mesenchymal-progenitor cells produced between 2 and 9 times less ACTA2 and
between 5 and 50 times less calponin than SMC 119. EndMT would result in higher
ACTA2 and calponin abundance than those found in this experiment.
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This experiment found that static culture time was a variable contributing to
changes in gene expression. However, dedifferentiation towards a mesenchymal state was
not observed over culture time. Since culture duration influences gene expression, several
passage numbers were included in experiments which tested multiple flow conditions.

2.4.2 Experiment 2
With the effect of static culture time determined by Experiment 1, the second part
of Aim 1 could be pursued: to investigate the effect of flow conditions on HUVEC gene
expression. Experiment 2 served to establish a disturbed flow condition; this disturbed
flow, as well as the static culture, was used for comparing the effect of laminar flow on
HUVECs in the BVMs. The SMC media treatment group served as a positive control for
gene expression change towards a mesenchymal state. GUS𝛽 expression remained stable
despite the addition of two new treatments, meaning that GUS𝛽 retained its viability as a
housekeeper.
The non-treatment, or static culture in HUVEC media, group resulted in similar
trends as seen in Experiment 1. Gene expression in the SMC media treatment group
trended in a direction that aligns with a mesenchymal shift; VE-cad and VEGFR2
expression decreased as passage number increased, and ACTA2 expression had an
increasing trend with passage number. While PECAM expression was stable with
passage number for the SMC media treatment group, expression was lower than that of
the non-treatment group. These results confirmed that the treatment of HUVECs with
SMC media served as a positive control for EndMT. It is important to note that SMC
media treatment length was not a variable, as all passages of HUVECs were treated with
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SMC media for the same length of time; therefore, any trends in gene expression can be
attributed to the culture duration variable.
Since a high enough concentration of RNA was only isolated from the disturbed
flow treatment at passage 14, passage number did not serve as a variable in this case.
However, the data collected at the singular passage number was still interesting. The
disturbed flow HUVECs had significantly lower expression of VE-cad and VEGFR2 than
all non-treatment group passages. The SMC media treated passage 10 HUVECs had
similar expression to the passage 14 disturbed flow cells. Passage 6 SMC-media treated
cells had higher expression of VE-cad than the disturbed flow cells, while the passage 14
cells had lower expression. The disturbed flow condition had lower expression of
VEGFR2 compared to all SMC media treated passages. PECAM expression was not
different between disturbed flow and SMC media treatments. Surprisingly, ACTA2
expression of the disturbed flow condition resembled non-treatment expression, which
was lower than that of SMC media treatment. Taken together, these comparisons
indicated that the SMC media-treated group succeeded as a positive control for EndMT
while the disturbed flow condition achieved some loss in endothelial markers and some
gain of mesenchymal markers.
PECAM expression in the disturbed flow group was not different than the nontreatment group, so the effects of disturbed flow on VE-cad and VEGFR2 expression
worked independent of PECAM expression. It is not necessarily surprising that PECAM
expression remained constant regardless of treatment; changes in PECAM expression are
more heavily connected to cell-cell contact than to shear stress. Balaguru et al. found that
PECAM expression remained stable between static and disturbed flow conditions 120.
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Changes in VE-cad and VEGFR2 expression are more correlated with flow changes,
which was observed by the results of this experiment. The downregulation of VE-cad and
VEGFR2 compared to the non-treatment group demonstrated the utility of the disturbed
flow condition in being an inducer of EndMT.
While EC marker expression indicated induction of EndMT by the disturbed flow
protocol, it did not align with the expression of mesenchymal markers. The trends that
would be expected from EndMT induction were observed by the positive control
treatment of SMC media, supporting the treatment’s use as a positive control for EndMT.
This treatment also aligned well with the result of the disturbed flow condition, except
with regards to ACTA2. This could simply be a limitation of the time point at which
HUVECs were exposed to disturbed flow. Despite this, Experiment 2 succeeded in
validating the method of inducing disturbed flow and establishing gene expression
changes of a single passage of HUVECs exposed to this flow.

2.4.3 Experiment 3 Pilot
Experiment 3 was intended to combine previously investigated flow conditions
with BVMs to provide an encompassing set of data on how gene expression changed
between static culture, disturbed flow, and laminar flow as culture time increased. The
pilot for this study eliminated the factor of culture time, and only investigated flow
conditions at a single passage of HUVECs.
As with previous experiments, the stability of the reference gene GUS𝛽 had to be
determined. Upon plotting the Ct values, it appeared that GUS𝛽 was not stable with the
addition of new flow conditions. The two BVMs had Ct averages of 27.72 and 23.56
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cycles, which was higher than the Ct average of the static culture at 19.9 cycles. While
the static culture maintained a Ct value similar to previous experiments, the disturbed
flow condition did not. Experiment 2 resulted in a Ct average of 20.45 cycles, while this
pilot resulted in a Ct value of 39.49 cycles. This discrepancy between Ct values for the
disturbed flow condition between the two experiments was alarming. It indicated that the
gene was barely expressed at all and took almost all the cycles for a signal to be detected.
Since this was not observed in Experiment 2 for the same treatment condition, other
factors were looked at to explain this. Only one of the three wells ran with this treatment
resulted in a signal, indicating a potential issue with the either the RNA quality or cDNA
concentration. The disturbed flow RNA had 260/280 and 260/230 ratios of 2.01 and 2.18,
respectively. These values were within the accepted range for RNA purity, so the
dissociation curves were analyzed to determine whether the reaction products caused an
issue.
It was found that all GOI besides PECAM had multiple peaks in the disturbed
flow condition, and therefore were omitted from analysis in this experiment only. Even
though PECAM had a single peak in its dissociation curve, it was still omitted as an
outlier because of the extremity of the resulting abundance value. There was most likely
an issue with this individual PECAM sample, and the disturbed flow condition itself did
not cause the high Ct value observed here. However, the exact cause of this was unclear.
More repetitions of the flow condition are required to identify the source of this issue, or
whether this issue will persist. The issues found by the dissociation curve with all other
GOI in this group was also surprising, since the same issues were not found in a similar
treatment group in Experiment 2.
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The BVM RNA values were also concerning. The 260/280 ratios were 1.63 and
1.81 and the 260/230 ratios were 0.35 and 0.60. While the 260/280 ratios were only
slightly below an ideal ratio, the 260/230 ratios were excessively low. A cause for both
low 260/280 and 260/230 ratios is contaminating phenol from the isolation protocol 121.
Phenol is a main component of Trizol, and if the supernatant is not carefully separated
during the isolation phenol could remain in the final product. This explanation is
plausible, but unlikely considering the RNA purity of the static and disturbed flow
samples were isolated using the same protocol and resulted in appropriate purity ratios.
The BVMs, unlike the other two conditions, had scaffolds that were homogenized. It is
unknown how the scaffolds affect the purity of the isolated RNA but could potentially
cause contamination. The dissociation curve for each gene had a singular peak, shown in
Figure 30, so the low RNA purity ratios may have not affected the quality of the PCR
products.

Figure 30: Dissociation Curves for GOI for EC-only BVMs.
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The results of this experiment were not expected. Shear stress has been shown to
increase VE-cad and VEGFR2 expression in ECs compared to ECs in static culture 92,122.
The opposite was found in this experiment; VE-cad and VEGFR2 expression decreased
relative to static culture. Two theories persist to explain these results. First, the amount of
shear stress in the BVMs may be too low to induce EC activation. The shear stress in
BVMs is approximately 0.35 dyne/cm2, which is significantly lower than shear stresses
used in literature that showed upregulation of VE-cad and VEGFR2 which were between
10 and 20 dyne/cm2.
A more likely explanation is that the 24-hour time point used for the BVMs was
too short a duration to observe changes in EC expression. A study using a similar shear
stress to the one in BVMs found that VE-cad was significantly downregulated 24 hours
after flow induction123. VE-cad interactions must be broken to adapt to changes in
stimulus, such as during the induction of flow. The studies that found an increase in VEcad and VEGFR2 expression used between 3 and 7 days of flow exposure. This
explanation also gains merit from the expression of PECAM in this study. The previous
experiments in this aim saw relatively stable expression of PECAM. However, this study
saw lower expression of PECAM in the BVMs than in the static culture. This indicates
that the cell-cell contact, which is necessary for PECAM expression, may have not been
reestablished at this time point.
While it is disappointing that the disturbed flow condition was emitted, it may not
have contributed to an explanation of these findings because of the short duration.
Expression levels of mesenchymal markers were also not meaningful if the time point
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was too short. ACTA2 abundance was higher in static culture than in BVMs. It would be
interesting to see if this trend persists at longer time point BVM, such as at 3 or 7 days.
The data collected by the pilot stemmed the decision to not pursue a full study.
The experiments did not indicate EndMT occurring during culture or within the two
BVMs of this pilot. The exploration of EndMT was the main topic of interest, and while
the results gathered by these experiments were useful, they did not support any
dedifferentiation occurring.

2.4.4 Aim 1: Limitations and Future Work
Several limitations became clear from these experiments. The stability of GUS𝛽
in BVMs was a limitation, but this was worked around by averaging GUS𝛽 Ct values in
experiment 3. Another limitation was the quality of RNA from the BVMs. This could
have been caused by the isolation protocol, but more likely was a result of introducing
scaffolds in the RNA isolation. How, and why this would occur is unclear. However, the
greatest limitation was not completing a full Experiment 3 study. Even if passage number
was kept constant, a full experiment that included many replicates of vessels would have
helped discern the consistency from vessel to vessel, both regarding genes of interest
variability and housekeeping gene stability. It is disappointing to have established the
methods and completed the prerequisite work for a full experiment to compare the three
flow conditions, only to not complete the full study; however, this decision was logical.
Since the results previously discussed did not indicate a shift towards a mesenchymal
phenotype, it did not seem productive to continue this exploration.
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This area of the project still has areas that can be explored and improved. A full
experiment could be conducted to compare the three flow conditions established here, not
as a means to determine dedifferentiation but to better understand how the laminar flow
in our model affects the cell-cell interactions. This experiment could be set up to study
the effect of increasing RPMs on our model; increasing the flow rate would improve the
physiological relevance of the model by increasing the shear stress. Shear stress would
not be able to reach the conditions of the native vessel without changes to the viscosity of
the media, but the methods explored here could be utilized for this exploration 37. A
different experiment could also include BVMs at different timepoints to verify if trends
from longer timepoints agree with those from literature. A disturbed flow condition
would be beneficial if that study was to be performed. Hui et al. found that VE-cad
distribution was intermittent after exposure to disturbed flow, whereas a continuous
distribution of VE-cad was observed after exposure to laminar flow 124. This study could
compare the effects of disturbed flow to laminar flow since the extent of mechanosensory
complex reestablishment differs depending on flow type.
The methods used in these experiments could also be improved in the future. By
using 6-well plates, two flow conditions are present within that flow treatment. The edges
of the well plate are exposed to disturbed flow at a higher shear than the center. Well
plates shaped like a ring are available, which eliminates the center of the well plate so the
shear on all cells would be similar. More time points could be explored for the disturbed
flow condition to observe how expression changes after multiple days of exposure to
disturbed flow. This could be used to compare against 3, 7 or 14-day BVMs.
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These methods can also be used to generate data in support of other projects. One
possible application is in the exploration of novel scaffolds to understand how the cellcell interaction changes between scaffold types. A scaffold that retains cells better within
the lumen should have higher expression of the three mechanosensory complex markers
used in the previous experiments. Specifically, this scaffold material would result in EConly BVMs with elevated expression of PECAM, VE-cad, and VEGFR2 because more
cell-cell junctions exist. However, for the current thesis, five markers were used to asses
EndMT for increasing cell passages and for static, disturbed, and laminar flow conditions
through changes in gene expression.
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CHAPTER 3. AIM 2: CHARACTERIZATION OF NOVEL SCAFFOLDS
THROUGH HUVEC CASPASE ACTIVITY AND SCAFFOLD COVERAGE

3.1 Introduction
After evaluating gene expression changes in Aim 1, Aim 2 sought to establish
methods to better understand how cells and scaffolds interact in the BVM model.
Methods for quantifying cytotoxicity, short-term cell adhesion, and long-term cell
coverage were investigated. These methods were applied by comparing the current
scaffolds with novel, nanofiber scaffolds. The following sections will overview how cells
interact with and respond to scaffolds in tissue engineering applications. It will also
introduce the novelty of adding BTEAC salt to scaffolds for nanofiber production.

3.1.1 Scaffold Effects on Cells
Tissue engineers attempt to create biomaterial scaffolds that resemble the native
ECM of the tissue that is being mimicked. Electrospinning is a useful technique for
creating scaffolds because scaffolds can be customized during fabrication by adjusting a
variety of parameters, like voltage, percent polymer, polymer solution flow rate, and
collector speed. Regardless of the fabrication process and material used, there are some
general trends between scaffold characteristics and cell interactions. These scaffold
characteristics include fiber diameter, fiber alignment, porosity, stiffness, topography,
and scaffold degradation. Understanding the possible effects of these characteristics on
cells is important when fabricating a scaffold using new solvents or additives.
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3.1.1.1 Fiber Diameter
Figure 31 demonstrates how fiber size affects cell attachment. Microfiber
scaffolds encourage cell attachment to single fibers, which does not resemble a normal
cellular interaction with native ECM. Nanofiber scaffolds encourage cells to form
attachments with multiple fibers, which is closer to resembling native ECM where cells
have many attachment sites125. As a result, fiber size effects cell morphology. This was
demonstrated by Hodgkinson et al., where they found that primary human dermal
fibroblasts became more elongated on microfiber scaffolds whereas cells on nanofiber
scaffolds had a spread morphology126. These smaller fibers enhance cell attachment
through increasing the available attachment sites, and the likelihood of these attachment
forming is increased since the specific surface area of small fiber scaffolds is larger than
that of scaffolds with larger fiber sizes. A higher surface area is also useful during the
conditioning processes, as smaller fibers have increased protein adsorption 127. As a result
of increased protein adsorption and cell attachment, it is unsurprising that a decreased
fiber diameter is associated with increased cell proliferation and viability 126–128.

Figure 31: Cell Interactions with Fibers of Varying Sizes 125.
87

3.1.1.2 Fiber Alignment
Fiber orientation can be controlled during electrospinning but depends on the
collector type and electrospinning parameters. The application of the scaffold dictates the
benefits of aligned, semi-aligned, or random fibers. The Tissue Engineering Lab’s PLGA
scaffolds are fabricated such that the fiber orientation is random. However, it has been
found that HUVECs adhere better to aligned fibers. Whited et al. found that aligned
fibers led to increased HUVEC attachment to collagen-I/PCL scaffolds. Cells were
seeded onto aligned, semi-aligned, or random fiber orientations and exposed to 20
dyne/cm2 of shear stress. The aligned fiber scaffold had 95% cell adherence, while the
semi-aligned and random fiber scaffolds had 80% and 60% adherence 129. The aligned
fibers in this study were oriented in the direction of flow, which is not possible to
fabricate using the current electrospinning system in the Tissue Engineering Lab. Aligned
fibers on a cylindrical mandrel would be perpendicular to flow, and it is unclear how this
would affect adhesion.

3.1.1.3 Porosity
The electrospinning process results in a porous scaffolds, and random fibers have
a higher porosity than aligned fibers127. Porosity mediates cell infiltration into scaffolds;
if pores are too small cells cannot migrate into the scaffold, but if pores are too large the
specific surface area is decreased and limits the area for cell attachment 130,131. The
migration or infiltration of cells in the scaffold is also dependent on the model or tissue
being mimicked. For BVMs, a confluent monolayer of HUVECs should line the lumen,
so cell infiltration would ideally be avoided. The fiber packing density is inversely
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correlated with porosity, where high fiber packing density results in low porosity 132.
Therefore, BVMs should have a high fiber packing density that encourages cells to
proliferate along the lumen wall. For co-cultures of ECs and SMCs, like in the case of
standard BVMs, it was found that pore diameters of 0.02, 0.4, 0.6, and 0.8 µm were
optimal, whereas pore sizes greater than 2 µm resulted in SMC migration into the
scaffold133.
Pore sizes can be divided into three categories: nano (>100 nm), micro (100 nm 100 µm), macro (100 µm - millimeters)134. In vivo, macropores are useful for cell
migration and vascularization, while micropores are effective for nutrient, oxygen, and
chemical delivery135. Higher porosity in scaffolds is associated with greater cell
deposition and adhesion. Murphy et al. used collagen-glycosaminoglycan scaffolds
seeded with osteoblasts and found that the largest pore size resulted in the highest cell
count at all time points. It was assumed that this was a result of cell migratory capacity,
where at late time points small pores inhibited migration and proliferation 130. The higher
cell number could have also been a result of better cell adhesion due to increased protein
deposition on the scaffolds, since scaffolds with higher porosity have been found to have
higher protein adsorption than those with smaller pores 135.

3.1.1.4 Stiffness
ECM stiffness can fluctuate drastically across tissue in vivo, as cells respond to
the stiffness through changes in actomyosin interaction with the ECM 136. A similar
response with adhesion proteins occurs in vitro137. Stiffness is measured in terms of
elastic modulus, where a stiff material has a high elastic modulus. Cell adhesion,
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spreading, proliferation, and even cell lineage is affected by scaffold elasticity, but how
those characteristics are affected depend on the cell type132,138. For HUVECs, it was
found that cells spread better and had a higher metabolic activity on stiffer
surfaces137,139. Stiffness also effects the shear level necessary to affect morphology.
Stiffer surfaces required less shear stress to align in bovine aorta endothelial cells
(BAECs) than soft surfaces. These stiffer surfaces also showed less of an inflammatory
response140.

3.1.1.5 Topography
The surface roughness of the PLGA scaffolds used in BVMs should be low upon
removal from mandrels but may increase during ethanol sterilization and conditioning.
Surface roughness can be divided into macroroughness (100 μm – millimeters),
microroughness (100 nm – 100 μm), and nanoroughness (less than 100 nm) 132. Increasing
surface microroughness is associated with an increase in cell adhesion and proliferation.
Osteoblasts attached and proliferated most effectively on a surface with a roughness of
0.81 μm than a smooth surface134. HUVECs showed increased cell adhesion and growth
with increasing microroughness between 10 nm and 102 nm 132. This trend could be a
result of increased attachment sites on more rough surfaces.

3.1.1.6 Scaffold Degradation
PLGA degrades faster than either of its components, hydrophilic PGA and
hydrophobic PLA, so PLGA composition percentages heavily effects degradation
through changes in hydrophobicity. PLGA degradation occurs mainly as a result of ester
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bond hydrolysis, which forms acidic monomers than can reduce pH 141. Degradation of
PLGA in BVMs is reduced using 75:25 PLGA, while acidic byproducts are distributed
throughout the system by dynamic flow so local pH around the scaffold does not
increase. Despite this, scaffold degradation can have unintended byproducts that affect
cell health and result in apoptosis.

3.1.2 Measurement of Cell Responses
Scaffold characteristics have diverse effects on cellular response, including
apoptosis and adhesion. These are two of the most important cellular responses in relation
to the BVM model and must be evaluated when proposing the use of a new scaffold.
Assessment of apoptosis and adhesion will provide evidence for the benefits, or
detriments, of introducing scaffold changes.

3.1.2.1 Apoptosis
Apoptosis is the mechanism by which cells are killed and removed by the body in
a controlled procedure that includes membrane dissociation, cell shrinkage, condensation
of chromatin, DNA fragmentation, engulfment, and removal142. In vivo, physiologic
apoptosis occurs in natural and controlled processes, and is often associated with
developmental biology where overproduction of cells is necessary to develop the nervous
and immune systems. Pathologic apoptosis results from abnormal and uncontrolled levels
of cell death, which is associated with cancer, AIDS, and Parkinson’s disease 143.
Apoptosis also occurs in vitro, except for events mediated by lymphocytes such as
engulfment and removal. The inability to remove dead cells enhances cell apoptosis if

91

cell debris is not cleared144. In the case of BVMs, apoptosis can occur through several
factors. Scaffold degradation and improper CO2 conditions can lead to increased pH and
apoptosis. Cell over-confluence or reduced cell adhesion also increases apoptosis.
Therefore, induction of apoptosis must be understood.

3.1.2.1.1 Apoptosis Pathways
Apoptosis can be induced by either the extrinsic, intrinsic, or perforin/granzyme
pathway, which converge on the execution pathway to end the cascade 143. The extrinsic
pathway initiates through tumor necrosis factor (TNF) transmembrane receptor-mediated
interactions. These receptors transmit the signals through the membrane to initiate further
intracellular signals. One common death ligand and receptor is Fas. The Fas ligand binds
its receptor on the surface of the cells, which recruits Fas-associated protein with death
domain (FADD) intracellularly. FADD associates and activates procaspase-8, activating
caspase-8 and the execution pathway145,146.
The intrinsic pathway is stimulated by positive or negative intracellular signals
that cause changes to the mitochondrial membrane. Negative signals include the lack of
growth factors, hormones, or cytokines. Positive signals include radiation, toxins,
hypoxia, free radicals, and viral infections. These signals result in the opening of the
mitochondrial permeability transition (MPT) pore that releases pro-apoptotic proteins,
such as the intermembrane mitochondrial protein cytochrome C. Cytochrome C binds
Apaf-1 and procaspase-9 upon being released into the cytosol, forming an apoptosome.
Apaf-1 contains a caspase recruitment domain, and the clustering of procaspase-9 to
cytochrome C and apaf-1 results in caspase-9 activation145,146.
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The perforin/granzyme pathway is activated by cytotoxic T lymphocytes (CTLs),
which mainly targets tumor and virus-infected cells. CTLs secrete perforin, a poreforming transmembrane molecule, and then secrete cytoplasmic granules into the cell.
Granzyme A and B are included in these granules; granzyme A activates DNA nicking,
while granzyme B activates procaspase-10145,146.
Caspase 8 in the extrinsic pathway, caspase 9 in the intrinsic pathway, and
caspase 10 in the perforin/granzyme pathway all activate caspase-3, the initiator of the
execution pathway. While caspase-3 is the initiator, caspase-6 and caspase 7 are also
considered execution caspases. The three caspases activate cytoplasmic endonuclease to
degrade nuclear material and proteases to degrade cytoskeletal proteins, ultimately
resulting in cell death145,146.

Figure 32: The Apoptosis Pathway. The three arms of the apoptosis pathways,
converging on the execution pathway and cell death 143.
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3.1.2.1.2 Caspases
Caspases, which stands for cysteine aspases, are heavily involved in the apoptosis
cascade147. There are at least 14 identified caspases, with 10 being major caspases. These
include initiators (caspases 2, 8, 9, 10), proinflammatory cytokine activators (caspases 1,
4, 5), and executioners (caspases 3, 6, 7)148. Caspases remain in an inactive proenzyme
form until activation, referred to as procaspases 143. Once active, caspases have two main
functions: to breakdown proteins into smaller peptides and to activate other caspases to
amplify the apoptotic signal. The proteins targeted include mediators and regulators of
apoptosis, structural proteins, cellular DNA repair proteins, and cell cycle-related
proteins145. Since caspases are almost always associated with apoptosis, measurement of
caspase activity can be used to assess apoptosis positive cells 147.

3.1.2.1.3 Apoptosis Detection and Quantification
Methods exist to detect apoptosis in vitro, mostly through staining or collecting
absorbance values. Toluidine and methylene blue are dyes that reveal intensely stained
apoptotic cells. This method preserves the tissue or cells well but can underestimate
apoptosis because it lacks the ability to detect smaller apoptotic proteins. Annexin V is a
protein that binds phosphatidylserine present only on cell membrane surfaces of cells
undergoing apoptosis. Annexins are proteins that bind phospholipids in the presence of
calcium, which occurs on phosphatidylserine149. Since mitochondrial membrane potential
changes occur early in apoptosis, cationic fluorescent dyes can be used to identify
apoptotic cells. Healthy cells accumulate the dye in the mitochondria, while the stain
remains in the cytosol of apoptotic cells150.
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Methods to label fragmented DNA are also used to detect apoptosis. DNA
laddering through gel electrophoresis can be used in cases where high numbers of
apoptotic cells are present. Since DNA is cut in relatively consistent sizes during
apoptosis, regularly spaced bands can be identified on agarose gel. Terminal dUTP Nick
End-Labeling (TUNEL) assays label DNA fragments with fluorescent nucleotides and
use fluorescent intensity to identify apoptotic activity. However, this assay is known to
falsely identify cells undergoing DNA repair or are active in gene transcription 151.
As mentioned previously, caspase activity can be used to detect and quantify
apoptosis, which can be achieved through fluorescent microscopy or measuring
absorbance. One common caspase 3 assay, which indicates the initiation of the execution
pathway, requires tissue homogenization to expose the active caspases 151.
Immunostaining kits are also available which target the execution pathway, staining
caspase 3 and 7, while others more broadly stain for caspase activity and label caspases 1
through 10152.

3.1.2.2 Cell Adhesion

3.1.2.2.1 Passive In Vitro Cell Adhesion
If endothelial cells are unable to form interactions with the surrounding scaffold
within 24 to 48 hours after sodding, they will undergo apoptosis 153. The adhesion process
that occurs in culture flasks, petri dishes, and scaffolds of BVMs is known as static cell
adhesion. This adhesion process differs greatly from the events that occur in vivo, where
endothelium adhesion processes occur in dynamic conditions defined by tethering,
rolling, adhesion, and transmigration154. In vitro adhesion can be divided into non95

receptor and receptor-mediated binding. Non-receptor-mediated cell adhesion includes
weak chemical bonds between cell membranes and substrates, such as electrostatic, polar,
or ionic interactions. Receptor-mediated adhesion creates far stronger and specific
interactions, in which interactions occur between matrix molecules and cell adhesion
proteins153.
Static adhesion has three main phases, shown in Figure 33: cell attachment,
flattening and spreading, and reorganization of the cytoskeleton with the development of
focal adhesion complexes (FAC). Integrin interactions with the substrate are responsible
for the initial cell attachment, and the strength of the interaction increases over time as
more receptor-ligand bonds are formed154. As more interactions form, cell spreading
begins where the cell body decreases in height and increases contact area with the
substrate. During spreading the actin cytoskeleton of the cell begins to reorganize. With
this reorganization comes the formation of FAC, which connect integrins and other
adhesion molecules to the cytoskeleton155.

Figure 33: Cell Adhesion Phases. The progression of cell adhesion in vitro over three
phases 154.
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Fully developed focal adhesions are formed from over 150 proteins and
researchers are still discovering exactly how these interactions develop; however, two
kinases in particular are well researched and essential for FAC development 156. Focal
adhesion kinase (FAK) interacts with 𝛽1 integrin cytoplasmic tails, as well as
cytoskeletal proteins like paxillin. FAK is important for phosphorylation and assembly of
focal adhesion components, where it functions mainly as a scaffold for other proteins to
interact with. This function was determined through studies of kinase-dead FAK, where it
was found that most of FAK’s function was retained155.
Another essential kinase is Src, which is activated through its binding to FAK.
While Src binds directly to 𝛽 integrins, the complex formed by FAK and Src plays
important roles in cell spreading by relieving cytoskeletal tension during spreading and
inhibiting cytoskeletal contractility156. These events are important for creation of stable
focal adhesions and strong cell adhesion interactions.

3.1.2.2.2 Cell Adhesion Tests
Many tests exist to test cell adhesion to polymer surfaces, which can be divided
broadly into tests for strength of adhesion and tests for percent adhesion. Some strength
of adhesion test methods, like polyacrylamide-traction force microscopy (PA-TFM) and
biomembrane force probes (BFPs), study single cell events. In PA-TFM, fluorescent
beads are embedded near the surface of a polyacrylamide gel. When cell adhesion occurs,
traction forces on the gel displace the beads so that bead movement can be quantified and
related to adhesion force157. BFPs use a force transducer composed of two micropipettes,
one holding a cell and the other holding an antibody-coated bead attached to the cell.
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Adhesion forces are quantified by cell displacement as a pulling force is exerted between
the cell and bead158. Other tests for adhesion strength quantify the cell response through
detachment. Centrifugation assays measure the number of cells that detach during
centrifugation, which is reflective of cell adhesion strength 154.
Tests for the percent of cell adhesion require knowledge of the initial number of
cells seeded to a surface and are limited to short time points so that cell proliferation does
not occur. Wash assays estimate cells remaining on a surface through counting removed
cells. After performing wash steps on a surface with seeded cells, the cells from the wash
solution are counted and subtracted from the known number of cells seeded to the
surface154. Cell counting techniques have also been implemented that involve
immunostaining and counting cells on a small fraction of the polymer surface, which can
then be used to estimate cell adhesion density. These tests can be useful for determining
cell adhesion potential, such as when investigating cell interactions with a novel scaffold.

3.1.3 Addition of BTEAC Salt in Electrospinning of Scaffolds
It has already been established that decreasing fiber diameter and porosity will
increase EC adhesion to polymer scaffolds, making fiber diameter and porosity reduction
a plausible solution to successfully creating BVMs that only use ECs. Therefore, methods
for decreasing these scaffold characteristics were pursued in our laboratory by a different
student researcher. One method investigated was to add benzyl triethyl ammonium
chloride (BTEAC) salt to the PLGA and chloroform mixture before electrospinning.
Figure 34 and Figure 35 compare standard electrospun scaffold versus a scaffold spun
with 3% BTEAC in the Tissue Engineering Lab (unpublished data). The average fiber
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diameter of the standard PLGA scaffolds was 5.55 µm, while the 3% BTEAC scaffold
had significantly smaller fibers with an average of 0.826 µm (p<0.01).

Figure 34: SEM of Standard Scaffold. Standard scaffold SEM images at 100x (left) and
600x (right) magnification.

Figure 35: SEM of Salt Scaffold. 3% benzyl triethyl ammonium chloride (BTEAC) salt
scaffold SEM images at 100x (left) and 600x (right) magnification.

The addition of BTEAC has been shown to decrease fiber diameters of
electrospun scaffolds159–161. The addition of the ionic salts like BTEAC increases the
electrical conductivity of the solution by increasing the charge density. Within the
electric field, the salt ions electrostatically repel each other, increasing the stretch of the
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polymer jet and reducing fiber diameter162. You et al. showed decreasing fiber diameter
with increasing BTEAC content in PLGA scaffolds using chloroform as the solvent, seen
in Figure 36160. Fiber diameter reduction is limited at salt concentrations above 3% w/v.
The same study also saw a decrease in porosity from 88% to 77.2%. Another study which
electrospun poly(hydroxybutrate-co-hydroxyvalerate) (PHBV) dissolved in chloroform
saw a reduction in fiber diameter from 1662 ± 490 nm to 603 ± 250 nm after the addition
of BTEAC163.

Figure 36: Fiber Diameter Reduction with BTEAC Percentage. The average fiber
diameters of electrospun PLGA with varying percentages of BTEAC 160.

The addition of BTEAC does not affect other important characteristics of the
electrospinning solution, such as viscosity and surface tension, making it simple to
implement in existing protocols159,160. Thorsten et al. electrospun PLA dissolved in either
chloroform or dichloromethane and showed that, while electrical conductivity increases
as BTEAC weight percentage increases, the surface tension of the solution remains
constant159. While the solution characteristics remain constant, the addition of BTEAC
affects the mechanical strength of the resulting scaffolds. Scaffolds spun with BTEAC
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had a decreased ultimate tensile strength and Young’s modulus as compared to those
spun without the salt, but scaffolds with BTEAC had increased elongation at fracture 163.
Interestingly, electrospun scaffolds with BTEAC have been investigated for
antimicrobial properties for use as filters. Quaternary ammonium compounds (QACs),
such as BTEAC, target and disrupt the cytoplasmic membrane of bacteria and the viral
envelopes of viruses161. Park et al. characterized the antibacterial and antiviral effects of
electrospun polyvinyl alcohol (PVA) with BTEAC dissolved in water. They found that
the growth of K. pneumonia, E. coli, and S. aureus were inhibited at BTEAC
concentrations above 2.6%. Besides inhibiting growth, the scaffolds also reduced live
bacteria and viruses over time. There was reduction of S. aureus and K. pneumoniae from
30 to 120 minutes, as well as reduction of PhiX174 and MS2 from 60 to 300 minutes 161.
These properties that make the BTEAC a good antimicrobial agent may disqualify it as a
candidate for use in biomaterial scaffolds. If the salt has toxic interactions with cells, like
it does with bacteria and viruses, cell death would increase while proliferation decreases.
However, no current published studies have investigated the interaction of these scaffolds
with human cells. Park et al. investigated BTEAC toxicity through leaching scaffolds and
observing the effect of the leaching product on daphnia magna, a planktonic crustacean.
They found that D. magna was not affected by BTEAC concentration between 0.1 mg/L
and 5 mg/L. The highest concentration leached from the scaffolds was 0.72 mg/L, far less
than a concentration that would be toxic to D. magna 164.
While the addition of BTEAC salt to electrospinning solutions is a simple method
to create nanofibers in scaffolds, there is potential for toxicity when cells interact with
these fibers. For example, BTEAC salts have been shown to elute from the scaffolds in
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small amounts, but the effect of these salts has not been tested on cells 164. Therefore,
investigation of the cell interactions is necessary to determine the viability of these
scaffolds for tissue engineering applications.

3.1.4 Summary
The prospect of implementing a new scaffold for use in BVMs requires an
understanding of the interaction between cells and scaffold. This section outlines the
effect of scaffold characteristics on cells, cell adhesion in vitro, and the apoptosis
pathway. The following sections will describe how this knowledge was applied to create
assays for testing scaffold cytotoxicity and cell adhesion along with experiments
performed to verify the utility of these assays.

3.2 Materials and Methods
In order to implement a novel scaffold in the BVM model, three different assays
were developed. The following sections will describe methods establishing these assays
to compare BTEAC salt scaffolds against standard PLGA scaffolds. A large portion of
developing these methods involved quantifying images that were collected through
immunostaining and confocal imaging. The cytotoxicity elution assay tested scaffold
viability indirectly, while the short-term adhesion and BVM cultivation assays
determined direct utility of scaffolds on HUVECs. These direct toxicity assays provided
useful data on HUVEC adhesion to and coverage on different scaffold types at increasing
time intervals.
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3.2.1 Caspase Stain Implementation and Verification
Caspases are enzymes that are activated throughout the apoptosis cascades, so
caspase activity is useful for assessing apoptosis. The Image-iT LIVE Green Poly
Caspases Detection Kit (Molecular Probes) was used for immunostaining cells to
visualize apoptotic activity. The kit also includes a Hoechst 33342 stain, which stains cell
nuclei, and a Propidium Iodide stain, which stains dead cells. Besides the three stains, an
Apoptosis wash buffer and Apoptosis fixative solution were included. The fixative
solution was a 10% formaldehyde solution.
It was first necessary to establish positive controls to verify if the kit was
performing properly; in this case, the positive control was a treatment that induced
apoptosis. The caspase activity in this treatment serves as a baseline to compare the
caspase activity of treatments in which toxicity is unknown. Hydrogen peroxide (H 2O2)
and dimethylsulfoxide (DMSO) are known to be cytotoxic to cells, so these were chosen
as candidates for the positive control treatments165. HUVECs were grown to confluency
in 8-well plates before receiving one of the following 16 treatments: 2%, 5%, 10%, or
15% DMSO in EC media for 30 minutes or 60 minutes, or 0.05%, 0.1%, 0.5%, or 1%
H2O2 in EC media for 2 minutes or 5 minutes. A negative control that received EC media,
and no DMSO or H2O2, was also included.
After treatment, each well was washed with EC media before staining with the
caspase kit. Cells were incubated for 90 minutes with 200 µL of caspase detection
reagent diluted in EC media. The staining solution was removed, and cells were washed
with EC media before separately staining with Hoechst and Propidium Iodide, both at
dilutions of 1:500 in EC media for 10 minutes. The cells were then washed twice with
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Apoptosis wash buffer before being fixed with Apoptosis fixative solution for at least 12
hours at room temperature before imaging. All samples in this aim were stained using
this protocol; therefore, other sections will simply refer to this as “apoptosis staining
protocol”. This protocol is provided in Appendix J. Samples were imaged on the
Confocal Microscope at a 40x magnification and the laser settings as seen in Table 4.
Images were analyzed qualitatively based on caspase signal intensity. Samples with a
strong caspase signal in the cytosol and nucleus but with low Propidium Iodide activity
were selected as positive control treatments.

Table 4: Confocal Microscope Lasers and Settings.
Laser
Laser Power
High Voltage

Hoechst
405
15%
700

Caspase
488
30%
700

Propidium Iodide
559
30%
700

Once positive control treatments were selected, each of the three individual stains
needed to be checked for bleed-through to ensure that signal from one stain was not being
detected by a separate laser. HUVECs cultured in 8-well plates were stained with either
no stain, Hoechst stain only, Caspase stain only, Propidium Iodide stain only, or all three
stains. These samples were imaged at 20x magnification and analyzed to determine if any
bleed-through occurred. With these stains verified and positive controls established, the
stain was then used with confidence to assess treatments in the following assays.
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3.2.2 Cytotoxicity Assay
The cytotoxicity of scaffolds was first assessed using a standard elution approach.
This means that the assay was performed without direct cell-scaffold contact, but rather
by treating cells with media that had been eluted with a scaffold. An elution is a liquid
that has been incubated with a substance at a certain temperature for a length of time. The
theory behind this is that any toxic particles will be drawn into the solution and the effect
of this elution on cells will indicate the toxic effects of that original eluted substance 166.
In this assay, standard PLGA scaffolds and 3% BTEAC salt scaffolds were eluted
in EC media for 72 hours at 50º C as advised by ISO-10993. To prepare the elution,
scaffolds were cut to 43 mm and attached to fittings before being sterilized in 70%
ethanol for 20 minutes. Using sterile technique, the scaffolds were then removed from the
ethanol and flushed transluminally and transmurally with DPBS and EC media. The
scaffolds were then placed in 10 mL of EC media and placed in a water bath heated to
50º C. After 72 hours, the scaffolds were removed from the elution and stored at 4º C
until use, approximately five to seven days. pH measurements were also taken of each
elution to determine if heat or scaffold degradation had changed the media to be more
acidic or basic.
The elution was next applied to HUVECs grown to approximately 80%
confluence in 8-well plates. Cells were either treated with pure eluted media or eluted
media that had been diluted by 50% for 24 or 48 hours. The dilution group was included
because the strength of the original elution was unknown. If the full elution treatment was
too cytotoxic there would be no way to discern between treatments. The dilution should
emphasize any difference between the salt scaffold and standard scaffold elution, if a
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difference exists. After the treatment lengths, cells were stained using the apoptosis
staining protocol and imaged at 40x magnification. Positive and negative controls were
also included in each time group, where a positive control was treated with hydrogen
peroxide just before staining and a negative control was treated with standard EC media.
Image quantification methods had to be established to determine how many cells
from each treatment group were positive for caspase or propidium iodide staining. To do
this, images were separated by channel and false colored to the respective laser color
(blue, green, or red). Nuclei were counted automatically using the Analyze Particle
function in ImageJ, which required a maximum pixel area to be set. Therefore, any area
below that set value would be excluded in the count, which prevented non-nuclei from
being counted. Before counting, a threshold was set, and the image was made binary. An
example of this process can be seen in Figure 37. Because of the variability in manually
setting the threshold and the possibility of setting the size restriction too high, these
settings needed to be verified.

A

B

C

Figure 37: Hoechst Channel Automatic Cell Counting. (A) Raw Hoechst channel
image with cell nuclei. (B) Threshold applied, reducing noise and making the image
binary. (C) Outlines of automated cell count.
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The settings were tested by manually counting a sample of images and comparing
the manual count to the automated count. The threshold values used varied but were set
between 1000 and 1200, depending on the image and necessity to eliminate signals that
were non-nuclei. Two magnifications were tested, 20x and 40x, and the smallest area
excluded was set to 20 pixels2 and 50 pixels2 for the two magnifications, respectively. For
the 20x magnification, it was found that there was an average error of 40.03% between
the manual and automated counts with an average error of 18.5 nuclei per image. For the
40x magnification, there was an average error of 9.15% with an average error of 5.2
nuclei. With this data, it was clear that the 40x magnification was superior for analyzing.
After automatically counting the Hoechst channel, the Caspase and Propidium
Iodide channels needed to be quantified. These channels had to be counted manually
because of the variability in signal location; some cells were positive for the stains in
only the nucleus, others only in the cytoplasm, while some had signal throughout the
entire cell. There was also overlap between cells, so automated counting would not be
able to discern between large groups of cells. To aid with manual counting, pixel
intensities below a certain value were eliminated to ensure that background noise did not
appear to be a signal indicating the cells were positive for apoptosis or cell death. This
pixel reduction value had to be set to avoid eliminating cells that were truly positive for
the stain versus those that were noise. Examples of these methods can be seen in Figure
38 and Figure 39.

107

A

B

C

Figure 38: Pixel Reduction in Caspase Channel. (A) Raw image of Caspase channel.
(B) Caspase channel after pixel reduction. (C) Overlay of Hoechst and Caspase channels,
which was used for counting Caspase positive cells.
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Figure 39: Pixel Reduction in Propidium Iodide Channel. (A) Raw image of
Propidium Iodide channel. (B) Propidium Iodide channel after pixel reduction. (C)
Overlay of Hoechst and Propidium Iodide channels, which was used for counting
Propidium Iodide positive cells.

Graphs were created for Caspase and Propidium Iodide channels of pixel
reduction values versus number of cells manually counted. Pixel intensity values range
from 0 (black) to 255 (white), so the values tested were in the lower range of intensities.
For both stains cell count started to decrease rapidly after eliminating pixels with an
intensity over 15, so this was set as the pixel elimination quantity for the Caspase and
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Propidium Iodide images. After eliminating these pixels, the Hoechst channel was
overlaid on both channels separately. Only signals that surrounded or overlaid with nuclei
were counted, so signals not associated with a nucleus were not counted as cells. After
quantification, the percent Caspase positive cells and percent Propidium Iodide cells were
calculated by comparing the number of positive stained cells to the total number of
nuclei. Finally, the percent positive cells for both caspase and propidium iodide were
normalized to the negative control (non-treatment) group, which were cells with only EC
media, essentially subtracting out the natural population of positive cells for both stains
that were present in groups that did not receive an elution treatment.

3.2.3 Cell Adhesion and Viability Assay
The nanofibers of the BTEAC salt scaffolds have much smaller fiber diameters
than the standard scaffolds, which should improve EC adhesion 167. Therefore, it was
valuable to investigate cell adhesion to the scaffold at a short time point. This adhesion
assay involved pressure sodding ECs to both types of scaffolds and analyzing the
scaffolds after 4 hours. Methods were also determined to quantify cell adhesion and
short-term data on Caspase activity and number of dead cells.
Since this time point was short, the assay could be conducted without using sterile
technique. Standard scaffolds and 3% BTEAC salt scaffolds were attached to fittings and
sterilized in 70% ethanol for 20 minutes. The scaffolds were then flushed transluminally
and transmurally in DPBS and EC media. HUVECs were then pressure sodded into the
scaffolds by placing a stop-cap on one end of the scaffold, and then using a syringe to
push cells resuspended in media into the scaffold. The cell density of the resuspended
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cells was counted, and the volume of cell solution sodded for each scaffold was recorded.
The cell-scaffold construct was then incubated at 37ºC for 4 hours in a petri dish filled
with EC media. After 4 hours, constructs were removed and stained using the apoptosis
staining protocol. The media that the constructs were incubated in was collected and spun
down, and the cells that had adhered to the petri dish were also trypsinized and spun
down. These cells were counted to determine how many cells did not adhere to the
scaffold from the volume that was sodded.
Image quantification methods had to be established to determine cell coverage,
caspase activity, and dead cell coverage from the images taken on the confocal
microscope. Images were taken at 20x magnification, as the focal plane of the
microscope does not reach the curved scaffold at 40x magnification. Due to this,
individual cell nuclei could not accurately be counted. Instead, an assumption regarding
the size of a cell nuclei compared to the whole area had to be made to estimate the
number of cells present. Using sample 20x magnification images from literature of
HUVECs stained with Hoechst and cadherin (which outlines the cytosol), the ratio of
nucleus size compared to the entire cell size was estimated to be 23.42%. Dividing 100%
(the area of the entire cell) by 23.42% gives a value of 4.27, which acts as a
multiplication factor for the total stained nuclei area to extrapolate a cell coverage
estimation. The Analyze Particle function in ImageJ was used to calculate the total nuclei
area of each image in pixels2, seen in Figure 40, which was then multiplied by 4.27 to
estimate cell area. The cell area estimation was then compared to the whole image area to
determine percent of cell coverage.
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Figure 40: Hoechst Channel Coverage Quantification. (A) Raw Hoechst image. (B)
Hoechst channel with threshold applied. (C) Automated cell area quantification.

The Caspase and Propidium Iodide channel images were quantified in a similar
method, although the assumption was made that the whole cell was fluorescing in these
channels, so no multiplication factor was necessary to determine signal coverage. The
Analyze Particle function was used again to determine area of both Caspase and
Propidium Iodide activity, and a percent coverage was calculated. This coverage was then
normalized to the Hoechst channel cell coverage percentage of the same image to
determine an estimated percent apoptotic or dead cells. Salt scaffold coverage in all three
channels was compared against coverage of the standard scaffolds.

3.2.4 BVM Cell Coverage and Viability Assay
The final assay developed in this aim compared the standard scaffolds against two
types of BTEAC scaffolds in BVM constructs at 3 and 7-day time points. Seven vessels
were included in each time point: two standard PLGA scaffolds, two 0.5% BTEAC salt
scaffolds, two 3% BTEAC salt scaffolds, and one ePTFE scaffold. The 0.5% BTEAC salt
scaffold served as a low-salt group, while the 3% BTEAC salt was a high-salt group. The
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ePTFE served as a negative control because ePTFE is known to be bioinert and nontoxic
to cells. Since the standard PLGA scaffolds have not been characterized before, they
could not serve as a negative control.
The standard methods for constructing EC-only BVMs were used, which can be
found in Appendix H and Appendix I. One additional step had to be used on the salt
scaffolds; it had been found that these scaffolds shrink substantially upon ethanol
sterilization, both in length and circumferentially. Therefore, 4 mm salt scaffolds were
electrospun and were then pre-shrunk on 3 mm mandrels in 70% ethanol for 15 minutes
before being cut to the appropriate length and attached to fittings. Standard scaffolds
were still electrospun to be 3 mm. Changes in scaffold lengths were tracked throughout
the preshrink and cultivation.
At the 3 and 7-day timepoints, BVMs were removed from the bioreactors and cut
in half. One half of the scaffold was fixed in 2.5% glutaraldehyde and used for SEM
imaging, while the other half was immunostained using the apoptosis staining protocol.
Image quantification was performed for all three channels using the methods described in
Section 3.2.3.

3.3 Results
Due to the large number of images, only representative images will be included in
this section as needed. A larger set of images can be found in Appendix M, Appendix N,
Appendix O, and Appendix P.
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3.3.1 Stain Verification
Before applying the apoptosis stain kit to any experiment, the three stains
included in the kit were verified and optimized on the confocal microscope. Table 5
shows images of each case necessary to verify that no bleed through occurred between
channels during imaging. Each row shows the same imaging area taken with a different
laser in each channel. The three channels, Hoechst, Caspase, and Propidium Iodide,
correspond to the three stains in the apoptosis kit. The “no stain” group in the first row
serves to verify that no autofluorescence was present in the sample. The lack of signal in
each channel shows that there was no autofluorescence from the HUVECs used in these
images.

Table 5: Apoptosis Staining Kit Verification using HUVECs.
Hoechst

Caspase

No Stain
20x

Hoechst
only 20x
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Propidium Iodide

Caspase
only 20x

Propidiu
m Iodide
only 20x

All Stains
20x

The middle three rows in Table 5 show samples that have only been stained with
a single staining component from the kit. If bleed-through were occurring from one of the
three stains, more than one channel would have signal in it. In this case, each row has a
single image with signal in the correct channel. Therefore, no bleed-through was
occurring between channels in this kit. The fifth row shows HUVECs that were stained
with all three kit components, so each channel has signal in it. However, the Caspase
channel has little signal in it, which is expected for untreated HUVECs in culture that
should not be undergoing apoptosis. A positive control, in this case a treatment to induce
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apoptosis, was necessary in order to verify that the Caspase stain appropriately identifies
apoptotic cells.
The two inducers of apoptosis, hydrogen peroxide and DMSO, were applied to
HUVECs at increasing concentrations and lengths of time to determine a treatment that
resulted in appropriate apoptosis detection. This treatment group should result in nearly
all cells being labeled for apoptosis without completely killing the cells. This treatment
should also result in cells stained in the cytosol and the nucleus, as the poly caspase stain
used here should label caspases present in both areas of the cell. A sufficient apoptosis
inducer should result in the labeling of the whole cell. Figure 41 and Figure 42 show
treatment groups that were insufficient at inducing apoptosis. The 15% DMSO treatment
for 30 minutes in Figure 41 resulted in some signal in the cytosol of the cell. This signal,
however, was not as strong as would be expected from a positive control, and no cells
were stained in the nuclei. An important clarification is necessary to establish here: while
these cells do not have sufficient caspase activity to be positive controls, these cells are
still apoptotic. Any cell with caspase signal throughout the cytosol will still be considered
apoptotic and quantified as so in the remaining experiments. All DMSO treatment groups
were insufficient as the positive control, which can be seen in Appendix M.
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Figure 41: Ineffective Positive Control DMSO 15% 30 Minutes. HUVECs treated
with 15% DMSO for 30 minutes in Hoechst (left), Caspase (middle) and Propidium
Iodide (right) channels. These images indicate that 15% DMSO treatment for 30 minutes
was not a strong inducer of apoptosis. High resolution images can be obtained from Dr.
Cardinal.

Figure 42: Ineffective Positive Control Hydrogen Peroxide 1% 2 Minutes. HUVECs
treated with 1% hydrogen peroxide for 2 minutes in Hoechst (left), Caspase (middle) and
Propidium Iodide (right) channels. These images indicate that 1% hydrogen peroxide
treatment for 2 minutes was not a strong inducer of apoptosis. Red arrows point to cells
that are stained for Caspase in the cytosol but not the nuclei. High resolution images can
be obtained from Dr. Cardinal.
The 1% hydrogen peroxide treatment for 2 minutes shown in Figure 42 was
insufficient as well; while many of the cells were stained in the cytosol and nucleus, there
were some cells that lacked the stain in the nucleus. Many of the other hydrogen peroxide
treated groups were also insufficient, which can be seen in Appendix M. However, two
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hydrogen peroxide groups were identified as sufficient positive controls, which are
displayed in Figure 43 and Figure 44. Both groups had the cytosol and nucleus of all cells
intensely labeled for caspase activity without resulting in large amounts of dead cells.
These two treatment groups were used as positive controls in the cytotoxicity elution
tests.

Figure 43: Effective Positive Control Hydrogen Peroxide 0.5% 5 Minutes. HUVECs
treated with 0.5% hydrogen peroxide for 5 minutes in Hoechst (left), Caspase (middle)
and Propidium Iodide (right) channels. High resolution images can be obtained from Dr.
Cardinal.

Figure 44: Effective Positive Control Hydrogen Peroxide 1% 5 Minutes. HUVECs
treated with 1% hydrogen peroxide for 5 minutes in Hoechst (left), Caspase (middle) and
Propidium Iodide (right) channels. High resolution images can be obtained from Dr.
Cardinal.
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3.3.2 Cytotoxicity Elution Assay
The primary purpose of this study was to determine if the eluted contents from the
BTEAC salt scaffolds resulted in higher numbers of apoptotic cells than standard
scaffolds. Two elution methods were initially investigated, both of which were
recommended by ISO 10993, and evaluated based on scaffold degradation and pH.
Elutions were conducted at 70ºC for 24 hours and 50ºC for 72 hours. Figure 45 shows
scaffolds after removal from elutions, Figure 46 shows the color of the eluted media, and
Table 6 displays the pH of elution from different scaffold types from each protocol. Each
of these figures will be described and included below.
The 70ºC elution for 24 hours, shown in Figure 45A, resulted in warped and
crumbling scaffolds, many of which began to flake into the eluted media upon removal.
The 50ºC elution for 72 hours resulted in stiffening and brittleness of the scaffolds, but
they retained their shape and did not crumble during removal from the elution. There was
also a stark difference in media color from the two elution protocols, in which the color
was independent of the type of scaffold used. Figure 46B shows a yellow coloration to
the eluted media, while the eluted media in Figure 46C is pink in color. The pink color in
the 50ºC eluted media is like the color of the HUVEC media before the elution protocol.
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Figure 45: Scaffolds After Elution Treatment. (A) Scaffolds after 70ºC elution for 24
hours. (B) Scaffolds after 50ºC elution for 72 hours. In both A and B, two scaffolds on
the left are 3% salt scaffolds and the scaffolds on the right are standard scaffolds.
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B
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Figure 46: Media After Elution Treatment. (A) Standard media that has not been
eluted. (B) Media eluted at 70ºC for 24 hours. (C) Media eluted at 50ºC for 72 hours.

A change in color from pink to yellow generally indicates a change in pH towards
an acid. Based on the change in media color in the 70ºC elution, it would be expected that
this media would be acidic. This was confirmed after testing the pH, seen in Table 6. For
the 70ºC elution the standard scaffold resulted in a pH of 7.0, while the 3% salt scaffold
had a pH between 7.0 and 7.5. The 50ºC elution had consistent pH values of 7.5 for both
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scaffold types. These values were similar to the non-eluted media, which had a pH of 7.5.
It was unsurprising that some of the elutions were slightly acidic, as PLGA breaks down
into acidic byproducts168. Based on the structural retention of the scaffolds after the
elution and no observations of a color or pH change in the eluted media, it was decided to
use the 50ºC elution for 72 hours during the cytotoxicity study.

Table 6: pH of Elutions from Treatment Methods.
Non-eluted Media
Standard Scaffold
Average
3% Salt Scaffold
Average

70ºC Elution for 24
hours
7.0

50ºC Elution for 72
hours
7.5

7.0 - 7.5

7.5

7.5

The eluted media from each type of scaffold was then used to treat HUVECs for
24 or 48 hours before the samples were stained and imaged. The quantification methods
for each channel differed. An automated cell counter for the Hoechst channel was used to
count the nuclei; however, it was unknown what magnification was appropriate for
automated counting. Two magnifications were investigated, 20x and 40x, to determine
the accuracy of the automated counter compared to a manual count. It was found that the
automated cell count at a 20x magnification had an error of 40.02%, while the automated
cell count at 40x had an error of 9.15%. This data can be found in Appendix Q. With
such a high margin of error from the 20x magnification automated counting, images at
40x magnification were used for the cytotoxicity assay.
Unlike the Hoechst channel, the Caspase and Propidium Iodide channels had to be
quantified manually. In order to aid the counter, it was decided to eliminate pixels below
a certain intensity to emphasize cells that were truly apoptotic or dead. This would help
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reduce background noise and increase the accuracy of Caspase or Propidium Iodidepositive cell counts. In order to determine the range of pixel intensities to eliminate, a
manual cell count was performed on Caspase and Propidium Iodide channels at
increasing pixel reduction values. The cell count after each pixel reduction was then
compared to the original number of Caspase or Propidium Iodide-positive cells. The cell
count percent change for the Caspase channel and Propidium Iodide channel is presented
in Figure 47. It was hoped that a plateau region would be obvious in both graphs, which
would indicate an appropriate minimum pixel intensity. However, neither channel had a
plateau, so it was decided to limit the loss of signal positive cells to less than 10%.
Therefore, a pixel intensity reduction of 15 and 20 were used for the Caspase and
Propidium Iodide channels, respectively. The raw data for these graphs can be found in
Appendix R.
B

A

Figure 47: Cell Count Reduction Curves. (A) Caspase-positive cells percent change as
minimum pixel intensity increases. (B) Propidium Iodide-positive cells percent change as
minimum pixel intensity increases.
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With the image quantification methods established, the raw images of HUVECs
treated with either a dilution or non-dilution of eluted media from standard or salt
scaffolds could be quantified and analyzed. A negative control of HUVECs treated with
normal EC media was included, as well as two positive control groups using 0.5% and
1% hydrogen peroxide for 5 minutes. Representative raw images from this study can be
found in Appendix N.
Figure 48 displays the percent of Caspase-positive cells in each treatment group.
A three-way ANOVA was run for treatment length, dilution, and scaffold type. At each
treatment length there was no difference between the 50% dilution and no-dilution groups
regardless of scaffold type. For each treatment length, the negative control, 50% dilution
standard scaffold, and no-dilution standard scaffold groups had lower percentages of
Caspase-positive cells than the 50% dilution salt scaffold and no-dilution salt scaffold
groups. Furthermore, for each treatment length, the 50% dilution salt scaffold and nodilution salt scaffold groups had lower percentages of Caspase-positive cells than either
positive control groups. In summary, the negative control and standard scaffold groups
had less caspase activity than the salt scaffold groups, which had less activity than the
positive control groups.
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Figure 48: Cytotoxicity Elution Assay Percent Caspase Positive Cells. Percentage of
Caspase positive cells in each treatment group. The * indicates a difference in the 24hour timepoint compared to the 24 hour no dilution salt scaffold group and a difference in
the 48-hour timepoint compared to the 48-hour no dilution salt scaffold group (p<0.001).

In order to eliminate rates of naturally occurring apoptosis from the data, the
normal scaffold and salt scaffold treatment groups were normalized to the negative
control. This is shown in Figure 49, and this normalization eliminated significant
differences seen previously in Figure 48. No differences in percent caspase-positive cells
were found between time points, within timepoints of the same treatment, between
scaffold types, nor between dilution groups.
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Figure 49: Normalized Cytotoxicity Elution Assay Percent Caspase Positive Cells.
Percentage of Caspase positive cells normalized to the negative control group. No
differences were observed between treatment groups nor timepoints.

Figure 50 shows the percent of Propidium Iodide positive cells per treatment
group, which includes a negative control and two positive controls. All treatment groups
had a higher percent of Propidium Iodide positive cells at the 48-hour treatment length
than at 24 hours. No differences were seen between treatment groups at 24 hours. For the
48-hour treatment length, there was no difference between the positive control groups
and the 50% dilution salt scaffold. However, the no dilution salt scaffold group had a
lower percentage of Propidium Iodide positive cells than the 50% dilution salt scaffold
group. Similarly, in the 48-hour treatment length, the no dilution standard scaffold had a
lower percentage of Propidium Iodide positive cells than both the 50% dilution standard
scaffold and the negative control group. These relationships between dilution and
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undiluted groups is surprising, as it is opposite of how a dilution group is expected to
affect cell death if the elution does have an effect.

Propidium Iodide Positive Cells
#
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Figure 50: Cytotoxicity Elution Assay Percent Propidium Iodide Positive Cells.
Percentage of Propidium Iodide positive cells in each treatment group. The * indicates a
difference in percentage at 48 hours compared to the no dilution salt scaffold group at 48
hours (p<0.05). The # indicates a difference between the 24 and 48-hour time point
within the group (p<0.05).

Like with the Caspase group, the treatment groups for Propidium Iodide positive
cells were normalized to the negative control group to eliminate natural cell death rates.
Figure 51 displays these results after normalization. This normalization did not eliminate
the pattern of dilution effects seen previously in Figure 50. At 48 hours, both the standard
scaffold and salt scaffold dilution groups had more Propidium Iodide positive cells than
their corresponding undiluted groups. At 24 hours, no difference persisted between all
treatment groups.
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100

Percent Propidium Iodide Positive Cells (%)

90
80
70
60

*

50

24 Hours

40

48 Hours

30
20
10

#

0
-10

50% Dilution Standard
Scaffold

50% Dilution Salt
Scaffold

No Dilution Standard
Scaffold

No Dilution Salt
Scaffold

-20

Figure 51: Normalized Cytotoxicity Elution Assay Percent Caspase Positive Cells.
Percentage of Propidium Iodide positive cells normalized to the negative control group.
The * indicates a difference compared to all other groups at both timepoints (p<0.01).
The # indicates a difference compared to the 48-hour no dilution standard scaffold group
(p<0.01).

3.3.3 Cell Adhesion and Viability Assay
The cytotoxicity elution assay assessed cell apoptosis and death without direct
scaffold contact. While these toxicity measurements are useful, other metrics are
necessary to assess novel scaffolds, especially regarding initial cell interactions.
Therefore, the cell adhesion assay assessed cell coverage and scaffold toxicity 4 hours
after HUVECs had been sodded onto the scaffolds. Some data regarding cell deposition
could be collected without imaging through cell counts. Estimations of cell sodding
numbers are shown in Table 7. While this data does not visually measure cell adhesion, it
is an indirect calculation of how many cells remained sodded to the scaffold. The
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standard scaffolds were sodded with 9.02 million cells, while the salt scaffolds were only
sodded with 3.76 million cells. The difference in the number of cells sodded is because,
unlike the standard scaffolds, only a portion of the desired cell solution could be injected
into the salt scaffolds due to pressure buildup. This pressure could be a result of cells
clogging the smaller pores of the salt scaffolds. Interestingly, a much higher percent of
the sodded cells was collected from the petri dishes of salt scaffolds even though less
cells were sodded. This would suggest that less of the cells sodded to the salt scaffolds
remained in the scaffolds, or that less cells are needed to sod salt scaffolds to create a
confluent cell lining.

Table 7: Short-term Adhesion Assay Cell Sodding and Collection Data.

Standard
Scaffold
3% Salt
Scaffold

Number of cells sodded
per scaffold
(cells/scaffold)
9.02E6

Collected cells from
petri dish (cells)

Percent of cells
collected (%)

1.17E6

12.97

3.76E6

1.59E6

42.29

The immunofluorescent imaging of the scaffolds was a more direct and visual
assessment of cell coverage. To estimate cell coverage, an assumption had to be made
regarding the size of a cell nucleus compared to the size of the entire cell. The ratio of
these measurements could then be used as a factor with which to multiply the area of cell
nuclei by to estimate the area of cell coverage. Since images were being taken at 20x
magnification, sample images from literature of HUVECs taken at 20x, seen in Figure 52,
were measured in ImageJ to determine the average nuclei and whole cell size. It is
unknown how these images may differ from the images taken from the 20x setting on the
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confocal microscope used in this aim, but this value was only intended to be an
estimation, so some difference was expected. Raw area measurements can be found in
Appendix S. The average nucleus was found to be 23.42% of the entire cell. Dividing
100% of the cell area by 23.42% results in the factor 4.27, which was used as the
multiplication factor to estimate cell coverage.

Figure 52: Sample 20x HUVECs. Images from literature of HUVECs taken at a 20x
magnification. These cells were stained with junctional markers, which outline the entire
cell169.

Figure 53 displays representative images of the Hoechst channel for standard and
salt scaffolds. Upon visual comparison, the salt scaffolds had a far greater number of cells
than the standard scaffolds. It also appeared that the standard scaffolds had decreasing
cell coverage from proximal to distal ends, while the salt scaffold had similar coverage
along the entire scaffold. Quantification data supported this visual assessment.
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Figure 53: Standard and Salt Scaffolds Hoechst Channel. Standard scaffolds
proximal (A), middle (B), and distal (C) show less coverage than salt scaffolds at
proximal (D), middle (E), and distal (F) locations. High resolution images can be
obtained from Dr. Cardinal.

Figure 54 compares estimated cell coverage between scaffold types at different
areas of the scaffold. Salt scaffolds had higher coverage than standard scaffolds. There
was also a trend of decreasing coverage along the length of the standard scaffold group.
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Figure 54: Short-term Adhesion Assay Percent Cell Coverage. Estimated percent cell
coverage for standard and salt scaffolds on the proximal, middle, and distal areas of the
scaffold. The * indicates a difference in coverage between the scaffold types (p<0.001).

Apoptosis and cell death were also quantified using the Caspase and Propidium
Iodide channels, respectively. Figure 55 shows representative images of Caspase and
Propidium Iodide channels for the different scaffolds. Figure 56 shows that no
differences were seen in the estimated percent of apoptotic cells between the standard
scaffolds and salt scaffolds. Even though apoptotic cells showed no differences, there
were differences in the percent of dead cells. Figure 57 shows that there was a higher
estimated percent of dead cells in the salt scaffold group than the standard scaffold group.
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Figure 55: Caspase and Propidium Iodide Channels Short-term Adhesion Assay.
Salt and standard scaffolds at 20x magnification. (A) Caspase channel for standard
scaffold. (B) Propidium Iodide channel for standard scaffold. (C) Caspase channel for salt
scaffold. (D) Propidium Iodide channel for salt scaffold. High resolution images can be
obtained from Dr. Cardinal.
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Figure 56: Short-term Adhesion Assay Percent Apoptotic Cells. Estimated percent
apoptotic cells for standard and salt scaffolds on the proximal, middle, and distal areas of
the scaffold. No differences were observed between scaffold types or areas of the
scaffold.
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Figure 57: Short-term Adhesion Assay Percent Dead Cells. Estimated percent dead
cells for standard and salt scaffolds on the proximal, middle, and distal areas of the
scaffold. The * indicates a difference in dead cells between the scaffold types (p<0.001).
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3.3.4 BVM Cell Coverage and Viability Assay
The 4-hour time point was useful for assessing immediate cell attachment and
interactions with the scaffold. However, to implement novel scaffolds these scaffolds
need to prove useful in BVMs for multiple days. This experiment investigated how low
and high percentage salt scaffolds compare to standard scaffolds at 3 and 7-day
timepoints. Since this assay has not been previously conducted on standard scaffolds, an
ePTFE scaffold was added as a negative control with which to compare all electrospun
scaffold types. At each time point, 2 vessels of each electrospun scaffold type were
fabricated. Unfortunately, one 0.5% vessel at the 7-day time point was lost due to
contamination.
Since it was previously noted that the salt scaffolds shrink during sterilization,
changes in scaffold size were measured throughout the fabrication of the BVMs.
Measurements of salt scaffold lengths were taken before and after preshrinking, and all
scaffolds were measured before and after BVM cultivation. Figure 58 shows the changes
in salt scaffolds from the preshrink and cultivation. The scaffold groups display a
proximal and distal, which is differentiating between the end of the mandrel in which the
scaffold was sourced since each mandrel produces two scaffolds. Scaffold length changed
more during preshrinking than during cultivation, which suggests that the preshrinking is
useful as a method of reducing salt scaffold shrinking during cultivation. The change in
length for all scaffolds after BVM cultivation is provided in Figure 59, which shows that
both salt scaffold groups shrank more than standard scaffolds. Surprisingly, the standard
scaffolds slightly expanded in length during the BVM cultivation.
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Figure 58: Salt Scaffold Shortening Before and After BVM Cultivation. Reduction in
salt scaffold lengths from preshrinking and from the BVM cultivation. The * indicates a
difference of change in length compared to the BVM cultivation group (p<0.01).
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Figure 59: Standard and Salt Scaffold Shortening After BVM Cultivation. Reduction
in the scaffold length during the 3 or 7-day BVM cultivation. The * indicates a difference
for change in scaffold length compared to the standard scaffold group (p<0.05).

The thickness of the scaffold walls was measured after BVM cultivation. There
was no difference in scaffold thickness between the 0.5% and 3% salt scaffold groups,
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but the 3% salt scaffold group had a greater wall thickness than the standard scaffold
group. This difference was expected; the salt scaffolds used 25% more PLGA than the
standard scaffolds to accommodate for the 4 mm mandrel.
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Figure 60: Wall Thicknesses of Scaffolds in BVMs. The * indicates a difference in
thickness compared to the standard scaffold group (p<0.05).

Like with the cell adhesion assay, cell coverage was first quantified for the BVMs
to investigate the effect of scaffold type and cultivation duration. Figure 61 shows images
of 3-day BVMs from each scaffold group, and Figure 62 shows 7-day BVM images from
each scaffold group.
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Figure 61: Representative 3-day BVM Hoechst Images. Proximal (left), middle
(middle), and distal (right) locations. (A) ePTFE scaffold, (B) standards scaffold, (C)
0.5% salt scaffold, (D) 3% salt scaffold. High resolution images can be obtained from Dr.
Cardinal.
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Figure 62: Representative 7-day BVM Hoechst Images. Proximal (left), middle
(middle), and distal (right) locations. (A) ePTFE scaffold, (B) standards scaffold, (C)
0.5% salt scaffold, (D) 3% salt scaffold. High resolution images can be obtained from Dr.
Cardinal.
137

The quantification results of BVM cell adhesion images are shown in Figure 63.
No differences between image locations (proximal, middle, distal) were detected, so these
images were averaged in the values seen in this figure. The 0.5% and 3% salt scaffold
BVMs had greater cell coverage than the ePTFE and standard scaffold BVMs. Every
scaffold type had a difference in coverage between the 3 and 7-day timepoints; however,
the 7-day vessels had less coverage than the 3-day vessels for all scaffold types. It would
be expected that the longer time point vessels would have a better cell coverage than the
shorter time point.

Average BVM Coverage by Scaffold Type
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Figure 63: BVM Cell Coverage in 3 and 7-Day BVMs. The * indicates a difference in
3-day cell coverage compared to the 3-day ePTFE group and a difference 7-day cell
coverage compared to the 7-day ePTFE group (p<0.05). The # indicates a difference in
cell coverage between timepoints within the scaffold type (p<0.05).

Cell viability was also of interest, which was determined through Caspase and
Propidium Iodide activity. Figure 64 and Figure 65 show representative images of the
Caspase and Propidium Iodide channels from every BVM type at each time point. The
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quantification results of these images are shown in terms of estimated percent apoptotic
and dead cells, as the Caspase and Propidium Iodide coverage was normalized to the cell
coverage. The standard and 3% salt scaffold BVM groups at 3 and 7 days, as well as the
7-day time point of the 0.5% salt scaffold BVM group, had a higher percent of apoptotic
cells than the ePTFE BVM group, shown in Figure 66. The 0.5% salt scaffold BVM was
the only treatment group to show a difference between the 3 and 7-day timepoints, in
which the 7-day BVMs had a higher percentage of apoptotic cells than the 3-day BVMs.
For this group the 3-day time point showed levels of apoptosis similar to that of the
ePTFE BVMs. Estimated dead cells did not reflect this pattern.
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Figure 64: Images of 3-day BVM Caspase and Propidium Iodide Channels. Caspase
channel (left) and Propidium Iodide channel (right) for all BVM types: (A) ePTFE
scaffold, (B) standards scaffold, (C) 0.5% salt scaffold, (D) 3% salt scaffold. High
resolution images can be obtained from Dr. Cardinal.
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Figure 65: Images of 7-day BVM Caspase and Propidium Iodide Channels. Caspase
channel (left) and Propidium Iodide channel (right) for all BVM types: (A) ePTFE
scaffold, (B) standards scaffold, (C) 0.5% salt scaffold, (D) 3% salt scaffold. High
resolution images can be obtained from Dr. Cardinal.
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Figure 66: Percent Apoptotic Cells in 3 and 7-Day BVMs. The * indicates a difference
in 3-day apoptosis percentage compared to the 3-day ePTFE group and a difference 7-day
apoptosis percentage compared to the 7-day ePTFE group (p<0.05). The & indicates a
difference in apoptosis percentage from the ePTFE group compared only the 7-day time
point (p<0.05). The # indicates a difference in percent apoptosis between timepoints
within the scaffold type (p<0.01).

Figure 67 shows that there were no differences in cell death between BVM types
at 3 days, and at 7 days only the 3% salt group was higher than the other three groups.
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Figure 67: Percent Dead Cells in 3 and 7-Day BVMs. The * indicates a difference
when compared to all other timepoints and scaffold types (p<0.01).

3.4 Discussion and Conclusion
The purpose of Aim 2 was to establish methods with which to assess novel
scaffolds through the cell-scaffold interactions. The primary measurements by which to
achieve this were estimates of cell coverage and cell viability through measuring
apoptotic and dead cells. It should be noted that it is possible for cells to be positive for
both Caspase and Propidium Iodide170.

3.4.1 Cytotoxicity Elution Assay
The cytotoxicity assay treated cells with diluted or undiluted media that had been
eluted with standard or salt scaffolds. Eluted media was applied for 24 and 48-hour
timepoints. This study found that the 3% salt treated groups resulted in more apoptotic
143

cells than the standard scaffold treated groups, either diluted or undiluted, until being
normalized to the negative control. Once this data was normalized, this difference was no
longer significant. This displays the importance of including appropriate controls within
experiments; without removing the natural amount of apoptosis, incorrect conclusions
could be drawn. The knowledge that the salt scaffold elutions were comparable to
standard scaffolds in inducing apoptosis will be important when considering whether salt
scaffolds should be used in BVMs.
After normalization, more dead cells were present at the 48-hour time point than
the 24-hour time point for all treatment groups except the no dilution standard scaffold
group. An unexpected trend was found between the diluted and undiluted treatments. It
would be expected that the undiluted treatments would result in more dead cells because
there are more cytotoxic substances than in the dilution group. However, for both types of
scaffolds the dilution groups resulted in more Propidium Iodide positive cells than the
undiluted treatments. This disconnect between how the elutions are affecting the cells
implies an unknown variable affecting cell death.
While conclusions regarding the effectiveness of the dilution groups cannot be
drawn, it can be concluded that undiluted eluted media did not cause extensive levels of
apoptosis or cell death. The dilution groups were a preemptive measure. If the undiluted
elutions, regardless of the scaffold type, were too cytotoxic to the cells and killed all
treatment groups, the resulting data would have been largely inconclusive. Since the
undiluted treatments did not result in high amounts of apoptosis and dead cells, the
dilution groups would serve no purpose in future studies and should therefore not be
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included. A control group of cell media heated at the elution settings should be added to
future work to ensure that the elution process is not affecting the media characteristics.
Overall, this assay was useful in determining differences in cytotoxicity between
scaffolds. It confirmed the results seen in the cytotoxicity study by Park et al in which a
small planktonic crustacean was treated with BTEAC scaffold elution product and found
to be unaffected164. Since the scaffolds were not cytotoxic in this assay, further
experiments were carried out to address direct scaffold cytotoxicity and cell adhesion.

3.4.2 Cell Adhesion and Viability Assay
Theoretically, the nanofibers of the salt scaffolds should improve cell adhesion
compared to the microfibers of the standard scaffolds128. The present work found that the
3% salt scaffolds had higher cell coverage than the standard scaffolds. Two to three times
the number of cells were adhered to the salt scaffolds, even though half the number of
cells had been initially sodded as compared to the standard scaffold. On top of that, a far
greater percentage of those sodded cells were collected from the petri dish in which the
scaffolds had been sodded. This speaks to the sodding efficiency of these scaffolds and
implies that perhaps only 1.58E6 cells/mL, or about 6.7E5 cells/cm 2, would have been
needed.
Another important observation was the resistance of the salt scaffolds during
pressure sodding. The reason that less cells were sodded on the salt scaffolds as
compared with the standard scaffolds was that more cell solution could not be physically
forced through the salt scaffolds. It is possible that the cells quickly clogged the small
pores in the salt scaffolds, blocking additional cells from being sodded. The standard
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scaffolds did not react in this way; little resistance was felt during pressure sodding. One
explanation for this is that the cells were either passing through the standard scaffold
pores or were populating within the walls of the scaffolds. The latter is more likely, as a
low percentage of the sodded cells was collected from the petri dish, indicating that the
cells remained in the scaffold. This could be verified through hematoxylin and eosin
staining of cross-sections of scaffold wall to determine cell infiltration.
The estimated percent of apoptotic cells in the 3% salt scaffold group was not
found to be different than that of the standard scaffolds, continuing to support the utility
of salt scaffolds as replacements for standard scaffolds. Even though the percent of
apoptotic cells did not differ, the percent of dead cells did, with the salt scaffolds having a
higher percentage of dead cells than standard scaffolds. Since this difference was not seen
regarding apoptosis, one of two explanations could explain this data. Either cells are
dying as a result of pathways outside of apoptosis, or the methods used to remove
background noise from the Propidium Iodide channel were insufficient. The second
option is more likely than the first because it is unlikely that many cells are dying as a
result of necrosis instead of apoptosis. The Propidium Iodide channel had a high amount
of background noise in the images, so pre-quantification alterations should be revisited
during image analysis of future studies.

3.4.3 BVM Cell Coverage and Viability Assay
Since the salt scaffolds improved cell adhesion without affecting apoptosis in the
previous two studies, the scaffolds were tested for efficacy in BVMs. The salt scaffolds
required preshrinking, and this method was shown to be effective at eliminating
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shrinkage before conditioning scaffolds in the bioreactors. Aside from this step, the salt
scaffolds did not react differently than standard scaffolds when preparing them for or
securing them in bioreactors. In fact, the salt scaffolds were often easier to secure to
fittings because the material was more elastic than standard scaffolds, so the scaffold
ends could be widened more easily without risk of tearing the scaffolds.
Cell coverage was greater in the 0.5% and 3% salt scaffold BVMs than the
standard scaffold, which reflects the findings of the cell adhesion study. Cell adhesion
between the two types of salt scaffolds was comparable. Regarding scaffold effects on
apoptosis in BVMs, standard and 3% salt scaffold BVMs at both timepoints had a higher
percent of apoptotic cells than the ePTFE BVM. The 7-day time point for the 0.5% salt
scaffold also had this difference from the ePTFE scaffold, but the 3-day time point did
not. The 0.5% salt scaffold was the only group to have a difference in apoptosis between
timepoints. The 0.5% salt scaffold at 7 days only had a single repetition (as a result of
contamination), so this difference may not present itself with increasing repetitions of 7day BVMs. This difference did not translate to estimated dead cells. Only the 7-day 3%
salt scaffold had a higher percentage of dead cells than any of the other treatment groups.
The 0.5% salt group was comparable to the standard scaffold group at both timepoints.
While these findings support the utility of the salt scaffolds in BVMs, there was
one surprising trend in cell coverage. Each treatment group had lower coverage at the 7day time point than the 3-day time point. Since apoptosis did not increase between
timepoints (except for the 0.5% salt scaffold BVM), scaffold cytotoxicity over time is
unlikely to be the cause of this decreased coverage. Since this trend is consistent, it is
possible that user error was a result. Since the two timepoints were not started on the
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same day and not sodded with the same cell solution, variability in the number of sodded
cells and how the cells were sodded on that day may exist. Since the same concentration
of cells was used on both timepoints, differences in sodding technique each day may be
the cause. To eliminate this possible variability in the future, sets of BVMs should
include vessels of both timepoints.
This study also dispelled concerns about salt scaffold cytotoxicity through direct
contact. Park et al. documented the use of electrospun BTEAC salt scaffolds as antiviral
and antibacterial surfaces161. This antiviral and antibacterial characteristic could
negatively affect cells in direct contact with the scaffold. However, the work in this thesis
did not show that high or low concentrations of BTEAC salt scaffolds caused more
cytotoxicity than standard PLGA scaffolds. Furthermore, even though these scaffolds
were shown to be antibacterial by Park et al., a 0.5% salt scaffold did become
contaminated with what was most likely bacteria. The contamination of this 0.5% salt
scaffold BVM was unlike past contaminations of standard scaffold BVMs. Usually, the
bioreactor and reservoir media changes color and becomes cloudy. However, this BVM
only showed this color change in the reservoir and not in the bioreactor. This indicates
that the salt scaffold contained the contamination to only the flow loop from the lumen of
the scaffold to the bioreactor. If this is the case, then this suggests that salt scaffolds may
allow little perfusion of media through the wall of the scaffolds.

3.4.4 Limitations and Future Work
A substantial limitation in this aim was the use of a poly-Caspase stain, which
stained many types of Caspase in the cell. While this stain was useful for initial
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investigations, it may have been nonspecific. Other stains are available which only stain
for Caspase that are active in the execution pathway of the apoptosis cascade. Future
work should investigate and, most likely, implement a more specific Caspase stain, such
as the Image-IT LIVE Green Caspase-3 and 7 Detection Kit (Molecular Probes). This
would only label cells in the execution pathway which will apoptose, unlike with other
Caspases that may be active even though the cell will save itself from apoptosis.
The quantification method for analyzing cells on scaffolds was limited by several
assumptions. The first assumption was the factor used to multiply the nucleus area to
estimate the cell coverage. This is not necessarily an accurate estimate because it does not
reflect coverage in areas where cells are clumped. Clumped cells reflect a higher cell
coverage than should be represented. This factor, while limiting, does not change the
trends seen by the data because the value is constant. Since it was possible for this factor
to be incorrect, conclusions were not made that mentioned specific coverage percentages.
Another concern was the possibility that the Caspase antibody stained both active
caspase and procaspases. The fluorochrome-labeled inhibitors of caspase (FLICA)
method of labelling, which was utilized by the Caspase stain in these studies, binds the
active centers of caspases with a fluoromethyl ketone (FMK) 171. The active recognition
sequence on which FMK binds is valine-alanine-aspartic acid (VAD); this active site
should only be available in active caspases in which the small subunit and large subunit
of the procaspase bind. Procaspase to not have this active site 170,171. However, a procaspase 3 monoclonal antibody (ThermoFisher Scientific) could be compared against an
active caspase 3 immunostain (Abcam) to determine if this staining mechanism is
nonspecific. Active caspase 3 should only be present in the execution phase of apoptosis,
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while procaspase 3 should be present in non-apoptotic and apoptotic cells. Therefore,
procaspase would be visible in healthy cells, while a high abundance of active caspase
would only be present after an apoptosis-inducing treatment.
The BVM cell coverage and viability assay showed some cell clumping, which
was not observed in the short-term cell adhesion and viability assay of cells on scaffolds
in static media. The concern with this is that these clumps do not display standard
endothelial morphology and have some areas that look like scaffold stained with
antibodies. It was verified that salt and standard scaffolds do not autofluorescence using
the Hoechst, Caspase, and Propidium Iodide stains, and that these cell clumps contained
individual nuclei in the Hoechst channel. Despite this, future work should make note of
cell clumping when working with the BTEAC salt scaffolds to ensure that cell clumping
does not present as a continued issue.
These three studies did not contain enough repetitions to be statistically
significant, which limits the conclusions drawn in this aim. The cost and labor associated
with creating BVMs generally make a statistically designed study less plausible.
However, power analyses of cell coverage, percent apoptotic cells, and percent dead cells
of cell coverage for a power of 0.80 found that five repetitions per treatment is necessary
for cell coverage and percent apoptotic cells, while six repetitions per treatment are
necessary for percent dead cells. It would be possible to conduct an experiment with 48
vessels, but would require a huge effort by the Tissue Engineering Lab. It is, however,
more plausible to design experiments for the cytotoxicity elution assay and short-term
cell adhesion assay that include enough repetitions of each treatment group to be
statistically significant. Power assessments found that 6 scaffolds of each type are
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necessary for a statistically designed cytotoxicity elution study, while 3 scaffolds of each
type are necessary for a short-term adhesion study. Future studies of scaffold cytotoxicity
and cell adhesion should be planned and executed for both assays to draw conclusions
backed by statistical repetitions.
Modifications could be made to the elution protocol in future studies by
concentrating the eluted media. This would allow for control of the intensity of the media
in which is being delivered to cells. Using a more concentrated product may make
evident trends that could not be identified with less concentrated eluted media.
Concentration of the media could be achieved through filtration using the Ultrafree15
(Sigma-Aldrich) or through phenol extraction172.
Other experiments and analysis could be conducted to investigate the use of these
scaffolds in BVMs. BVM cross-sections could be stained to compare and determine
differences in cell penetration into the scaffold walls. Cryosectioning scaffolds and
staining with hematoxylin and eosin would provide this information.
Since the purpose of the BVM model is to test vascular devices, scaffold types
should eventually be compared for sue as BVMs with stents deployed within them. If
HUVEC-only BVMs using salt scaffolds displayed similar efficacy to dual-sodded
standard scaffolds with stents deployed in both groups, the salt scaffolds would be
superior due to the cell sodding efficiency and simplicity of EC-only BVMs and could be
implemented for future BVM studies.
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3.4.5 Summary
This aim was successful in implementing methods and comparing scaffold
cytotoxicity and cell adhesion between BTEAC salt and standard PLGA scaffolds. No
differences were seen in apoptotic activity between the 3% salt and standard scaffolds in
the cytotoxicity elution assay or short-term adhesion assay. This trend continued between
the 3% salt and standard scaffolds in BVMs, while the 0.5% scaffold had less activity at
the shorter time point but caught up by the 7-day time point. Cell coverage was superior
in the salt scaffolds. With this knowledge, it can be concluded that the salt scaffolds are
comparable to the standard scaffolds regarding cytotoxicity but superior in cell adhesion
and coverage. However, further comparisons of the 0.5% and 3% salt scaffolds still must
be conducted. This conclusion may rely upon some physical evaluations of 0.5% and 3%
salt scaffolds, such as yield strength and fiber diameter. Regardless, testing the
interaction of cells on electrospun BTEAC salt scaffolds is novel, as it has not been
previously documented in published literature. The results in this aim support the
conclusion that standard, 0.5% salt, and 3% salt scaffolds have similar cell viability, as
assessed through Caspase and Propidium Iodide activity, and salt scaffolds have higher
cell adhesion and coverage than standard scaffolds.
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Chapter 4: DISCUSSION AND CONCLUSION

4.1 Summary and Aims of the Thesis
BVMs have proven useful as a preclinical model for testing vascular devices by
providing initial data on how the device interacts with cells 4,9. This success warrants
further investigation into the individual components of the model. Improvements to these
components must be justified and reinforced before implementing them as standard
procedures. Therefore, after identifying an area of improvement, methods must be
established to measure changes in component responses.
The overall goal of this thesis was to establish methods to characterize the
endothelial cells used in the BVM model. The endothelial cell component is, arguably,
the most important part of the model since the EC interaction with vascular devices is the
most important measured response173. Two aspects of EC involvement were identified
which could be improved but lacked established methods to support any changes. Aim 1
established methods to compare EC gene expression at different passages and in different
flow conditions in the context of studying EC dedifferentiation. The use of ECs that
respond like endothelial cells and appropriately express endothelial markers is necessary
to claim that the cell interaction with the vascular device is reflective of an interaction
that would occur in vivo. Aim 2 established methods to compare standard PLGA
scaffolds to BTEAC salt-PLGA scaffolds through studying scaffold cytotoxicity on ECs
and EC cell coverage at varying lengths of time. These methods and the subsequent
results contributed to the model in two ways. The Tissue Engineering lab had no previous
methods for implementing new scaffolds despite having investigated and designed other
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types of scaffolds in the past, so this aim established methods that can be used for future
scaffolds. This aim also identified and tested a novel scaffold that could be implemented
as an improved scaffold for creating BVMs.

4.2 Results and Discussion
Aim 1 can be divided into two subsections: changes in EC gene expression over
culture time, and changes in EC gene expression as a result of various flow conditions.
EndMT would result in downregulation of endothelial markers and upregulation of
mesenchymal markers, while ECs which retain their phenotype would increase
expression of VEGFR2 and VE-cad through VEGF signaling. In the first set of
experiments, a trend was identified of increasing expression of the endothelial markers
VE-cadherin and VEGFR2 as culture time increased. The EC marker PECAM, as well as
the mesenchymal markers ACTA2 and Calponin, remained stable as culture time
increased. These trends do not support culture time contributing to EC dedifferentiation;
EC dedifferentiation would result in loss of EC markers and an increase in mesenchymal
markers.
The second set of experiments in this aim studied gene expression changes in ECs
cultured in static, disturbed, or laminar flow conditions. The establishment of a disturbed
flow condition was successful in that it showed a decrease in VE-cadherin and VEGFR2
abundance compared to ECs in static culture. Unfortunately, the disturbed flow condition
had to be removed from the analysis. The dissociation curves for this group showed
untargeted amplification during qPCR, indicating contaminants within the RNA or
cDNA. However, the static culture group was still compared to the laminar flow group of
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the BVMs. This found that the laminar flow group had lower expression of all three
endothelial markers and ACTA2 than the static culture group, which contradicts trends
seen in literature. These findings are likely explained by the 24-hour time point used for
the BVM, which may have not allowed enough time for ECs to re-establish the cell-cell
junctions measured by the EC markers.
The investigations in Aim 1 were largely inconclusive, although the methods
established can be applied to ongoing and future work. Some trends were identified, but
they did not provide evidence of EC dedifferentiation occurring. These trends are positive
for the BVM model, as they suggest cells retaining an EC phenotype. However, all
studies in this Aim were investigational for method development and not statistically
powered. Properly powered studies would have been conducted had the initial data
suggested that further studies would provide useful data. Unfortunately, this was not the
case, so further studies were not pursued. Despite this, the methods developed here may
prove useful in future studies, which will be discussed in Section 4.4, so gene expression
analysis through qPCR should continue to be implemented as an analysis technique by
the Tissue Engineering Lab.
Aim 2 was composed of three parts corresponding to each of the three assays
developed. In the first part, the cytotoxicity elution assay treated ECs with scaffold-eluted
media for 24 or 48 hours. No differences were found in apoptosis between scaffold type,
and more dead cells were found in the 48-hour group regardless of scaffold type. Since
the change in dead cells was not a factor of scaffold type and apoptotic activity was not
different between scaffold types, it was concluded that salt scaffolds did not adversely
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affect cell viability. This elution assay did not test viability through direct cell contact,
but the two other assays did.
In the second part, the cell adhesion and viability assay looked at initial cell
deposition and apoptotic activity at a 4-hour timepoint. The salt scaffold did not differ in
Caspase activity compared to standard scaffolds, but cell death was higher in the salt
scaffold group than the standard scaffold group. Cell adhesion was higher for salt
scaffolds than standard scaffolds. This suggested that, while more HUVECs adhered at a
short timepoint, the cells may not persist as time increased.
The final part of this aim, the BVM cell coverage and viability assay, was similar
to the previous assay but compared scaffold types in BVMs over multiple days. Cell
coverage was higher in the 0.5% and 3% salt scaffolds than standard scaffolds regardless
of time point. Apoptosis was not higher in the salt scaffolds than the standard scaffolds.
This was also true for cell death, except in the 7-day 3% salt scaffold group which had
more cell death than any of the other scaffold types at that time point. These findings
suggested that HUVECs had similar rates of survival but better coverage in BTEAC salt
scaffolds than standard PLGA scaffolds.
These three parts of Aim 2 found that apoptosis did not differ between standard
PLGA scaffolds and salt scaffolds, but cell adhesion and coverage was notably improved
for salt scaffolds. The only adverse effect of the salt scaffolds was regarding cell death.
This may have been due to the quantification method because it would be expected that
apoptotic activity would reflect the trends of cell death, which was not seen. The form in
which cells died may have also contributed to this result; if cells died through necrosis,
the apoptosis pathway and caspases would not have been activated. A comparison of
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apoptosis to necrosis could be evaluated through immunofluorescence using an
Apoptosis/Necrosis Assay Kit (Abcam), which identifies all cells, apoptotic cells, and
necrotic cells. Nonetheless, it can be concluded from this data that the salt scaffolds are
superior to the standard scaffolds. The 0.5% salt scaffold is recommended as the scaffold
candidate to pursue if the comparison of fiber diameter and other physical characteristics
in the 0.5% and 3% salt scaffolds do not reveal significant differences.

4.3 Challenges and Limitations
The greatest limitation of both Aim 1 and Aim 2 was the lack of statistical
significance in any of the studies. Since both aims were investigational and intended for
method development, the experiments were not designed with statistical power. The
intent of these studies was to properly design experiments if the initial pilots revealed
promising information. For Aim 1, this was not the case, which lead to no statistically
powered studies being conducted. For Aim 2, the pilot studies did reveal promising
information that warranted full studies to be conducted, which will be discussed in the
next section.
A similar limitation has to do with designing properly powered experiments that
use BVMs. The amount of resources and time necessary to produce a small amount of
BVMs makes it difficult to design and complete properly powered experiments. In order
to statistically power Aim 2, 48 BVMs would have been necessary. This is not a practical
amount of BVMs to fabricate for a single study. Issues with contamination can further
reduce the repetitions of treatment groups. Triplicates of each BVM treatment group is a
feasible goal that could be used in place of a statistically powered study.

157

The main challenges in Aim 1 were with the disturbed flow condition. In the
second set of experiments, which compared the disturbed flow condition to a negative
control (static EC media treated) and positive control (static SMC media treated), there
was a high amount of cell death which yielded too low of RNA concentrations to run
qPCR on the samples. As a result, only one of the disturbed flow passages could be
compared with the other two treatments, so comparisons of expression change over
culture time were lost. There were also issues with the disturbed flow treatment group in
the third experiment comparing all three flow groups. A ramp up period was introduced
in this study, which greatly reduced the cell death in the disturbed flow group and a high
enough concentration of RNA was isolated to run qPCR. However, the dissociation curve
for this group showed nonspecific targets in the qPCR products, so they were removed
from the study. It was unclear at which step this issue occurred.
A main limitation of Aim 2 was having no SEM images of BVMs, as it was
initially planned to include these images. This would have provided additional images
from which to observe cell coverage. These images may have been able to visualize
differences cell morphology on the scaffold types. Unfortunately, the SEM was broken,
and images could not be taken in time to include in this thesis.

4.4 Future Work
Although this thesis served to establish methods to characterize endothelial cells
for specific applications, these methods are generic and can be implemented for other
studies. Many other applications of these methods may exist and will prove to be useful
in future studies that have not yet been identified. These sections outline some
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applications that could be investigated in the future, and some applications that are
already being investigated.
A study that links Aim 1 and Aim 2 would be an investigation of gene expression
changes with different scaffold types. This could provide further data to support
implementing salt scaffolds for general use by providing evidence of scaffold type
promoting an endothelial phenotype or endothelial growth. Since calponin did not prove
to be a useful gene in characterizing EC expression changes, that marker could be
removed from the GOI and replaced by a proliferation marker like Ki67. This marker
would indicate whether the sodded cells were quiescent, or whether the cells were
proliferating in the BVM. The sodding density used within BVMs should not promote
proliferation, but this marker would provide information to determine scaffold effects on
proliferative potential.
Aim 1 has already proven effective at steering current work. The previous
immunostaining protocol implemented in the Tissue Engineering Lab used PECAM and
ACTA2 as markers to discern between ECs and SMCs, respectively. However, as
previously established, HUVECs co-expressed PECAM and ACTA2. Through the gene
expression studies in Aim 1, it was clear that Calponin was not expressed in HUVECs.
However, Aim 1 did establish that Calponin was abundant in HUASMCs, making
Calponin an excellent marker to replace ACTA2 for immunostaining. This
recommendation was implemented, and no signal was observed in immunostaining for
Calponin in HUVECs. The Calponin stain also proved to be a clear marker for
immunostaining HUASMCs, shown in Figure 68.

159

Figure 68: Calponin immunostaining of HUVECs and HUASMCs. No Calponin
signal is seen in HUVECs (top row), while Calponin signal is abundant in HUASMCs
(bottom row).

The three EC markers used in Aim 1 could also be applied for studies related to
changing flow rates within BVMs. The current maximum pump rate used in BVMs is 90
RPMs, which translates to only 5.9 mL of media being pushed through BVMs each
minute. Increasing this pump rate or increasing the viscosity of media would increase
shear stress, which is currently far below physiologic levels. Aim 1 showed HUVECs
survived under higher levels of shear stress in the disturbed flow condition, which had
shear stress values ranging from 5 to 15 dyne/cm2. Changes to the pump rate may be
reflected by changes in the mechanosensory complex genes.
Regarding Aim 2, and as mentioned in Section 4.3, a major limitation was not
running statistically powered studies. The data from the cytotoxicity elution study and
short time point adhesion study provided useful data regarding cytotoxicity and cell
adhesion, so properly designed studies using both assays have been planned. The
cytotoxicity study will include three time points (24, 48, 72 hours) and three scaffold
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types (standard, 0.5% salt, 3% salt), but will eliminate the dilution group. The 4-hour
adhesion and viability assay will add the 0.5% salt scaffold group as well. These two
experiments will continue to build upon conclusions made in Aim 2.
The cytotoxicity elution assay is also already being implemented for testing the
cytotoxicity of aneurysm scaffolds. Wax is molded in the shape of the aneurysm on a
mandrel before electrospinning the mandrel. After electrospinning, the wax is dissolved
in a warm media solution to remove the wax. However, some wax remains in the lumen
of the scaffold after dissolving. Multiple types of wax have been used to make these
aneurysm geometries. An ongoing study uses the elution assay to determine whether wax
remaining in the scaffold is cytotoxic, and whether there is a difference in toxicity
between wax types.
Future process adjustments can utilize the cytotoxicity assay to support viability
assessments. A possible application is switching from ethanol sterilization of scaffolds to
ethylene oxide (EtO) sterilization. Concern of EtO gas residuals in the scaffolds has
always precluded this prospect. Current methods for testing EtO residuals involve
extraction in water, so the cytotoxicity elution assay would be an appropriate method to
determine the effect of residuals on cell viability174. Most importantly, EtO sterilization
would substantially simplify the BVM fabrication process; scaffolds could be secured in
bioreactors before sterilization, so only media would need to be added to the bioreactors
and the flow circuit assembled before starting conditioning. No sterile gloves would need
to be used since the scaffolds would not need to be flushed or secured in the sterile
bioreactor. The removal of these steps would considerably decrease the amount of time
necessary to create BVMs. Currently, it takes about 10 hours to set up six BVMs.
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However, the removal of these steps would decrease that time to approximately five
hours, which would allow the Tissue Engineering Lab to substantially increase the
amount of BVMs produced. EtO sterilization is also a superior sterilization method.
Ethanol sterilization is considered a chemical disinfectant, not a sterilization process,
because certain viruses and bacterial spores are resistant to the effects of ethanol 175. An
experiment could be run which used the cytotoxicity elution assay or direct contact
assays to determine how EtO sterilized scaffolds affect cell viability.
A discussion of the future use of salt scaffolds must also be had within the Tissue
Engineering Lab. Based on the literature, nanofiber scaffolds will likely be advantageous
to implement because of the superiority to microfibers, and the data in Aim 2 suggests
that the BTEAC salt scaffolds are a viable option for fabricating nanofibers. The question
is not if, but when, nanofiber scaffolds replace the current microfiber scaffolds. A
discussion must be had of what further testing of these scaffolds needs to be completed to
justify implementation. Some potential further testing includes mechanical testing of
scaffold characteristics like yield strength, fiber diameter assessment in larger data sets to
ensure consistent sized nanofibers, and deployment of intravascular devices within
BVMs using these scaffolds to determine that these scaffolds are useful for obtaining
safety data of intravascular devices. Logistics of salt scaffold use must be explored as
well, such as whether one or two cell types will be used, and the appropriate sodding
density.
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4.5 Conclusion
Aim 1 of this thesis established methods for evaluating endothelial cells and
BVMs through gene expression analysis and results supported the conclusion that
HUVECs used in BVMs are retaining an endothelial phenotype during culture and not
dedifferentiating from EndMT. In fact, longer culture lengths trended towards increased
expression of VEGFR2 and VE-cadherin, indicating a stronger endothelial phenotype.
Disturbed flow conditions were established as a positive control for dedifferentiation,
which decreased VEGFR2 and VE-cadherin expression. Gene expression comparisons of
BVMs to static and disturbed flow cultures were inconclusive.
Aim 2 of this thesis successfully developed protocols to evaluate scaffold
cytotoxicity, as well as cell viability and coverage. These assays were applied to novel
BTEAC salt scaffolds to compare against standard PLGA scaffolds. These studies found
that BTEAC salt scaffolds do not affect cytotoxicity and cell viability more than standard
PLGA scaffolds. The BTEAC salt scaffolds also have more cell coverage than standard
scaffolds at all timepoints. Therefore, the integration of BTEAC salt scaffolds into the
BVM model should be considered, replacing the current scaffolds.
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APPENDICES
Appendix A: Preverified Primer Sequences and Characteristics
Primer
Name

Primer Sequence

Exon
Locati
on

Molecul
ar
Weight
(Da)

Extinction GC
Coefficient Conte
(L/(mol*c nt (%)
m))

PECAM
1 Primer
1

5’ATTGCTCTGGTCACTTCTCC3’

1b-2b

6,009.9

172,300.0

50.0

PECAM
1 Primer
2

5’-CAGGCCCCATTGTTCCC-3’ 1b-2b

5,082.3

146,700

64.7

CDH5
(VEcadherin
) Primer
1

5’TGCCCACATATTCTCCTTTG
AG-3’

2-3

6,636.4

198,100.0

45.5

CDH5
(VEcadherin
) Primer
1

5’2-3
GAACCAGATGCACATTGATG
AAG-3’

7,105.7

237,000.0

43.5

7,456.9

244,800.0

45.8

KDR
5’18-19
(VEGFR GAGGATCTTGAGTTCAGACA
2)
TGAG-3’
Primer 1
186

KDR
5’18-19
(VEGFR TTGGAATTGACAAGACAGCA
2)
AC-3’
Primer 2

6,776.5

224,000.0

40.9

ACTA2
(𝛼SMA)
Primer 1

5’CTGTTGTAGGTGGTTTCATG
GA-3’

8-9

6,827.5

211,700.0

45.5

ACTA2
(𝛼SMA)
Primer 2

5’AGAGTTACGAGTTGCCTGAT
G-3’

8-9

6,501.3

209,000.0

47.6

CNN1
Primer 1

5’CATGAAGTTGTTGCCGATGC
-3’

1-2

6,148.0

189,400.0

50.0

CNN1
Primer 2

5’TCAGCCGAGGTTAAGAACA
AG-3’

1-2

6,488.3

216,700.0

47.6

ACTB
Primer 1

5’-CCTTGCACATGCCGGAG3’

1-2

5,171.4

155,300.0

64.7

ACTB
Primer 2

5’-ACAGAGCCTCGCCTTTG-3’ 1-2

5,146.4

154,700.0

58.8

GUS𝛽
Primer 1

5’GTTTTTGATCCAGACCCAGA
TG-3’

10-11

6,725.4

210,600.0

45.5

GUS𝛽
Primer 2

5’GCCCATTATTCAGAGCGAGT
A-3’

10-11

6,430.2

208,900.0

47.6
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Appendix B: Primer Efficiency Testing SOP

Appendix C: RNA Isolation and Evaluation SOP

Appendix D: cDNA through Reverse Transcription SOP

Appendix E: qPCR SOP

Appendix F: qPCR Data Analysis SOP
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Appendix G: Primer Efficiency Plots
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Appendix H: BVM Conditioning SOP

Appendix I: Endothelial Cell-only BVM Sodding SOP

Appendix J: Apoptosis Kit Staining SOP

Appendix K: Cytotoxicity Elution Assay SOP
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Appendix L: Scaffold Adhesion Assay SOP

Appendix M: Positive Control Test Representative Images
Hoechst

Caspase

192

Propidium Iodide

DMSO
2% 30
minute
s 40x

DMSO
5% 30
minute
s 40x

DMSO
10% 30
minute
s 40x

DMSO
15% 30
minute
s 40x

193

DMSO
2% 1
hour
40x

DMSO
5% 1
hour
40x

DMSO
10% 1
hour
40x

DMSO
15% 1
hour
40x

194

H2O2
0.05%
2
minute
s 40x

H2O2
0.1% 2
minute
s 40x

H2O2
0.5% 2
minute
s 40x

H2O2
1% 2
minute
s 40x

195

H2O2
0.05%
5
minute
s 40x

H2O2
0.1% 5
minute
s 40x

H2O2
0.5% 5
minute
s 40x

H2O2
1% 5
minute
s 40x
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Appendix N: Cytotoxicity Elution Assay Representative Images
24 Hours, 40x
Hoechst

Caspase

Negative
Control

Positive
Control
0.5%

Positive
Control
1%

197

Propidium Iodide

Standard
Scaffold 1
No
Dilution

Standard
Scaffold 2
No
Dilution

3% Salt
Scaffold 1
No
Dilution

3% Salt
Scaffold 2
No
Dilution
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Standard
Scaffold 1
50%
Dilution

Standard
Scaffold 2
50%
Dilution

3% Salt
Scaffold 1
50%
Dilution

3% Salt
Scaffold 2
50%
Dilution

48 Hours, 40x
Hoechst

Caspase
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Propidium Iodide

Negative
Control

Positive
Control
0.5%

Positive
Control
1%

Standard
Scaffold
1 No
Dilution
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Standard
Scaffold
2 No
Dilution

3% Salt
Scaffold
1 No
Dilution

3% Salt
Scaffold
2 No
Dilution

Standard
Scaffold
1 50%
Dilution
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Standard
Scaffold
2 50%
Dilution

3% Salt
Scaffold
1 50%
Dilution

3% Salt
Scaffold
2 50%
Dilution
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Appendix O: Scaffold Adhesion Assay Representative Images
Hoechst

Caspase

Negative
Control
of
Standard
Scaffold

Negative
Control
of Salt
Scaffold

Standard
Scaffold
1
Proximal
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Propidium Iodide

Standard
Scaffold
1 Middle

Standard
Scaffold
1 Distal

Standard
Scaffold
2
Proximal

Standard
Scaffold
2 Middle
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Standard
Scaffold
2 Distal

3% Salt
Scaffold
1
Proximal

3% Salt
Scaffold
1 Middle

3% Salt
Scaffold
1 Distal
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3% Salt
Scaffold
2
Proximal

3% Salt
Scaffold
2 Middle

3% Salt
Scaffold
2 Distal
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Appendix P: BVM Study Representative Images
Hoechst

Caspase

ePTFE
3-Day
Proxim
al

ePTFE
3-Day
Middle

ePTFE
3-Day
Distal
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Propidium Iodide

ePTFE
7-Day
Proxim
al

ePTFE
7-Day
Middle

ePTFE
7-Day
Distal

Standar
d
Scaffol
d 3-Day
Proxim
al
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Standar
d
Scaffol
d 3-Day
Middle

Standar
d
Scaffol
d 3-Day
Distal

Standar
d
Scaffol
d 7-Day
Proxim
al

Standar
d
Scaffol
d 7-Day
Middle

Standar
d
Scaffol
d 7-Day
Distal

209

0.5%
Salt
Scaffol
d 3-Day
Proxim
al

0.5%
Salt
Scaffol
d 3-Day
Middle

0.5%
Salt
Scaffol
d 3-Day
Distal

0.5%
Salt
Scaffol
d 7-Day
Proxim
al

0.5%
Salt
Scaffol
d 7-Day
Middle

210

0.5%
Salt
Scaffol
d 7-Day
Distal

3% Salt
Scaffol
d 3-Day
Proxim
al

3% Salt
Scaffol
d 3-Day
Middle

3% Salt
Scaffol
d 3-Day
Distal

3% Salt
Scaffol
d 7-Day
Proxim
al
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3% Salt
Scaffol
d 7-Day
Middle

3% Salt
Scaffol
d 7-Day
Distal
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Appendix Q: Magnification Justification Raw Data
Cytotoxicity 24 Hours 40x
Image
Name

Manual
Difference
Cell
Automated (AutomatedCount Cell Count Manual)

Smallest
Threshold Cell Size
(1st slider) (pizels^2)

No
Dilution
No Salt 1
40x 1

44

34

-10

863

No
Dilution
No Salt 1
40x 2

57

59

2

No
Dilution
No Salt 2
40x 1

72

64

No
Dilution
No Salt 2
40x 2

46

No
Dilution
No Salt 2
40x 3

16

Cell
Density Notes

Percent
Error

20 Medium

29.41176471

1371

30 Low

3.389830508

-8

1776

30 High

12.5

43

-3

1390

30 Medium

6.976744186

18

2

1466

30 Low

11.11111111

No
Dilution
No Salt 2
40x 4

22

24

2

1729

50 Low

No
Dilution
Salt 1
40x 1

68

53

-15

1070

50 Medium

28.30188679

No
Dilution
Salt 1
40x 2

68

70

2

1546

30 Low

2.857142857
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Lots of
cell
debris

8.333333333

No
Dilution
Salt 1
40x 3

30

30

0

1005

50 Low

No
Dilution
Salt 1
40x 4

101

111

10

1070

50 Medium

9.009009009

No
Dilution
Salt 1
40x 5

105

111

6

1101

50 Medium

5.405405405

No
Dilution
Salt 2
40x 1

110

123

13

1031

50 Medium

10.56910569

No
Dilution
Salt 2
40x 2

108

111

3

1014

50 Medium

2.702702703

No
Dilution
Salt 2
40x 3

28

30

2

1009

50 Low

6.666666667

No
Dilution
Salt 2
40x 4

40

40

0

1000

50 Low

0

0
Average
Error
9.148980198

Cytotoxicity 24 hours 20x
Image
Name

Manual
Cell
Count

Automated
Cell Count

Difference
(AutomatedManual)

Threshold
(1st slider)

Smallest
Cell Size
(pizels^2)

Cell
Density

Notes

Error

No Salt
1 20x 1

17

17

0

1009

20 Low

No Salt
1 20x 2

42

37

5

1334

20 Medium

No Salt
1 20x 3

31

23

8

1008

20 Low

34.7826087

No Salt
1 20x 4

81

43

38

1009

20 High

88.37209302

214

0
13.51351351

No Salt
2 20x 1

127

73

54

1102

20 Medium

No Salt
2 20x 2

22

20

2

1084

20 Low

No Salt
2 20x 3

100

101

-1

1101

20 Medium

No Salt
2 20x 4

101

64

37

1181

20 High

57.8125

No Salt
2 20x 5

120

90

30

1087

20 High

33.33333333

Salt 1
20x 1

49

22

27

1087

20 Medium

122.7272727

Salt 1
20x 2

55

35

20

1060

20 High

57.14285714

Salt 1
20x 4

84

67

17

811

20 Medium

25.37313433

Salt 2
20x 1

96

82

14

1149

20 Low

17.07317073

Salt 2
20x 2

74

79

-5

1027

20 Medium

6.329113924

Salt 2
20x 3

59

51

8

1009

20 Medium

15.68627451

Salt 2
20x 4

66

36

30

1227

20 Low

83.33333333

73.97260274
10
0.9900990099

Average

40.02761919

Appendix R: Pixel Intensity Reduction Raw Data
Propidium
Iodide

Min
Intensity

Cell
Count
0
5
10
15
20
25
30

Percent Cell Count
Reduction
22
21
21
21
18
15
13

0
4.545454545
4.545454545
4.545454545
18.18181818
31.81818182
40.90909091
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Average Percent Cell Count
Reduction
0
1.515151515
4.62701022
6.25302648
10.79848103
20.08181054
27.17715422

35
40
45
50
55
60
65
70
75
80
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70

10
9
5
3
1
1
1
1
1
1
41
41
40
38
38
35
30
28
23
20
16
14
14
14
14
14
10
29
29
27
27
27
25
25
22
22
22
22
20
20
20
19

54.54545455
59.09090909
77.27272727
86.36363636
95.45454545
95.45454545
95.45454545
95.45454545
95.45454545
95.45454545
0
0
2.43902439
7.317073171
7.317073171
14.63414634
26.82926829
31.70731707
43.90243902
51.2195122
60.97560976
65.85365854
65.85365854
65.85365854
65.85365854
65.85365854
75.6097561
0
0
6.896551724
6.896551724
6.896551724
13.79310345
13.79310345
24.13793103
24.13793103
24.13793103
24.13793103
31.03448276
31.03448276
31.03448276
34.48275862
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36.79690088
42.37709305
50.8767235
57.15905905
64.11422892
64.11422892
64.11422892
65.2636542
65.2636542
68.51568672

75
80

Caspase

Min
Intensity

19
19
Cell
Count

0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
0
5
10
15

34.48275862
34.48275862
Percent Cell Count
Reduction

22
22
21
18
15
15
12
11
11
11
11
8
6
6
6
4
3
55
55
53
52
52
52
48
47
45
40
40
40
37
37
37
32
30
47
47
47
43

0
0
4.545454545
18.18181818
31.81818182
31.81818182
45.45454545
50
50
50
50
63.63636364
72.72727273
72.72727273
72.72727273
81.81818182
86.36363636
0
0
3.636363636
5.454545455
5.454545455
5.454545455
12.72727273
14.54545455
18.18181818
27.27272727
27.27272727
27.27272727
32.72727273
32.72727273
32.72727273
41.81818182
45.45454545
0
0
0
8.510638298

217

Average Percent Cell Count
Reduction
0
0
2.727272727
10.71566731
17.38878143
17.38878143
26.48613798
28.6073501
29.81947131
37.81431335
37.81431335
43.77820761
52.88201161
55.00967118
56.4281109
64.61637653
67.34364926

20
25
30
35
40
45
50
55
60
65
70
75
80

40
40
37
37
37
30
30
28
22
19
17
14
14

14.89361702
14.89361702
21.27659574
21.27659574
21.27659574
36.17021277
36.17021277
40.42553191
53.19148936
59.57446809
63.82978723
70.21276596
70.21276596

Appendix S: Nuclei Area Multiplication Factor Raw Data
Cell
1
2
3
4
5
6
7

Nucleus Size Whole Cell Size
14
84
29
209
48
171
26
135
38
137
50
158
44
84
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Nucleus %
Multiplication Factor
16.66666667
6
13.87559809
7.206896552
28.07017544
3.5625
19.25925926
5.192307692
27.73722628
3.605263158
31.64556962
3.16
52.38095238
1.909090909

8
9
10
11
12
13
14
15
16
17
18
19
20

22
44
57
27
20
24
40
26
29
52
23
29
21

100
105
169
141
161
110
328
173
161
245
91
158
119
Nucleus %
Average
Multiplication
Factor

22
41.9047619
33.72781065
19.14893617
12.42236025
21.81818182
12.19512195
15.02890173
18.01242236
21.2244898
25.27472527
18.35443038
17.64705882
23.41973244
4.269903606

Appendix T: Statistical Tests for Cytotoxicity Elution Assay
ANOVA for Caspase Activity without normalizing to negative control
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4.545454545
2.386363636
2.964912281
5.222222222
8.05
4.583333333
8.2
6.653846154
5.551724138
4.711538462
3.956521739
5.448275862
5.666666667

ANOVA for Caspase Activity after normalizing to negative control
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ANOVA for Propidium Iodide Activity without normalizing to negative control

221

ANOVA for Propidium Iodide Activity after normalizing to negative control
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Appendix U: Statistical Tests for Scaffold Adhesion Assay
ANOVA for Cell Coverage

ANOVA for Percent Apoptotic Cells
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ANOVA for Percent Dead Cells

224

Appendix V: Statistical Tests for BVM Study
ANOVA for Change in Scaffold Thickness

ANOVA for Scaffold Shrinkage during pre-shrinking versus during BVM culture
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ANOVA for Change in BVM Lengths

ANOVA for Cell Coverage
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ANOVA for Percent Apoptotic Cells

227

ANOVA for Percent Dead Cells

228

